CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: maneb
Accession: CHEBI:52497
browse the term
Definition: A polymeric complex of manganese with the ethylene bis(dithiocarbamate) anionic ligand. An agrochemical fungicide, it is used to control a variety of diseases including blight, leaf spot, rust, downy mildew and scab.
Synonyms: exact_synonym: [{2-[(sulfanylcarbothioyl)amino]ethyl}carbamodithioato(2-)-kappa(2)S,S']manganese
related_synonym: Formula=(C4H6MnN2S4)n; manganese ethane-1,2-diyldicarbamodithioate
xref: Beilstein:3747585; CAS:12427-38-2; KEGG:C15231
xref_mesh: MESH:D008344
xref: PMID:18605226; PMID:20188092; PMID:20430411; PMID:21314462; PMID:21402726; PMID:23764462; PMID:24936438; PMID:25275677; PPDB:426; Pesticides:maneb; Reaxys:3747585; Wikipedia:Maneb
G
Aak1
AP2 associated kinase 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of AAK1 mRNA
CTD
PMID:36117858
NCBI chr 6:86,826,252...86,980,209
Ensembl chr 6:86,826,499...86,980,205
G
Aass
aminoadipate-semialdehyde synthase
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of AASS mRNA
CTD
PMID:36117858
NCBI chr 6:23,072,172...23,132,985
Ensembl chr 6:23,072,172...23,132,985
G
Abat
4-aminobutyrate aminotransferase
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ABAT mRNA
CTD
PMID:36117858
NCBI chr16:8,331,293...8,439,432
Ensembl chr16:8,331,293...8,439,432
G
Abca2
ATP-binding cassette, sub-family A member 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ABCA2 mRNA
CTD
PMID:36117858
NCBI chr 2:25,318,611...25,338,556
Ensembl chr 2:25,318,715...25,338,552
G
Abca5
ATP-binding cassette, sub-family A member 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ABCA5 mRNA
CTD
PMID:36117858
NCBI chr11:110,160,195...110,228,542
Ensembl chr11:110,160,195...110,228,542
G
Abcd2
ATP-binding cassette, sub-family D member 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ABCD2 mRNA
CTD
PMID:36117858
NCBI chr15:91,029,874...91,076,013
Ensembl chr15:91,030,074...91,076,002
G
Abhd8
abhydrolase domain containing 8
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ABHD8 mRNA
CTD
PMID:36117858
NCBI chr 8:71,909,344...71,917,351
Ensembl chr 8:71,909,349...71,916,299
G
Abi2
abl interactor 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ABI2 mRNA
CTD
PMID:36117858
NCBI chr 1:60,444,927...60,521,104
Ensembl chr 1:60,448,778...60,520,317
G
Abi3bp
ABI family member 3 binding protein
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ABI3BP mRNA
CTD
PMID:36117858
NCBI chr16:56,298,179...56,510,498
Ensembl chr16:56,298,241...56,510,498
G
Ablim2
actin-binding LIM protein 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ABLIM2 mRNA
CTD
PMID:36117858
NCBI chr 5:35,915,200...36,042,323
Ensembl chr 5:35,915,224...36,042,317
G
Acads
acyl-Coenzyme A dehydrogenase, short chain
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA]
CTD
PMID:23963992
NCBI chr 5:115,248,358...115,257,405
Ensembl chr 5:115,248,358...115,257,405
G
Ace
angiotensin I converting enzyme
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ACE mRNA
CTD
PMID:36117858
NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790
G
Ache
acetylcholinesterase
multiple interactions decreases expression
EXP ISO
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of ACHE mRNA Maneb results in decreased expression of ACHE protein
CTD
PMID:3868355 PMID:23017109
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
G
Aco2
aconitase 2, mitochondrial
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of ACO2 mRNA
CTD
PMID:18386188
NCBI chr15:81,756,664...81,799,338
Ensembl chr15:81,756,510...81,799,334
G
Acsl4
acyl-CoA synthetase long-chain family member 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ACSL4 mRNA
CTD
PMID:36117858
NCBI chr X:141,100,989...141,173,792
Ensembl chr X:141,100,989...141,173,531
G
Actl6b
actin-like 6B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ACTL6B mRNA
CTD
PMID:36117858
NCBI chr 5:137,551,784...137,567,844
Ensembl chr 5:137,551,779...137,567,844
G
Adal
adenosine deaminase-like
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ADAL mRNA
CTD
PMID:36117858
NCBI chr 2:120,970,525...120,989,921
Ensembl chr 2:120,970,909...120,987,161
G
Adam11
a disintegrin and metallopeptidase domain 11
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ADAM11 mRNA
CTD
PMID:36117858
NCBI chr11:102,652,261...102,671,089
Ensembl chr11:102,652,265...102,671,088
G
Adam22
a disintegrin and metallopeptidase domain 22
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of ADAM22 mRNA
CTD
PMID:22563483
NCBI chr 5:8,122,353...8,418,312
Ensembl chr 5:8,122,352...8,418,160
G
Adar
adenosine deaminase, RNA-specific
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ADAR mRNA
CTD
PMID:36117858
NCBI chr 3:89,622,321...89,660,756
Ensembl chr 3:89,622,329...89,660,753
G
Adcy2
adenylate cyclase 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ADCY2 mRNA
CTD
PMID:36117858
NCBI chr13:68,768,162...69,147,719
Ensembl chr13:68,768,162...69,147,660
G
Adgrb1
adhesion G protein-coupled receptor B1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ADGRB1 mRNA
CTD
PMID:23017109
NCBI chr15:74,388,045...74,461,314
Ensembl chr15:74,388,044...74,461,314
G
Adgrb2
adhesion G protein-coupled receptor B2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ADGRB2 mRNA
CTD
PMID:36117858
NCBI chr 4:129,878,566...129,916,426
Ensembl chr 4:129,878,663...129,916,426
G
Adgrg1
adhesion G protein-coupled receptor G1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of ADGRG1 mRNA
CTD
PMID:18386188
NCBI chr 8:95,701,321...95,740,836
Ensembl chr 8:95,701,379...95,740,845
G
Adgrl3
adhesion G protein-coupled receptor L3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ADGRL3 mRNA
CTD
PMID:36117858
NCBI chr 5:81,167,600...81,980,556
Ensembl chr 5:81,167,985...81,972,980
G
Adm
adrenomedullin
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ADM mRNA
CTD
PMID:36117858
NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027
G
Adora1
adenosine A1 receptor
multiple interactions
EXP
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ADORA1 mRNA
CTD
PMID:23017109
NCBI chr 1:134,126,953...134,163,195
Ensembl chr 1:134,126,963...134,163,169
G
Adora2a
adenosine A2a receptor
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ADORA2A mRNA
CTD
PMID:36117858
NCBI chr10:75,152,711...75,170,626
Ensembl chr10:75,152,711...75,170,618
G
Aff3
AF4/FMR2 family, member 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of AFF3 mRNA
CTD
PMID:36117858
NCBI chr 1:38,212,936...38,704,036
Ensembl chr 1:38,216,407...38,704,036
G
Afg3l2
AFG3-like AAA ATPase 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of AFG3L2 mRNA
CTD
PMID:36117858
NCBI chr18:67,537,830...67,582,277
Ensembl chr18:67,537,834...67,582,242
G
Ago3
argonaute RISC catalytic subunit 3
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of AGO3 mRNA
CTD
PMID:22563483
NCBI chr 4:126,220,797...126,323,360
Ensembl chr 4:126,225,497...126,323,349
G
Aif1
allograft inflammatory factor 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of AIF1 protein; [Paraquat co-treated with Maneb] results in increased expression of AIF1 protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of AIF1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of AIF1 protein]
CTD
PMID:28202386 PMID:32375810
NCBI chr17:35,389,967...35,394,977
Ensembl chr17:35,389,967...35,395,044
G
Ajap1
adherens junction associated protein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of AJAP1 mRNA
CTD
PMID:36117858
NCBI chr 4:153,457,678...153,568,313
Ensembl chr 4:153,457,678...153,567,268
G
Ak5
adenylate kinase 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of AK5 mRNA
CTD
PMID:36117858
NCBI chr 3:152,168,461...152,373,992
Ensembl chr 3:152,168,452...152,373,997
G
Akr1b1
aldo-keto reductase family 1 member B
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of AKR1B1 mRNA
CTD
PMID:18386188
NCBI chr 6:34,280,865...34,294,424
Ensembl chr 6:34,279,369...34,294,413
G
Akt1
thymoma viral proto-oncogene 1
multiple interactions
EXP
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of AKT1 protein; [alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of AKT1 protein; [Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA]
CTD
PMID:19883720 PMID:23963992
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
G
Alas2
aminolevulinic acid synthase 2, erythroid
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of ALAS2 mRNA
CTD
PMID:22563483
NCBI chr X:149,330,443...149,353,614
Ensembl chr X:149,330,371...149,353,634
G
Alb
albumin
increases secretion
EXP
Maneb results in increased secretion of ALB protein
CTD
PMID:28322069
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
G
Aldh2
aldehyde dehydrogenase 2, mitochondrial
decreases activity multiple interactions
ISO
Maneb results in decreased activity of ALDH2 protein [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of ALDH2 mRNA; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of and results in decreased activity of ALDH2 protein
CTD
PMID:17010440 PMID:34830855
NCBI chr 5:121,704,090...121,731,887
Ensembl chr 5:121,704,090...121,731,887
G
Aldh5a1
aldhehyde dehydrogenase family 5, subfamily A1
decreases activity multiple interactions
ISO EXP
Maneb results in decreased activity of ALDH5A1 protein [Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA]
CTD
PMID:17010440 PMID:23963992
NCBI chr13:25,091,562...25,121,740
Ensembl chr13:25,091,562...25,121,644
G
Aldoc
aldolase C, fructose-bisphosphate
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of ALDOC mRNA
CTD
PMID:18386188
NCBI chr11:78,213,899...78,218,607
Ensembl chr11:78,213,794...78,218,607
G
Als2
alsin Rho guanine nucleotide exchange factor
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ALS2 mRNA
CTD
PMID:36117858
NCBI chr 1:59,201,915...59,276,390
Ensembl chr 1:59,202,085...59,276,390
G
Amigo2
adhesion molecule with Ig like domain 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of AMIGO2 mRNA
CTD
PMID:36117858
NCBI chr15:97,141,955...97,145,168
Ensembl chr15:97,142,006...97,145,168
G
Amn
amnionless
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of AMN mRNA
CTD
PMID:22563483
NCBI chr12:111,237,530...111,242,860
Ensembl chr12:111,237,529...111,242,860
G
Ampd3
adenosine monophosphate deaminase 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of AMPD3 mRNA
CTD
PMID:36117858
NCBI chr 7:110,367,291...110,411,612
Ensembl chr 7:110,367,413...110,411,612
G
Angel1
angel homolog 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ANGEL1 mRNA
CTD
PMID:36117858
NCBI chr12:86,740,185...86,781,075
Ensembl chr12:86,747,276...86,780,995
G
Ankrd13d
ankyrin repeat domain 13 family, member D
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ANKRD13D mRNA
CTD
PMID:36117858
NCBI chr19:4,320,208...4,333,165
Ensembl chr19:4,320,208...4,333,165
G
Ankrd26
ankyrin repeat domain 26
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ANKRD26 mRNA
CTD
PMID:36117858
NCBI chr 6:118,478,261...118,539,244
Ensembl chr 6:118,478,269...118,539,187
G
Anks1b
ankyrin repeat and sterile alpha motif domain containing 1B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ANKS1B mRNA
CTD
PMID:36117858
NCBI chr10:89,707,238...90,809,162
Ensembl chr10:89,709,371...90,809,162
G
Ano3
anoctamin 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ANO3 mRNA
CTD
PMID:36117858
NCBI chr 2:110,485,546...110,780,854
Ensembl chr 2:110,485,546...110,781,268
G
Ap3b2
adaptor-related protein complex 3, beta 2 subunit
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of AP3B2 mRNA
CTD
PMID:18386188
NCBI chr 7:81,110,147...81,143,722
Ensembl chr 7:81,110,147...81,143,673
G
Ap3d1
adaptor-related protein complex 3, delta 1 subunit
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of AP3D1 mRNA
CTD
PMID:18386188
NCBI chr10:80,542,790...80,578,137
Ensembl chr10:80,542,790...80,578,098
G
Apbb1
amyloid beta precursor protein binding family B member 1
multiple interactions
EXP
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of APBB1 mRNA
CTD
PMID:23017109
NCBI chr 7:105,207,691...105,231,151
Ensembl chr 7:105,207,690...105,230,860
G
Arc
activity regulated cytoskeletal-associated protein
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ARC mRNA
CTD
PMID:36117858
NCBI chr15:74,540,930...74,544,419
Ensembl chr15:74,540,932...74,544,419
G
Arf3
ADP-ribosylation factor 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ARF3 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of ARF3 mRNA
CTD
PMID:18386188 PMID:36117858
NCBI chr15:98,635,505...98,660,999
Ensembl chr15:98,634,515...98,661,095
G
Arg1
arginase, liver
multiple interactions decreases expression
EXP ISO
[Maneb co-treated with Paraquat] results in increased expression of ARG1 mRNA; [Paraquat co-treated with Maneb] results in increased expression of ARG1 mRNA; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ARG1 mRNA] Maneb results in decreased expression of ARG1 mRNA
CTD
PMID:29568078 PMID:32194361 PMID:32375810 PMID:34052309
NCBI chr10:24,791,105...24,803,368
Ensembl chr10:24,791,119...24,803,382
G
Arhgap26
Rho GTPase activating protein 26
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ARHGAP26 mRNA
CTD
PMID:36117858
NCBI chr18:38,734,531...39,509,338
Ensembl chr18:39,126,198...39,509,337 Ensembl chr18:39,126,198...39,509,337
G
Arhgap32
Rho GTPase activating protein 32
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ARHGAP32 mRNA
CTD
PMID:36117858
NCBI chr 9:31,927,921...32,176,061
Ensembl chr 9:32,027,432...32,179,742
G
Arhgap44
Rho GTPase activating protein 44
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ARHGAP44 mRNA
CTD
PMID:36117858
NCBI chr11:64,892,865...65,053,779
Ensembl chr11:64,892,865...65,053,787
G
Arl5a
ADP-ribosylation factor-like 5A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ARL5A mRNA
CTD
PMID:36117858
NCBI chr 2:52,287,961...52,314,886
Ensembl chr 2:52,287,963...52,314,913
G
Arnt2
aryl hydrocarbon receptor nuclear translocator 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ARNT2 mRNA
CTD
PMID:23017109
NCBI chr 7:83,895,486...84,059,201
Ensembl chr 7:83,895,486...84,059,384
G
Arx
aristaless related homeobox
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ARX mRNA
CTD
PMID:36117858
NCBI chr X:92,330,113...92,341,963
Ensembl chr X:92,330,051...92,341,963
G
Asah2
N-acylsphingosine amidohydrolase 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ASAH2 mRNA
CTD
PMID:36117858
NCBI chr19:31,962,046...32,080,540
Ensembl chr19:31,959,997...32,085,611
G
Ascc1
activating signal cointegrator 1 complex subunit 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ASCC1 mRNA
CTD
PMID:36117858
NCBI chr10:59,838,414...59,935,812
Ensembl chr10:59,838,627...59,935,810
G
Ascl1
achaete-scute family bHLH transcription factor 1
multiple interactions
EXP
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ASCL1 mRNA
CTD
PMID:23017109
NCBI chr10:87,326,681...87,329,522
Ensembl chr10:87,326,681...87,329,522
G
Aspn
asporin
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ASPN mRNA
CTD
PMID:36117858
NCBI chr13:49,697,919...49,721,041
Ensembl chr13:49,697,919...49,721,041
G
Atad2
ATPase family, AAA domain containing 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ATAD2 mRNA
CTD
PMID:36117858
NCBI chr15:57,957,440...57,998,516
Ensembl chr15:57,957,440...57,998,478
G
Atf3
activating transcription factor 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ATF3 mRNA
CTD
PMID:36117858
NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236
G
Atg12
autophagy related 12
multiple interactions
EXP
Maneb promotes the reaction [Paraquat results in increased expression of ATG12 protein]
CTD
PMID:22292029
NCBI chr18:46,865,484...46,874,683
Ensembl chr18:46,863,211...46,874,647
G
Atg16l2
autophagy related 16 like 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ATG16L2 mRNA
CTD
PMID:36117858
NCBI chr 7:100,935,521...100,951,474
Ensembl chr 7:100,912,241...100,951,458
G
Atosa
atos homolog A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of FAM214A mRNA
CTD
PMID:36117858
NCBI chr 9:74,860,162...74,939,750
Ensembl chr 9:74,860,151...74,939,746
G
Atp5f1a
ATP synthase F1 subunit alpha
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ATP5F1A protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP5F1A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP5F1A protein]
CTD
PMID:23562983
NCBI chr18:77,861,468...77,870,569
Ensembl chr18:77,861,429...77,870,569
G
Atp5mc1
ATP synthase membrane subunit c locus 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of ATP5MC1 mRNA
CTD
PMID:18386188
NCBI chr11:95,963,619...95,966,520
Ensembl chr11:95,959,678...95,966,496
G
Atp6v0b
ATPase, H+ transporting, lysosomal V0 subunit B
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of ATP6V0B mRNA
CTD
PMID:18386188
NCBI chr 4:117,741,523...117,744,548
Ensembl chr 4:117,741,523...117,744,530
G
Atp6v0c
ATPase, H+ transporting, lysosomal V0 subunit C
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of ATP6V0C mRNA
CTD
PMID:18386188
NCBI chr17:24,382,839...24,388,652
Ensembl chr17:24,382,840...24,388,676
G
Atp6v1c1
ATPase, H+ transporting, lysosomal V1 subunit C1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA]
CTD
PMID:23963992
NCBI chr15:38,662,096...38,692,688
Ensembl chr15:38,662,177...38,692,690
G
Atp8a2
ATPase, aminophospholipid transporter-like, class I, type 8A, member 2
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of ATP8A2 mRNA
CTD
PMID:22563483
NCBI chr14:59,884,980...60,324,363
Ensembl chr14:59,875,989...60,434,628
G
Atxn1
ataxin 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ATXN1 mRNA
CTD
PMID:36117858
NCBI chr13:45,703,231...46,118,467
Ensembl chr13:45,703,231...46,118,484
G
Aven
apoptosis, caspase activation inhibitor
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of AVEN mRNA
CTD
PMID:36117858
NCBI chr 2:112,323,231...112,461,598
Ensembl chr 2:112,323,309...112,464,918
G
B3galt1
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of B3GALT1 mRNA
CTD
PMID:36117858
NCBI chr 2:67,395,528...67,953,226
Ensembl chr 2:67,396,215...67,953,033
G
B3galt2
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of B3GALT2 mRNA
CTD
PMID:36117858
NCBI chr 1:143,516,435...143,525,675
Ensembl chr 1:143,516,402...143,530,352
G
B3gat2
beta-1,3-glucuronyltransferase 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of B3GAT2 mRNA
CTD
PMID:36117858
NCBI chr 1:23,801,007...23,886,946
Ensembl chr 1:23,800,834...23,888,239
G
B4galt5
UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of B4GALT5 mRNA
CTD
PMID:36117858
NCBI chr 2:167,140,364...167,191,155
Ensembl chr 2:167,140,364...167,191,103
G
Bad
BCL2-associated agonist of cell death
multiple interactions
ISO
[Paraquat co-treated with Maneb] results in increased phosphorylation of BAD protein
CTD
PMID:15824117
NCBI chr19:6,919,229...6,929,273
Ensembl chr19:6,919,229...6,929,267
G
Bahcc1
BAH domain and coiled-coil containing 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of BAHCC1 mRNA
CTD
PMID:36117858
NCBI chr11:120,123,696...120,183,123
Ensembl chr11:120,123,773...120,183,108
G
Bak1
BCL2-antagonist/killer 1
multiple interactions affects response to substance increases expression
EXP ISO
[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA] BAK1 protein affects the susceptibility to Maneb Maneb results in increased expression of BAK1 mRNA; Maneb results in increased expression of BAK1 protein [Paraquat co-treated with Maneb] results in increased expression of BAK1 protein; Maneb inhibits the reaction [BAK1 protein affects the susceptibility to Paraquat]; Paraquat inhibits the reaction [BAK1 protein affects the susceptibility to Maneb]
CTD
PMID:18266926 PMID:23963992
NCBI chr17:27,238,786...27,247,601
Ensembl chr17:27,238,784...27,247,983
G
Bax
BCL2-associated X protein
multiple interactions increases expression
ISO EXP
[Paraquat co-treated with Maneb] results in increased expression of BAX protein; BAX protein affects the susceptibility to [Paraquat co-treated with Maneb] [Maneb co-treated with Paraquat] results in increased expression of BAX mRNA; [Paraquat co-treated with Maneb] results in increased expression of BAX protein; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BAX protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAX mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BAX protein] Maneb results in increased expression of BAX protein
CTD
PMID:15824117 PMID:18266926 PMID:20964710 PMID:23963992
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
G
Bbc3
BCL2 binding component 3
increases expression multiple interactions
ISO
Maneb results in increased expression of BBC3 protein 3-(4-(morpholin-4-yl)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)benzonitrile inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BBC3 protein]; [Paraquat co-treated with Maneb] results in increased expression of BBC3 protein; Plant Extracts inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BBC3 protein]
CTD
PMID:18266926 PMID:34897981
NCBI chr 7:16,042,307...16,052,130
Ensembl chr 7:16,042,318...16,052,130
G
Bcas3
BCAS3 microtubule associated cell migration factor
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of BCAS3 mRNA
CTD
PMID:36117858
NCBI chr11:85,243,611...85,716,884
Ensembl chr11:85,243,993...85,716,884
G
Bcat1
branched chain aminotransferase 1, cytosolic
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of BCAT1 mRNA
CTD
PMID:36117858
NCBI chr 6:144,939,561...145,021,883
Ensembl chr 6:144,939,561...145,021,910
G
Bckdhb
branched chain ketoacid dehydrogenase E1, beta polypeptide
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of BCKDHB mRNA
CTD
PMID:36117858
NCBI chr 9:83,807,190...84,006,293
Ensembl chr 9:83,807,198...84,006,293
G
Bcl11a
BCL11 transcription factor A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of BCL11A mRNA
CTD
PMID:36117858
NCBI chr11:24,026,498...24,123,558
Ensembl chr11:24,028,056...24,124,123
G
Bcl2
B cell leukemia/lymphoma 2
multiple interactions increases expression
EXP ISO
[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA] Maneb results in increased expression of BCL2 mRNA; Maneb results in increased expression of BCL2 protein
CTD
PMID:18266926 PMID:23963992 PMID:36117858
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
G
Bcl2a1b
B cell leukemia/lymphoma 2 related protein A1b
multiple interactions increases expression
ISO
[Paraquat co-treated with Maneb] results in increased expression of BCL2A1 protein Maneb results in increased expression of BCL2A1 mRNA
CTD
PMID:18266926
NCBI chr 9:89,081,326...89,089,891
Ensembl chr 9:89,081,262...89,089,880
G
Bcl2l1
BCL2-like 1
multiple interactions increases expression
ISO
[Paraquat co-treated with Maneb] results in decreased expression of BCL2L1 protein Maneb results in increased expression of BCL2L1 mRNA
CTD
PMID:15824117 PMID:18266926
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
G
Bcl2l11
BCL2 like 11
multiple interactions increases expression
ISO
[Paraquat co-treated with Maneb] results in increased expression of BCL2L11 protein Maneb results in increased expression of BCL2L11 protein
CTD
PMID:18266926
NCBI chr 2:127,967,958...128,004,467
Ensembl chr 2:127,967,958...128,004,467
G
Bdnf
brain derived neurotrophic factor
multiple interactions
EXP ISO
[Maneb co-treated with Paraquat] results in decreased expression of BDNF mRNA [Paraquat co-treated with Maneb] results in decreased expression of BDNF mRNA; [Paraquat co-treated with Maneb] results in decreased expression of BDNF protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of BDNF mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of BDNF protein]
CTD
PMID:23017109 PMID:27460631 PMID:33368748 PMID:36117858
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
G
Becn1
beclin 1, autophagy related
increases expression multiple interactions
EXP
Maneb results in increased expression of BECN1 protein [Paraquat co-treated with Maneb] results in increased expression of BECN1 protein
CTD
PMID:22292029 PMID:26884967
NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112
G
Bend7
BEN domain containing 7
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of BEND7 mRNA
CTD
PMID:36117858
NCBI chr 2:4,722,593...4,807,035
Ensembl chr 2:4,722,642...4,806,953
G
Bex2
brain expressed X-linked 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of BEX1 mRNA
CTD
PMID:36117858
NCBI chr X:134,967,314...134,968,985
Ensembl chr X:134,967,313...134,968,985
G
Bicd1
BICD cargo adaptor 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of BICD1 mRNA; [Paraquat co-treated with Maneb] affects the expression of BICD1 mRNA
CTD
PMID:22563483 PMID:36117858
NCBI chr 6:149,310,322...149,464,827
Ensembl chr 6:149,310,384...149,464,827
G
Bicral
BRD4 interacting chromatin remodeling complex associated protein like
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of BICRAL mRNA
CTD
PMID:36117858
NCBI chr17:47,109,046...47,201,329
Ensembl chr17:47,109,046...47,169,408
G
Bid
BH3 interacting domain death agonist
multiple interactions increases expression
ISO
[Maneb co-treated with Paraquat] results in increased expression of BID protein Maneb results in increased expression of BID protein
CTD
PMID:18266926
NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814
G
Bik
BCL2-interacting killer
increases expression multiple interactions
ISO
Maneb results in increased expression of BIK mRNA; Maneb results in increased expression of BIK protein [Paraquat co-treated with Maneb] results in increased expression of BIK protein
CTD
PMID:18266926
NCBI chr15:83,410,992...83,428,836
Ensembl chr15:83,411,063...83,428,835
G
Bltp3b
bridge-like lipid transfer protein family member 3B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of UHRF1BP1L mRNA
CTD
PMID:36117858
NCBI chr10:89,580,830...89,655,753
Ensembl chr10:89,580,853...89,655,733
G
Bmp2
bone morphogenetic protein 2
multiple interactions
EXP
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP2 mRNA
CTD
PMID:23017109
NCBI chr 2:133,394,079...133,404,816
Ensembl chr 2:133,394,079...133,404,805
G
Bmp4
bone morphogenetic protein 4
multiple interactions
EXP
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA
CTD
PMID:23017109
NCBI chr14:46,620,982...46,628,126
Ensembl chr14:46,620,977...46,628,126
G
Bmt2
base methyltransferase of 25S rRNA 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of BMT2 mRNA
CTD
PMID:36117858
NCBI chr 6:13,625,674...13,677,965
Ensembl chr 6:13,625,672...13,677,965
G
Bnip3
BCL2/adenovirus E1B interacting protein 3
increases expression
ISO
Maneb results in increased expression of BNIP3 mRNA; Maneb results in increased expression of BNIP3 protein
CTD
PMID:18266926
NCBI chr 7:138,492,565...138,511,235
Ensembl chr 7:138,492,565...138,511,248
G
Bnip3l
BCL2/adenovirus E1B interacting protein 3-like
increases expression
ISO
Maneb results in increased expression of BNIP3L mRNA
CTD
PMID:18266926
NCBI chr14:67,222,688...67,246,580
Ensembl chr14:67,222,688...67,246,326
G
Braf
Braf transforming gene
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of BRAF mRNA
CTD
PMID:36117858
NCBI chr 6:39,580,171...39,702,592
Ensembl chr 6:39,580,171...39,702,397
G
Brf1
BRF1, RNA polymerase III transcription initiation factor 90 kDa subunit
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of BRF1 mRNA
CTD
PMID:18386188
NCBI chr12:112,919,251...112,964,327
Ensembl chr12:112,923,705...112,964,324
G
Brsk2
BR serine/threonine kinase 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of BRSK2 mRNA
CTD
PMID:36117858
NCBI chr 7:141,503,488...141,557,981
Ensembl chr 7:141,503,488...141,557,984
G
Btbd3
BTB domain containing 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of BTBD3 mRNA; [Maneb co-treated with Paraquat] results in increased expression of BTBD3 mRNA
CTD
PMID:36117858
NCBI chr 2:138,098,478...138,129,344
Ensembl chr 2:138,098,485...138,431,212
G
C1qtnf4
C1q and tumor necrosis factor related protein 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of C1QTNF4 mRNA
CTD
PMID:36117858
NCBI chr 2:90,713,132...90,720,870
Ensembl chr 2:90,716,204...90,720,869
G
C2cd5
C2 calcium-dependent domain containing 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of C2CD5 mRNA
CTD
PMID:36117858
NCBI chr 6:142,956,646...143,045,878
Ensembl chr 6:142,956,646...143,045,867
G
Cacna1c
calcium channel, voltage-dependent, L type, alpha 1C subunit
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CACNA1C mRNA
CTD
PMID:36117858
NCBI chr 6:118,564,201...119,174,345
Ensembl chr 6:118,564,201...119,173,851
G
Cacna1e
calcium channel, voltage-dependent, R type, alpha 1E subunit
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of CACNA1E mRNA
CTD
PMID:22563483
NCBI chr 1:154,266,552...154,760,374
Ensembl chr 1:154,266,477...154,760,247
G
Cacnb2
calcium channel, voltage-dependent, beta 2 subunit
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CACNB2 mRNA
CTD
PMID:36117858
NCBI chr 2:14,608,672...14,993,622
Ensembl chr 2:14,607,899...14,992,719
G
Cacng4
calcium channel, voltage-dependent, gamma subunit 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CACNG4 mRNA
CTD
PMID:36117858
NCBI chr11:107,623,183...107,685,532
Ensembl chr11:107,623,183...107,685,383
G
Cacybp
calcyclin binding protein
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of CACYBP mRNA
CTD
PMID:18386188
NCBI chr 1:160,029,171...160,040,391
Ensembl chr 1:160,029,937...160,040,445
G
Cadps2
Ca2+-dependent activator protein for secretion 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CADPS2 mRNA
CTD
PMID:36117858
NCBI chr 6:23,262,765...23,840,662
Ensembl chr 6:23,262,772...23,839,420
G
Calb2
calbindin 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CALB2 mRNA
CTD
PMID:36117858
NCBI chr 8:110,869,158...110,894,844
Ensembl chr 8:110,864,134...110,894,842
G
Calm1
calmodulin 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA]
CTD
PMID:23963992
NCBI chr12:100,165,694...100,176,083
Ensembl chr12:100,165,694...100,176,073
G
Calm2
calmodulin 2
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of CALM2 mRNA
CTD
PMID:18386188
NCBI chr17:87,740,829...87,754,363
Ensembl chr17:87,740,840...87,754,363
G
Caln1
calneuron 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CALN1 mRNA
CTD
PMID:36117858
NCBI chr 5:130,398,245...130,876,253
Ensembl chr 5:130,398,296...130,876,253
G
Camk4
calcium/calmodulin-dependent protein kinase IV
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CAMK4 mRNA; [Maneb co-treated with Paraquat] results in increased expression of CAMK4 mRNA
CTD
PMID:36117858
NCBI chr18:33,067,995...33,328,820
Ensembl chr18:33,067,984...33,324,281
G
Camp
cathelicidin antimicrobial peptide
multiple interactions
EXP ISO
[Paraquat co-treated with Maneb] affects the expression of CAMP mRNA [Paraquat co-treated with Maneb] results in decreased expression of CAMP mRNA
CTD
PMID:22563483 PMID:27460631
NCBI chr 9:109,676,445...109,678,524
Ensembl chr 9:109,676,447...109,678,685
G
Capn11
calpain 11
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of CAPN11 mRNA
CTD
PMID:22563483
NCBI chr17:45,941,117...45,970,400
Ensembl chr17:45,941,130...45,970,251
G
Capn15
calpain 15
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of CAPN15 mRNA
CTD
PMID:36117858
NCBI chr17:26,177,338...26,204,753
Ensembl chr17:26,177,338...26,204,770
G
Car14
carbonic anhydrase 14
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CAR14 mRNA
CTD
PMID:36117858
NCBI chr 3:95,805,080...95,812,443
Ensembl chr 3:95,805,080...95,812,003
G
Car7
carbonic anhydrase 7
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CAR7 mRNA
CTD
PMID:36117858
NCBI chr 8:105,261,326...105,276,979
Ensembl chr 8:105,261,321...105,276,975
G
Carmil3
capping protein regulator and myosin 1 linker 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CARMIL3 mRNA
CTD
PMID:36117858
NCBI chr14:55,728,108...55,745,729
Ensembl chr14:55,728,108...55,745,729
G
Casp1
caspase 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased cleavage of CASP1 protein; [Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA; [Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased cleavage of CASP1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA]
CTD
PMID:23963992 PMID:32375810 PMID:34052309
NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290
G
Casp3
caspase 3
increases activity multiple interactions
ISO
Maneb results in increased activity of CASP3 protein 3-(4-(morpholin-4-yl)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)benzonitrile inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP3 protein modified form]; [Paraquat co-treated with Maneb] results in increased expression of CASP3 protein modified form; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP3 protein modified form]; Plant Extracts inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP3 protein modified form]
CTD
PMID:22824503 PMID:34897981
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
G
Casp7
caspase 7
increases activity
ISO
Maneb results in increased activity of CASP7 protein
CTD
PMID:22824503
NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776
G
Casp8
caspase 8
increases activity
ISO
Maneb results in increased activity of CASP8 protein
CTD
PMID:22824503
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
G
Casp9
caspase 9
multiple interactions increases activity
EXP ISO
[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA; [Paraquat co-treated with Maneb] results in increased expression of CASP9 protein; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP9 protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP9 protein] Maneb results in increased activity of CASP9 protein
CTD
PMID:20964710 PMID:22824503 PMID:23963992
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
G
Casq2
calsequestrin 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of CASQ2 mRNA
CTD
PMID:36117858
NCBI chr 3:101,993,731...102,053,830
Ensembl chr 3:101,993,731...102,053,830
G
Castor2
cytosolic arginine sensor for mTORC1 subunit 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GATSL2 mRNA
CTD
PMID:36117858
NCBI chr 5:134,128,587...134,170,621
Ensembl chr 5:134,128,550...134,173,182
G
Cat
catalase
decreases activity multiple interactions
EXP ISO
Maneb results in decreased activity of CAT protein [Maneb co-treated with Paraquat] results in increased expression of CAT mRNA
CTD
PMID:26210702 PMID:28322069 PMID:29859004
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
G
Ccdc148
coiled-coil domain containing 148
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CCDC148 mRNA
CTD
PMID:36117858
NCBI chr 2:58,701,637...58,991,167
Ensembl chr 2:58,711,082...58,991,027
G
Ccdc6
coiled-coil domain containing 6
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CCDC6 mRNA
CTD
PMID:36117858
NCBI chr10:69,932,709...70,029,030
Ensembl chr10:69,932,951...70,029,030
G
Ccdc88a
coiled coil domain containing 88A
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of CCDC88A mRNA
CTD
PMID:22563483
NCBI chr11:29,323,521...29,460,808
Ensembl chr11:29,323,658...29,460,808
G
Ccdc88c
coiled-coil domain containing 88C
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CCDC88C mRNA
CTD
PMID:36117858
NCBI chr12:100,877,778...100,995,610
Ensembl chr12:100,877,782...100,995,315
G
Ccdc92
coiled-coil domain containing 92
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CCDC92 mRNA
CTD
PMID:36117858
NCBI chr 5:124,911,482...124,939,261
Ensembl chr 5:124,911,482...124,939,488
G
Cck
cholecystokinin
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CCK mRNA
CTD
PMID:36117858
NCBI chr 9:121,318,890...121,324,728
Ensembl chr 9:121,318,890...121,324,760
G
Ccl19
C-C motif chemokine ligand 19
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of CCL19 mRNA
CTD
PMID:22563483
NCBI chr 4:42,754,525...42,756,558
Ensembl chr 4:42,754,525...42,756,577
G
Ccl21a
C-C motif chemokine ligand 21 (serine)
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of CCL21 mRNA; [Paraquat co-treated with Maneb] affects the expression of CCL21A mRNA
CTD
PMID:22563483
NCBI chr 4:42,772,860...42,773,991
Ensembl chr 4:42,772,860...42,773,993
G
Ccl21d
C-C motif chemokine ligand 21D
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of CCL21D mRNA
CTD
PMID:22563483
NCBI chr 4:41,896,187...41,904,743
Ensembl chr 4:41,903,610...41,904,743
G
Ccnd1
cyclin D1
multiple interactions
EXP ISO
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of CCND1 protein [Maneb co-treated with Paraquat] results in decreased expression of CCND1 mRNA
CTD
PMID:19883720 PMID:29859004
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
G
Ccnd2
cyclin D2
multiple interactions
ISO
[Maneb co-treated with Paraquat] results in decreased expression of CCND2 mRNA
CTD
PMID:29859004
NCBI chr 6:127,102,125...127,131,913
Ensembl chr 6:127,102,125...127,129,156
G
Ccp110
centriolar coiled coil protein 110
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CCP110 mRNA
CTD
PMID:36117858
NCBI chr 7:118,311,740...118,336,247
Ensembl chr 7:118,311,775...118,336,247
G
Cd24a
CD24a antigen
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of CD24A mRNA
CTD
PMID:36117858
NCBI chr10:43,454,433...43,460,261
Ensembl chr10:43,454,280...43,460,261
G
Cd34
CD34 antigen
increases expression
ISO
Maneb results in increased expression of CD34
CTD
PMID:25803990
NCBI chr 1:194,621,239...194,643,587
Ensembl chr 1:194,621,127...194,643,587
G
Cd68
CD68 antigen
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of CD68 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CD68 mRNA]
CTD
PMID:32169474
NCBI chr11:69,555,039...69,556,996
Ensembl chr11:69,555,039...69,556,979
G
Cdca7
cell division cycle associated 7
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of CDCA7 mRNA
CTD
PMID:36117858
NCBI chr 2:72,306,540...72,317,237
Ensembl chr 2:72,306,503...72,317,237
G
Cdh7
cadherin 7, type 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CDH7 mRNA
CTD
PMID:36117858
NCBI chr 1:109,909,967...110,073,002
Ensembl chr 1:109,910,161...110,067,887
G
Cdhr4
cadherin-related family member 4
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of CDHR4 mRNA
CTD
PMID:22563483
NCBI chr 9:107,869,656...107,876,880
Ensembl chr 9:107,869,696...107,876,883
G
Cdipt
CDP-diacylglycerol--inositol 3-phosphatidyltransferase
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of CDIPT mRNA
CTD
PMID:18386188
NCBI chr 7:126,575,630...126,579,671
Ensembl chr 7:126,575,086...126,579,673
G
Cdk2
cyclin dependent kinase 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA]
CTD
PMID:23963992
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
G
Cdk5r1
cyclin dependent kinase 5, regulatory subunit 1
multiple interactions
EXP
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5R1 mRNA
CTD
PMID:23017109
NCBI chr11:80,367,849...80,372,010
Ensembl chr11:80,367,849...80,372,010
G
Cdk5rap1
CDK5 regulatory subunit associated protein 1
multiple interactions
EXP
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5RAP1 mRNA
CTD
PMID:23017109
NCBI chr 2:154,063,931...154,216,170
Ensembl chr 2:154,177,300...154,214,930
G
Cdk5rap2
CDK5 regulatory subunit associated protein 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA; LRRK2 protein mutant form inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]; SNCA protein inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]
CTD
PMID:23017109
NCBI chr 4:70,135,092...70,328,672
Ensembl chr 4:70,135,093...70,328,680
G
Cdkn1a
cyclin dependent kinase inhibitor 1A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of CDKN1A mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDKN1A mRNA]
CTD
PMID:23963992
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
G
Cdkn2a
cyclin dependent kinase inhibitor 2A
multiple interactions increases expression
ISO
[Maneb co-treated with Paraquat] results in increased expression of CDKN2A mRNA Maneb results in increased expression of CDKN2A mRNA
CTD
PMID:29859004
NCBI chr 4:89,192,710...89,212,856
Ensembl chr 4:89,192,708...89,212,890
G
Cdo1
cysteine dioxygenase 1, cytosolic
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CDO1 mRNA
CTD
PMID:36117858
NCBI chr18:46,846,260...46,861,569
Ensembl chr18:46,846,260...46,861,462
G
Cds1
CDP-diacylglycerol synthase 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of CDS1 mRNA
CTD
PMID:36117858
NCBI chr 5:101,913,001...101,971,724
Ensembl chr 5:101,912,996...101,971,724
G
Cebpd
CCAAT/enhancer binding protein delta
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of CEBPD mRNA
CTD
PMID:22563483
NCBI chr16:15,705,150...15,707,409
Ensembl chr16:15,705,150...15,708,895
G
Celf3
CUGBP, Elav-like family member 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CELF3 mRNA
CTD
PMID:36117858
NCBI chr 3:94,385,581...94,405,822
Ensembl chr 3:94,385,602...94,399,505
G
Cend1
cell cycle exit and neuronal differentiation 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CEND1 mRNA
CTD
PMID:36117858
NCBI chr 7:141,006,359...141,009,475
Ensembl chr 7:141,006,359...141,009,404
G
Cenpc1
centromere protein C1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CENPC1 mRNA
CTD
PMID:36117858
NCBI chr 5:86,159,877...86,214,325
Ensembl chr 5:86,159,883...86,213,442
G
Cep290
centrosomal protein 290
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of CEP290 mRNA
CTD
PMID:22563483
NCBI chr10:100,323,410...100,409,527
Ensembl chr10:100,323,420...100,410,702
G
Cep295
centrosomal protein 295
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CEP295 mRNA
CTD
PMID:36117858
NCBI chr 9:15,228,210...15,269,145
Ensembl chr 9:15,228,211...15,269,084
G
Cercam
cerebral endothelial cell adhesion molecule
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CERCAM mRNA
CTD
PMID:36117858
NCBI chr 2:29,735,442...29,772,857
Ensembl chr 2:29,759,176...29,772,852
G
Chaf1a
chromatin assembly factor 1, subunit A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CHAF1A mRNA
CTD
PMID:36117858
NCBI chr17:56,347,404...56,375,027
Ensembl chr17:56,347,439...56,379,289
G
Chga
chromogranin A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CHGA mRNA
CTD
PMID:36117858
NCBI chr12:102,521,200...102,531,286
Ensembl chr12:102,521,228...102,531,287
G
Chil3
chitinase-like 3
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of CHIL3 mRNA
CTD
PMID:29568078 PMID:32375810
NCBI chr 3:106,054,870...106,074,852
Ensembl chr 3:106,054,870...106,074,880
G
Chpf2
chondroitin polymerizing factor 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CHPF2 mRNA
CTD
PMID:36117858
NCBI chr 5:24,788,950...24,799,396
Ensembl chr 5:24,791,739...24,799,554
G
Chrdl1
chordin-like 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CHRDL1 mRNA
CTD
PMID:36117858
NCBI chr X:142,068,670...142,177,282
Ensembl chr X:142,068,670...142,177,258
G
Chrm2
cholinergic receptor, muscarinic 2, cardiac
multiple interactions
EXP
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CHRM2 mRNA
CTD
PMID:23017109
NCBI chr 6:36,364,928...36,505,573
Ensembl chr 6:36,365,019...36,505,349
G
Chuk
conserved helix-loop-helix ubiquitous kinase
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased phosphorylation of CHUK protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of CHUK protein]
CTD
PMID:29568078
NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919
G
Ciart
circadian associated repressor of transcription
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CIART mRNA
CTD
PMID:36117858
NCBI chr 3:95,785,812...95,790,012
Ensembl chr 3:95,785,815...95,789,563
G
Cimap1b
ciliary microtubule associated protein 1B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ODF3B mRNA
CTD
PMID:36117858
NCBI chr15:89,261,652...89,263,817
Ensembl chr15:89,261,652...89,263,790
G
Cirbp
cold inducible RNA binding protein
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of CIRBP mRNA
CTD
PMID:18386188
NCBI chr10:80,001,824...80,008,620
Ensembl chr10:80,001,819...80,008,620
G
Ckmt1
creatine kinase, mitochondrial 1, ubiquitous
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CKMT1 mRNA
CTD
PMID:36117858
NCBI chr 2:121,188,257...121,194,218
Ensembl chr 2:121,188,195...121,194,218
G
Cks1b
CDC28 protein kinase 1b
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of CKS1B mRNA
CTD
PMID:36117858
NCBI chr 3:89,322,779...89,325,598
Ensembl chr 3:89,322,779...89,325,690
G
Clca1
chloride channel accessory 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CLCA1 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CLCA1 mRNA]
CTD
PMID:23963992
NCBI chr 3:144,710,298...144,738,537
Ensembl chr 3:144,709,578...144,738,537
G
Clcn5
chloride channel, voltage-sensitive 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CLCN5 mRNA
CTD
PMID:36117858
NCBI chr X:7,020,049...7,185,597
Ensembl chr X:7,020,049...7,185,597
G
Clcn7
chloride channel, voltage-sensitive 7
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of CLCN7 mRNA
CTD
PMID:36117858
NCBI chr17:25,352,353...25,381,077
Ensembl chr17:25,352,365...25,381,078
G
Cldn12
claudin 12
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CLDN12 mRNA
CTD
PMID:36117858
NCBI chr 5:5,555,109...5,564,953
Ensembl chr 5:5,539,537...5,564,958
G
Clec16a
C-type lectin domain family 16, member A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of CLEC16A mRNA
CTD
PMID:36117858
NCBI chr16:10,363,173...10,562,742
Ensembl chr16:10,363,203...10,562,742
G
Clip2
CAP-GLY domain containing linker protein 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CLIP2 mRNA
CTD
PMID:36117858
NCBI chr 5:134,518,237...134,582,922
Ensembl chr 5:134,518,237...134,581,288
G
Clip4
CAP-GLY domain containing linker protein family, member 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CLIP4 mRNA
CTD
PMID:36117858
NCBI chr17:72,076,674...72,171,205
Ensembl chr17:72,075,468...72,171,268
G
Clmp
CXADR-like membrane protein
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CLMP mRNA
CTD
PMID:36117858
NCBI chr 9:40,596,975...40,696,849
Ensembl chr 9:40,597,258...40,696,615
G
Clu
clusterin
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of CLU mRNA
CTD
PMID:18386188
NCBI chr14:66,206,093...66,218,992
Ensembl chr14:66,205,932...66,218,996
G
Cmbl
carboxymethylenebutenolidase homolog
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CMBL mRNA
CTD
PMID:36117858
NCBI chr15:31,565,314...31,590,266
Ensembl chr15:31,565,535...31,590,265
G
Cnih2
cornichon family AMPA receptor auxiliary protein 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of CNIH2 mRNA
CTD
PMID:36117858
NCBI chr19:5,142,896...5,148,549
Ensembl chr19:5,142,896...5,148,549
G
Cnih3
cornichon family AMPA receptor auxiliary protein 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CNIH3 mRNA
CTD
PMID:36117858
NCBI chr 1:181,178,024...181,288,059
Ensembl chr 1:181,180,193...181,288,206
G
Cntrob
centrobin, centrosomal BRCA2 interacting protein
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CNTROB mRNA
CTD
PMID:36117858
NCBI chr11:69,188,735...69,214,720
Ensembl chr11:69,190,313...69,214,601
G
Col14a1
collagen, type XIV, alpha 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of COL14A1 mRNA
CTD
PMID:36117858
NCBI chr15:55,171,040...55,384,199
Ensembl chr15:55,171,146...55,384,199
G
Col1a1
collagen, type I, alpha 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of COL1A1 mRNA
CTD
PMID:36117858
NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868
G
Cope
coatomer protein complex, subunit epsilon
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of COPE mRNA
CTD
PMID:18386188
NCBI chr 8:70,755,417...70,765,652
Ensembl chr 8:70,755,168...70,765,643
G
Cox5a
cytochrome c oxidase subunit 5A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein]
CTD
PMID:23562983
NCBI chr 9:57,423,012...57,439,710
Ensembl chr 9:57,428,557...57,439,709
G
Cox6a1
cytochrome c oxidase subunit 6A1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of COX6A1 mRNA
CTD
PMID:18386188
NCBI chr 5:115,483,711...115,487,017
Ensembl chr 5:115,483,701...115,487,040
G
Cox6b1
cytochrome c oxidase, subunit 6B1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA]
CTD
PMID:23963992
NCBI chr 7:30,316,396...30,325,539
Ensembl chr 7:30,316,286...30,325,576
G
Cox7a1
cytochrome c oxidase subunit 7A1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of COX7A1 mRNA
CTD
PMID:36117858
NCBI chr 7:29,883,596...29,885,455
Ensembl chr 7:29,883,569...29,885,503
G
Cox7a2
cytochrome c oxidase subunit 7A2
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of COX7A2 mRNA
CTD
PMID:18386188
NCBI chr 9:79,662,523...79,667,135
Ensembl chr 9:79,662,643...79,667,160
G
Cox7a2l
cytochrome c oxidase subunit 7A2 like
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of COX7A2L mRNA
CTD
PMID:18386188
NCBI chr17:83,809,346...83,821,762
Ensembl chr17:83,809,347...83,824,759
G
Cplx1
complexin 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of CPLX1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of CPLX1 protein
CTD
PMID:17532186
NCBI chr 5:108,666,420...108,697,893
Ensembl chr 5:108,666,420...108,697,890
G
Cpne4
copine IV
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CPNE4 mRNA
CTD
PMID:36117858
NCBI chr 9:104,443,900...104,911,747
Ensembl chr 9:104,424,485...104,911,743
G
Cpne5
copine V
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CPNE5 mRNA
CTD
PMID:36117858
NCBI chr17:29,375,495...29,456,764
Ensembl chr17:29,374,530...29,457,141
G
Cpne6
copine VI
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CPNE6 mRNA
CTD
PMID:36117858
NCBI chr14:55,747,902...55,754,892
Ensembl chr14:55,747,902...55,754,888
G
Cpne7
copine VII
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CPNE7 mRNA
CTD
PMID:36117858
NCBI chr 8:123,844,054...123,861,924
Ensembl chr 8:123,844,113...123,861,921
G
Creb1
cAMP responsive element binding protein 1
multiple interactions
EXP ISO
[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA] [Paraquat co-treated with Maneb] results in decreased expression of and results in decreased phosphorylation of CREB1 protein; [Paraquat co-treated with Maneb] results in decreased expression of CREB1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of CREB1 protein; [Paraquat co-treated with Maneb] results in decreased expression of CREB1 protein modified form; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of and results in decreased phosphorylation of CREB1 protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of CREB1 mRNA]
CTD
PMID:23963992 PMID:27460631 PMID:33368748
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
G
Crip2
cysteine rich protein 2
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of CRIP2 mRNA
CTD
PMID:18386188
NCBI chr12:113,103,856...113,109,126
Ensembl chr12:113,103,856...113,109,126
G
Crlf1
cytokine receptor-like factor 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CRLF1 mRNA
CTD
PMID:36117858
NCBI chr 8:70,945,798...70,956,728
Ensembl chr 8:70,945,808...70,956,731
G
Crlf2
cytokine receptor-like factor 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CRLF2 mRNA; [Paraquat co-treated with Maneb] affects the expression of CRLF2 mRNA
CTD
PMID:22563483 PMID:36117858
NCBI chr 5:109,702,575...109,707,301
Ensembl chr 5:109,702,575...109,706,859
G
Crot
carnitine O-octanoyltransferase
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of CROT mRNA
CTD
PMID:18386188
NCBI chr 5:9,016,033...9,047,926
Ensembl chr 5:9,016,033...9,047,324
G
Csf1r
colony stimulating factor 1 receptor
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of CSF1R mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CSF1R mRNA]
CTD
PMID:32169474
NCBI chr18:61,238,644...61,264,211
Ensembl chr18:61,233,670...61,265,221
G
Csf2ra
colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage)
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of CSF2RA mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CSF2RA mRNA]
CTD
PMID:32169474
NCBI chr19:61,205,629...61,221,141
Ensembl chr19:61,212,395...61,216,867
G
Ctsl
cathepsin L
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of CTSL mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CTSL mRNA]
CTD
PMID:23963992
NCBI chr13:64,509,704...64,518,586
Ensembl chr13:64,507,151...64,518,704
G
Cttnbp2
cortactin binding protein 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CTTNBP2 mRNA
CTD
PMID:36117858
NCBI chr 6:18,366,470...18,515,216
Ensembl chr 6:18,366,477...18,514,842
G
Cul5
cullin 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of CUL5 mRNA
CTD
PMID:36117858
NCBI chr 9:53,525,881...53,578,807
Ensembl chr 9:53,525,882...53,581,314
G
Cybb
cytochrome b-245, beta polypeptide
multiple interactions
ISO EXP
[Paraquat co-treated with Maneb] results in increased expression of CYBB mRNA; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB mRNA]; diphenyleneiodonium inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB mRNA] [Maneb co-treated with Paraquat] results in increased expression of CYBB protein; [Paraquat co-treated with Maneb] results in increased expression of CYBB protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CYBB protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB protein]
CTD
PMID:29568078 PMID:30797899 PMID:32375810 PMID:34052309
NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010
G
Cyc1
cytochrome c-1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of CYC1 mRNA
CTD
PMID:18386188
NCBI chr15:76,227,711...76,230,460
Ensembl chr15:76,227,723...76,230,460
G
Cyp1a1
cytochrome P450, family 1, subfamily a, polypeptide 1
increases activity increases expression decreases expression
ISO
Maneb results in increased activity of CYP1A1 protein Maneb results in increased expression of CYP1A1 mRNA; Maneb results in increased expression of CYP1A1 protein Maneb results in decreased expression of CYP1A1 mRNA
CTD
PMID:20888808 PMID:32194361
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
G
Cyp1a2
cytochrome P450, family 1, subfamily a, polypeptide 2
multiple interactions
ISO
[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein; [Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein]; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA]
CTD
PMID:23159886
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
G
Cyp2c38
cytochrome P450, family 2, subfamily c, polypeptide 38
decreases expression
ISO
Maneb results in decreased expression of CYP2C19 protein
CTD
PMID:32194361
NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519
G
Cyp2d22
cytochrome P450, family 2, subfamily d, polypeptide 22
multiple interactions decreases expression
EXP
Ketoconazole inhibits the reaction [Maneb results in decreased expression of CYP2D22 protein]
CTD
PMID:22334051
NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461
G
Cyp2e1
cytochrome P450, family 2, subfamily e, polypeptide 1
decreases activity multiple interactions increases activity increases expression
ISO EXP
Maneb results in decreased activity of CYP2E1 protein [Maneb co-treated with Paraquat] results in increased expression of CYP2E1 mRNA; [Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein; [Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA] Maneb results in increased activity of CYP2E1 protein [Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein; [Maneb co-treated with Paraquat] results in increased expression of CYP2E1 mRNA; Acetylcysteine inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein]; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Acetylcysteine inhibits the reaction [Maneb results in increased expression of and results in increased activity of CYP2E1 protein]; Acetylcysteine inhibits the reaction [Maneb results in increased expression of CYP2E1 mRNA]; Maneb results in increased expression of and results in increased activity of CYP2E1 protein; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of and results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [Maneb results in increased expression of CYP2E1 mRNA] Maneb results in increased expression of CYP2E1 mRNA; Maneb results in increased expression of CYP2E1 protein
CTD
PMID:11043497 PMID:16510128 PMID:20888808 PMID:20964710 PMID:23159886
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
G
Cyp7a1
cytochrome P450, family 7, subfamily a, polypeptide 1
decreases expression
ISO
Maneb results in decreased expression of CYP7A1 mRNA
CTD
PMID:32194361
NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633
G
Dab1
disabled 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DAB1 mRNA
CTD
PMID:36117858
NCBI chr 4:103,476,425...104,602,041
Ensembl chr 4:103,476,556...104,602,041
G
Dact3
dishevelled-binding antagonist of beta-catenin 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DACT3 mRNA
CTD
PMID:36117858
NCBI chr 7:16,609,242...16,621,226
Ensembl chr 7:16,609,242...16,621,387
G
Dap3
death associated protein 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of DAP3 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DAP3 mRNA]
CTD
PMID:23963992
NCBI chr 3:88,828,110...88,858,504
Ensembl chr 3:88,828,110...88,858,488
G
Dbi
diazepam binding inhibitor
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of DBI mRNA
CTD
PMID:18386188
NCBI chr 1:120,041,010...120,048,826
Ensembl chr 1:120,041,010...120,048,808
G
Dbn1
drebrin 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of DBN1 mRNA
CTD
PMID:36117858
NCBI chr13:55,621,241...55,635,874
Ensembl chr13:55,621,242...55,635,924
G
Dcaf12l1
DDB1 and CUL4 associated factor 12-like 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DCAF12L1 mRNA
CTD
PMID:36117858
NCBI chr X:43,875,444...43,879,074
Ensembl chr X:43,875,447...43,879,074
G
Dcaf5
DDB1 and CUL4 associated factor 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DCAF5 mRNA
CTD
PMID:36117858
NCBI chr12:80,382,622...80,483,375
Ensembl chr12:80,382,622...80,483,375
G
Dcaf6
DDB1 and CUL4 associated factor 6
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DCAF6 mRNA
CTD
PMID:36117858
NCBI chr 1:165,157,069...165,288,475
Ensembl chr 1:165,156,267...165,288,044
G
Dclre1b
DNA cross-link repair 1B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DCLRE1B mRNA
CTD
PMID:36117858
NCBI chr 3:103,707,921...103,716,703
Ensembl chr 3:103,707,921...103,716,760
G
Ddah1
dimethylarginine dimethylaminohydrolase 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DDAH1 mRNA
CTD
PMID:36117858
NCBI chr 3:145,464,447...145,600,032
Ensembl chr 3:145,464,430...145,600,032
G
Ddit4
DNA-damage-inducible transcript 4
increases expression
ISO
Maneb results in increased expression of DDIT4 protein
CTD
PMID:24764117
NCBI chr10:59,785,497...59,787,592
Ensembl chr10:59,785,491...59,787,656
G
Ddx20
DEAD box helicase 20
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DDX20 mRNA
CTD
PMID:36117858
NCBI chr 3:105,585,586...105,595,104
Ensembl chr 3:105,585,586...105,594,890
G
Ddx25
DEAD box helicase 25
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DDX25 mRNA
CTD
PMID:36117858
NCBI chr 9:35,453,144...35,469,766
Ensembl chr 9:35,447,943...35,469,824
G
Ddx5
DEAD box helicase 5
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of DDX5 mRNA
CTD
PMID:18386188
NCBI chr11:106,671,181...106,680,011
Ensembl chr11:106,671,181...106,680,011
G
Dennd6b
DENN domain containing 6B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DENND6B mRNA
CTD
PMID:36117858
NCBI chr15:89,066,416...89,080,793
Ensembl chr15:89,066,416...89,080,699
G
Depdc5
DEP domain containing 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DEPDC5 mRNA
CTD
PMID:36117858
NCBI chr 5:33,020,996...33,151,581
Ensembl chr 5:33,021,045...33,151,580
G
Desi1
desumoylating isopeptidase 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DESI1 mRNA
CTD
PMID:36117858
NCBI chr15:81,876,724...81,900,364
Ensembl chr15:81,876,724...81,918,063
G
Dgke
diacylglycerol kinase, epsilon
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DGKE mRNA
CTD
PMID:36117858
NCBI chr11:88,926,005...88,951,644
Ensembl chr11:88,926,005...88,957,676
G
Dgkg
diacylglycerol kinase, gamma
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DGKG mRNA
CTD
PMID:36117858
NCBI chr16:22,285,318...22,476,051
Ensembl chr16:22,287,211...22,475,971
G
Dgki
diacylglycerol kinase, iota
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of DGKI mRNA
CTD
PMID:22563483
NCBI chr 6:36,814,316...37,281,034
Ensembl chr 6:36,822,957...37,277,119
G
Dgkq
diacylglycerol kinase, theta
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DGKQ mRNA
CTD
PMID:36117858
NCBI chr 5:108,794,910...108,808,696
Ensembl chr 5:108,794,559...108,817,538
G
Dhx34
DExH-box helicase 34
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DHX34 mRNA
CTD
PMID:36117858
NCBI chr 7:15,931,145...15,956,005
Ensembl chr 7:15,931,072...15,955,962
G
Dio1
deiodinase, iodothyronine, type I
decreases activity
ISO
Maneb results in decreased activity of DIO1 protein
CTD
PMID:29228274
NCBI chr 4:107,148,662...107,164,365
Ensembl chr 4:107,148,662...107,164,366
G
Dip2b
disco interacting protein 2 homolog B
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of DIP2B mRNA
CTD
PMID:22563483
NCBI chr15:99,935,119...100,117,355
Ensembl chr15:99,936,545...100,117,354
G
Disc1
disrupted in schizophrenia 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DISC1 mRNA
CTD
PMID:36117858
NCBI chr 8:125,773,928...125,991,882
Ensembl chr 8:125,780,934...125,988,597
G
Dlg3
discs large MAGUK scaffold protein 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of DLG3 mRNA
CTD
PMID:36117858
NCBI chr X:99,811,200...99,862,016
Ensembl chr X:99,811,328...99,862,016
G
Dll1
delta like canonical Notch ligand 1
multiple interactions
EXP
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DLL1 mRNA
CTD
PMID:23017109
NCBI chr17:15,587,616...15,597,275
Ensembl chr17:15,587,616...15,597,134
G
Dlst
dihydrolipoamide S-succinyltransferase
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of DLST protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DLST protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DLST protein]
CTD
PMID:23562983
NCBI chr12:85,157,597...85,180,865
Ensembl chr12:85,157,607...85,181,619
G
Dmrta2
doublesex and mab-3 related transcription factor like family A2
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of DMRTA2 mRNA
CTD
PMID:22563483
NCBI chr 4:109,835,222...109,840,896
Ensembl chr 4:109,835,250...109,840,884
G
Dnajb6
DnaJ heat shock protein family (Hsp40) member B6
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of DNAJB6 mRNA
CTD
PMID:18386188
NCBI chr 5:29,940,896...29,991,476
Ensembl chr 5:29,940,686...30,023,132
G
Dnm2
dynamin 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA]
CTD
PMID:23963992
NCBI chr 9:21,336,167...21,419,055
Ensembl chr 9:21,336,204...21,419,055
G
Dock10
dedicator of cytokinesis 10
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DOCK10 mRNA
CTD
PMID:36117858
NCBI chr 1:80,478,785...80,736,482
Ensembl chr 1:80,478,790...80,736,244
G
Dok7
docking protein 7
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DOK7 mRNA
CTD
PMID:36117858
NCBI chr 5:35,213,922...35,245,183
Ensembl chr 5:35,214,110...35,245,183
G
Dph6
diphthamine biosynthesis 6
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DPH6 mRNA
CTD
PMID:36117858
NCBI chr 2:114,346,897...114,485,518
Ensembl chr 2:114,346,897...114,485,445
G
Dpy19l3
dpy-19 like C-mannosyltransferase 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DPY19L3 mRNA
CTD
PMID:36117858
NCBI chr 7:35,384,925...35,453,879
Ensembl chr 7:35,384,590...35,453,879
G
Dpyd
dihydropyrimidine dehydrogenase
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of DPYD mRNA
CTD
PMID:36117858
NCBI chr 3:118,355,758...119,226,573
Ensembl chr 3:118,355,778...119,226,573
G
Drd2
dopamine receptor D2
multiple interactions
EXP
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD2 mRNA
CTD
PMID:23017109
NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477
G
Drd4
dopamine receptor D4
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of DRD4 protein
CTD
PMID:22563483
NCBI chr 7:140,871,931...140,874,868
Ensembl chr 7:140,871,919...140,876,377
G
Drd5
dopamine receptor D5
multiple interactions
EXP
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD5 mRNA
CTD
PMID:23017109
NCBI chr 5:38,476,742...38,479,868
Ensembl chr 5:38,476,710...38,479,861
G
Drp2
dystrophin related protein 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DRP2 mRNA
CTD
PMID:36117858
NCBI chr X:133,304,868...133,357,323
Ensembl chr X:133,305,300...133,357,322
G
Dusp1
dual specificity phosphatase 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of DUSP1 mRNA
CTD
PMID:36117858
NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102
G
Dut
deoxyuridine triphosphatase
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DUT mRNA; [Maneb co-treated with Paraquat] results in increased expression of DUT mRNA
CTD
PMID:36117858
NCBI chr 2:125,089,168...125,100,969
Ensembl chr 2:125,089,110...125,100,528
G
Dync1i1
dynein cytoplasmic 1 intermediate chain 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DYNC1I1 mRNA
CTD
PMID:36117858
NCBI chr 6:5,725,772...6,028,030
Ensembl chr 6:5,725,639...6,028,039
G
Dync2li1
dynein cytoplasmic 2 light intermediate chain 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of DYNC2LI1 mRNA
CTD
PMID:36117858
NCBI chr17:84,933,903...84,962,996
Ensembl chr17:84,933,924...84,963,016
G
Dyrk2
dual-specificity tyrosine phosphorylation regulated kinase 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of DYRK2 mRNA
CTD
PMID:36117858
NCBI chr10:118,691,507...118,725,144
Ensembl chr10:118,691,508...118,706,114
G
E2f1
E2F transcription factor 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA]
CTD
PMID:23963992
NCBI chr 2:154,401,320...154,411,812
Ensembl chr 2:154,401,327...154,411,812
G
Ecm2
extracellular matrix protein 2, female organ and adipocyte specific
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ECM2 mRNA
CTD
PMID:36117858
NCBI chr13:49,658,259...49,686,267
Ensembl chr13:49,658,286...49,686,265
G
Eef1a1
eukaryotic translation elongation factor 1 alpha 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of EEF1A1 mRNA
CTD
PMID:18386188
NCBI chr 9:78,385,735...78,389,006
Ensembl chr 9:78,385,731...78,396,433
G
Eef1g
eukaryotic translation elongation factor 1 gamma
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA]
CTD
PMID:23963992
NCBI chr19:8,944,405...8,955,544
Ensembl chr19:8,944,405...8,955,843
G
Efna3
ephrin A3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of EFNA3 mRNA
CTD
PMID:36117858
NCBI chr 3:89,221,200...89,231,359
Ensembl chr 3:89,221,206...89,230,272
G
Efnb1
ephrin B1
multiple interactions
EXP
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of EFNB1 mRNA
CTD
PMID:23017109
NCBI chr X:98,179,667...98,192,628
Ensembl chr X:98,179,736...98,192,597
G
Efnb3
ephrin B3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of EFNB3 mRNA
CTD
PMID:36117858
NCBI chr11:69,444,918...69,452,428
Ensembl chr11:69,444,918...69,451,031
G
Efr3b
EFR3 homolog B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of EFR3B mRNA
CTD
PMID:36117858
NCBI chr12:4,012,554...4,089,199
Ensembl chr12:4,012,554...4,088,915
G
Egfl8
EGF-like domain 8
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of EGFL8 mRNA
CTD
PMID:36117858
NCBI chr17:34,832,174...34,835,536
Ensembl chr17:34,832,323...34,834,945
G
Egr1
early growth response 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of EGR1 mRNA
CTD
PMID:36117858
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
G
Egr4
early growth response 4
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of EGR4 mRNA
CTD
PMID:22563483
NCBI chr 6:85,488,103...85,490,571
Ensembl chr 6:85,488,103...85,490,571
G
Eid2
EP300 interacting inhibitor of differentiation 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of EID2 mRNA
CTD
PMID:36117858
NCBI chr 7:27,967,306...27,968,593
Ensembl chr 7:27,967,306...27,968,697
G
Eif2ak4
eukaryotic translation initiation factor 2 alpha kinase 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of EIF2AK4 mRNA
CTD
PMID:36117858
NCBI chr 2:118,219,065...118,305,715
Ensembl chr 2:118,219,099...118,305,715
G
Eif4g2
eukaryotic translation initiation factor 4, gamma 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of EIF4G2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EIF4G2 mRNA]
CTD
PMID:23963992
NCBI chr 7:110,667,192...110,682,237
Ensembl chr 7:110,666,957...110,682,237
G
Elavl4
ELAV like RNA binding protein 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ELAVL4 mRNA
CTD
PMID:36117858
NCBI chr 4:110,060,934...110,209,127
Ensembl chr 4:110,060,919...110,209,106
G
Elfn2
leucine rich repeat and fibronectin type III, extracellular 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ELFN2 mRNA
CTD
PMID:36117858
NCBI chr15:78,551,531...78,603,056
Ensembl chr15:78,551,531...78,602,971
G
Elk1
ELK1, member of ETS oncogene family
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ELK1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ELK1 mRNA]
CTD
PMID:23963992
NCBI chr X:20,799,634...20,816,847
Ensembl chr X:20,799,634...20,816,847
G
Elof1
ELF1 homolog, elongation factor 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ELOF1 mRNA
CTD
PMID:36117858
NCBI chr 9:22,024,282...22,028,491
Ensembl chr 9:22,024,285...22,028,468
G
Elovl6
ELOVL fatty acid elongase 6
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ELOVL6 mRNA
CTD
PMID:36117858
NCBI chr 3:129,326,035...129,432,144
Ensembl chr 3:129,326,004...129,432,144
G
Emb
embigin
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of EMB mRNA
CTD
PMID:36117858
NCBI chr13:117,357,109...117,410,951
Ensembl chr13:117,345,072...117,410,951
G
Emx2os
Emx2 opposite strand/antisense transcript, non-protein coding
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of EMX2OS mRNA
CTD
PMID:36117858
NCBI chr19:59,413,536...59,447,067
Ensembl chr19:59,413,536...59,447,067
G
Endou
endonuclease, polyU-specific
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ENDOU mRNA
CTD
PMID:36117858
NCBI chr15:97,608,896...97,629,286
Ensembl chr15:97,608,896...97,629,220
G
Eno1
enolase 1, alpha non-neuron
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ENO1 protein; [Paraquat co-treated with Maneb] results in decreased expression of ENO1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of ENO1 protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ENO1 protein]
CTD
PMID:17532186 PMID:18386188 PMID:23562983
NCBI chr 4:150,321,165...150,333,336
Ensembl chr 4:150,321,178...150,333,336
G
Eno2
enolase 2, gamma neuronal
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ENO2 protein
CTD
PMID:23562983
NCBI chr 6:124,737,018...124,746,489
Ensembl chr 6:124,737,016...124,746,636
G
Enpp1
ectonucleotide pyrophosphatase/phosphodiesterase 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ENPP1 mRNA
CTD
PMID:36117858
NCBI chr10:24,513,812...24,588,057
Ensembl chr10:24,513,812...24,588,057
G
Epb41
erythrocyte membrane protein band 4.1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of EPB41 mRNA
CTD
PMID:36117858
NCBI chr 4:131,650,724...131,802,824
Ensembl chr 4:131,650,724...131,802,632
G
Epb41l4b
erythrocyte membrane protein band 4.1 like 4b
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of EPB41L4B mRNA
CTD
PMID:36117858
NCBI chr 4:56,991,977...57,143,753
Ensembl chr 4:56,991,972...57,143,437
G
Ephb6
Eph receptor B6
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of EPHB6 mRNA
CTD
PMID:36117858
NCBI chr 6:41,581,940...41,597,445
Ensembl chr 6:41,582,416...41,597,443
G
Epm2a
epilepsy, progressive myoclonic epilepsy, type 2 gene alpha
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of EPM2A mRNA; [Maneb co-treated with Paraquat] results in increased expression of EPM2A mRNA
CTD
PMID:36117858
NCBI chr10:11,218,435...11,335,408
Ensembl chr10:11,219,148...11,335,388
G
Epm2aip1
EPM2A interacting protein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of EPM2AIP1 mRNA
CTD
PMID:36117858
NCBI chr 9:111,100,913...111,108,161
Ensembl chr 9:111,100,997...111,108,161
G
Ercc2
excision repair cross-complementing rodent repair deficiency, complementation group 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ERCC2 mRNA
CTD
PMID:36117858
NCBI chr 7:19,115,942...19,129,619
Ensembl chr 7:19,115,935...19,129,619
G
Ercc6l2
excision repair cross-complementing rodent repair deficiency, complementation group 6 like 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ERCC6L2 mRNA
CTD
PMID:36117858
NCBI chr13:63,958,793...64,048,116
Ensembl chr13:63,963,054...64,048,116
G
Errfi1
ERBB receptor feedback inhibitor 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ERRFI1 mRNA
CTD
PMID:36117858
NCBI chr 4:150,938,253...150,953,346
Ensembl chr 4:150,938,376...150,953,349
G
Etl4
enhancer trap locus 4
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of ETL4 mRNA
CTD
PMID:22563483
NCBI chr 2:19,915,018...20,815,346
Ensembl chr 2:19,914,591...20,815,524
G
Exosc2
exosome component 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of EXOSC2 mRNA; [Maneb co-treated with Paraquat] results in increased expression of EXOSC2 mRNA
CTD
PMID:36117858
NCBI chr 2:31,560,727...31,571,593
Ensembl chr 2:31,560,727...31,571,361
G
Ext1
exostosin glycosyltransferase 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of EXT1 mRNA
CTD
PMID:36117858
NCBI chr15:52,931,657...53,209,579
Ensembl chr15:52,927,434...53,209,555
G
Eya1
EYA transcriptional coactivator and phosphatase 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of EYA1 mRNA
CTD
PMID:36117858
NCBI chr 1:14,239,177...14,381,259
Ensembl chr 1:14,239,178...14,380,459
G
F8a
factor 8-associated gene A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of F8A mRNA
CTD
PMID:36117858
NCBI chr X:72,271,912...72,274,401
Ensembl chr X:72,271,897...72,274,401
G
Faah
fatty acid amide hydrolase
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of FAAH mRNA
CTD
PMID:36117858
NCBI chr 4:115,853,866...115,876,034
Ensembl chr 4:115,824,342...115,875,123
G
Fabp3
fatty acid binding protein 3, muscle and heart
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of FABP3 mRNA
CTD
PMID:36117858
NCBI chr 4:130,202,531...130,209,256
Ensembl chr 4:130,202,388...130,209,256
G
Fam118b
family with sequence similarity 118, member B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of FAM118B mRNA
CTD
PMID:36117858
NCBI chr 9:35,128,261...35,179,172
Ensembl chr 9:35,128,261...35,179,101
G
Fam171a2
family with sequence similarity 171, member A2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of FAM171A2 mRNA
CTD
PMID:36117858
NCBI chr11:102,327,807...102,338,551
Ensembl chr11:102,327,807...102,338,508
G
Fam241b
family with sequence similarity 241, member B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of FAM241B mRNA
CTD
PMID:36117858
NCBI chr10:61,943,435...61,946,829
Ensembl chr10:61,943,434...61,979,699
G
Fam72a
family with sequence similarity 72, member A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of FAM72A mRNA
CTD
PMID:36117858
NCBI chr 1:131,454,336...131,466,773
Ensembl chr 1:131,455,641...131,467,610
G
Fas
Fas cell surface death receptor
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA]
CTD
PMID:23963992
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
G
Fat4
FAT atypical cadherin 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of FAT4 mRNA
CTD
PMID:36117858
NCBI chr 3:38,939,867...39,066,134
Ensembl chr 3:38,941,089...39,066,134
G
Fbxo27
F-box protein 27
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of FBXO27 mRNA
CTD
PMID:36117858
NCBI chr 7:28,392,205...28,398,763
Ensembl chr 7:28,392,274...28,398,763
G
Fbxo41
F-box protein 41
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of FBXO41 mRNA
CTD
PMID:36117858
NCBI chr 6:85,446,556...85,479,976
Ensembl chr 6:85,446,556...85,479,976
G
Fdft1
farnesyl diphosphate farnesyl transferase 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of FDFT1 mRNA
CTD
PMID:36117858
NCBI chr14:63,382,599...63,419,136
Ensembl chr14:63,382,599...63,417,027
G
Fez1
fasciculation and elongation protein zeta 1
multiple interactions
EXP
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of FEZ1 mRNA
CTD
PMID:23017109
NCBI chr 9:36,732,694...36,790,220
Ensembl chr 9:36,733,160...36,790,220
G
Fgfr3
fibroblast growth factor receptor 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of FGFR3 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FGFR3 mRNA]
CTD
PMID:23963992
NCBI chr 5:33,879,068...33,894,412
Ensembl chr 5:33,879,018...33,894,412
G
Fhip2b
FHF complex subunit HOOK interacting protein 2B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of FAM160B2 mRNA
CTD
PMID:36117858
NCBI chr14:70,820,733...70,837,309
Ensembl chr14:70,820,736...70,837,275
G
Fhl2
four and a half LIM domains 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of FHL2 mRNA
CTD
PMID:36117858
NCBI chr 1:43,162,233...43,237,501
Ensembl chr 1:43,162,234...43,236,144
G
Fkbp4
FK506 binding protein 4
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of FKBP4 mRNA
CTD
PMID:18386188
NCBI chr 6:128,407,066...128,415,619
Ensembl chr 6:128,406,698...128,415,640
G
Fkbp5
FK506 binding protein 5
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of FKBP5 mRNA
CTD
PMID:18386188
NCBI chr17:28,617,727...28,705,123
Ensembl chr17:28,618,068...28,736,501
G
Flrt1
fibronectin leucine rich transmembrane protein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of FLRT1 mRNA
CTD
PMID:36117858
NCBI chr19:7,064,829...7,143,548
Ensembl chr19:7,069,366...7,083,094
G
Flrt2
fibronectin leucine rich transmembrane protein 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of FLRT2 mRNA
CTD
PMID:36117858
NCBI chr12:95,658,780...95,751,989
Ensembl chr12:95,659,000...95,751,989
G
Flywch2
FLYWCH family member 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of FLYWCH2 mRNA
CTD
PMID:36117858
NCBI chr17:23,995,888...24,005,190
Ensembl chr17:23,995,890...24,005,055
G
Fndc5
fibronectin type III domain containing 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of FNDC5 mRNA
CTD
PMID:36117858
NCBI chr 4:129,030,672...129,038,386
Ensembl chr 4:129,030,477...129,038,386
G
Fos
FBJ osteosarcoma oncogene
multiple interactions
EXP ISO
[Maneb co-treated with Paraquat] results in decreased expression of FOS mRNA; [Maneb co-treated with Paraquat] results in increased expression of FOS mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FOS mRNA] [Paraquat co-treated with Maneb] results in decreased expression of FOS mRNA; [Paraquat co-treated with Maneb] results in decreased expression of FOS protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of FOS mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of FOS protein]
CTD
PMID:23963992 PMID:27460631 PMID:33368748 PMID:36117858
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
G
Foxk1
forkhead box K1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of FOXK1 mRNA
CTD
PMID:36117858
NCBI chr 5:142,387,252...142,447,770
Ensembl chr 5:142,387,252...142,447,766
G
Foxred2
FAD-dependent oxidoreductase domain containing 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of FOXRED2 mRNA
CTD
PMID:36117858
NCBI chr15:77,824,722...77,842,701
Ensembl chr15:77,824,722...77,840,922
G
Frat1
frequently rearranged in advanced T cell lymphomas
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of FRAT1 mRNA
CTD
PMID:36117858
NCBI chr19:41,818,409...41,821,022
Ensembl chr19:41,818,409...41,821,022
G
Frrs1l
ferric-chelate reductase 1 like
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of FRRS1L mRNA
CTD
PMID:36117858
NCBI chr 4:56,957,173...56,990,408
Ensembl chr 4:56,957,173...56,990,391
G
Ftx
Ftx transcript, Xist regulator, non-protein coding
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of FTX mRNA
CTD
PMID:36117858
NCBI chr X:102,604,516...102,667,360
Ensembl chr X:102,604,513...102,667,396
G
Fxyd6
FXYD domain-containing ion transport regulator 6
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of FXYD6 mRNA
CTD
PMID:18386188
NCBI chr 9:45,280,768...45,307,457
Ensembl chr 9:45,281,483...45,307,457
G
G6pc1
glucose-6-phosphatase catalytic subunit 1
decreases expression
ISO
Maneb results in decreased expression of G6PC1 mRNA
CTD
PMID:32194361
NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729
G
G6pdx
glucose-6-phosphate dehydrogenase X-linked
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of G6PDX mRNA
CTD
PMID:36117858
NCBI chr X:73,453,089...73,472,486
Ensembl chr X:73,453,089...73,472,800
G
Gabra2
gamma-aminobutyric acid type A receptor subunit alpha 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GABRA2 mRNA
CTD
PMID:36117858
NCBI chr 5:71,115,735...71,253,192
Ensembl chr 5:71,114,940...71,253,192
G
Gabra6
gamma-aminobutyric acid type A receptor subunit alpha 6
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of GABRA6 mRNA
CTD
PMID:22563483
NCBI chr11:42,197,264...42,211,977
Ensembl chr11:42,197,264...42,211,899
G
Gabrg1
gamma-aminobutyric acid type A receptor subunit gamma 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GABRG1 mRNA
CTD
PMID:36117858
NCBI chr 5:70,906,512...70,999,960
Ensembl chr 5:70,908,390...70,999,960
G
Gak
cyclin G associated kinase
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GAK mRNA
CTD
PMID:36117858
NCBI chr 5:108,716,973...108,777,643
Ensembl chr 5:108,717,277...108,777,621
G
Galnt4
polypeptide N-acetylgalactosaminyltransferase 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of GALNT4 mRNA
CTD
PMID:36117858
NCBI chr10:98,943,997...98,949,109
Ensembl chr10:98,944,021...98,949,109
G
Gan
giant axonal neuropathy
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of GAN mRNA
CTD
PMID:36117858
NCBI chr 8:117,884,720...117,932,573
Ensembl chr 8:117,884,874...117,942,736
G
Gas5
growth arrest specific 5
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of GAS5 mRNA
CTD
PMID:18386188
NCBI chr 1:160,862,171...160,866,109
Ensembl chr 1:160,861,992...160,866,116
G
Gas6
growth arrest specific 6
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of GAS6 mRNA
CTD
PMID:36117858
NCBI chr 8:13,515,374...13,544,535
Ensembl chr 8:13,515,374...13,544,490
G
Gclc
glutamate-cysteine ligase, catalytic subunit
increases expression increases activity
ISO
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of GCLC mRNA Maneb results in increased activity of GCLC protein
CTD
PMID:15527874 PMID:21402726
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
G
Gda
guanine deaminase
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GDA mRNA
CTD
PMID:36117858
NCBI chr19:21,368,671...21,450,025
Ensembl chr19:21,368,671...21,450,809
G
Gdap1l1
ganglioside-induced differentiation-associated protein 1-like 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GDAP1L1 mRNA
CTD
PMID:36117858
NCBI chr 2:163,280,387...163,297,264
Ensembl chr 2:163,280,396...163,297,244
G
Gdf11
growth differentiation factor 11
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GDF11 mRNA
CTD
PMID:36117858
NCBI chr10:128,716,393...128,727,587
Ensembl chr10:128,718,164...128,727,587
G
Gfap
glial fibrillary acidic protein
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of GFAP protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of GFAP protein]
CTD
PMID:30797899
NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738
G
Gfra2
glial cell line derived neurotrophic factor family receptor alpha 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of GFRA2 mRNA
CTD
PMID:36117858
NCBI chr14:71,127,547...71,217,280
Ensembl chr14:71,127,560...71,217,278
G
Gfra4
glial cell line derived neurotrophic factor family receptor alpha 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GFRA4 mRNA
CTD
PMID:36117858
NCBI chr 2:130,881,552...130,885,008
Ensembl chr 2:130,881,552...130,885,008
G
Gh
growth hormone
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of GH mRNA
CTD
PMID:22563483
NCBI chr11:106,191,087...106,194,529
Ensembl chr11:106,191,097...106,192,691
G
Gkn3
gastrokine 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of GKN3 mRNA
CTD
PMID:36117858
NCBI chr 6:87,360,301...87,365,917
Ensembl chr 6:87,360,238...87,365,917
G
Glce
glucuronyl C5-epimerase
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GLCE mRNA
CTD
PMID:36117858
NCBI chr 9:61,964,526...62,029,891
Ensembl chr 9:61,964,530...62,029,937
G
Gm2a
GM2 ganglioside activator protein
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of GM2A mRNA
CTD
PMID:18386188
NCBI chr11:54,988,811...55,003,855
Ensembl chr11:54,988,941...55,003,855
G
Gm40318
predicted gene, 40318
increases expression
ISO
Maneb results in increased expression of S100P mRNA; Maneb results in increased expression of S100P protein
CTD
PMID:32194361
NCBI chr 5:36,919,848...36,924,763
Ensembl chr 5:36,919,961...36,924,039
G
Gmfb
glia maturation factor, beta
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of GMFB mRNA; [Paraquat co-treated with Maneb] results in decreased expression of GMFB protein
CTD
PMID:17532186
NCBI chr14:47,045,606...47,059,711
Ensembl chr14:47,045,606...47,059,699
G
Gnai1
G protein subunit alpha i1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GNAI1 mRNA
CTD
PMID:36117858
NCBI chr 5:18,470,133...18,565,411
Ensembl chr 5:18,470,133...18,565,353
G
Gnal
guanine nucleotide binding protein, alpha stimulating, olfactory type
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GNAL mRNA
CTD
PMID:36117858
NCBI chr18:67,221,369...67,359,863
Ensembl chr18:67,221,287...67,359,863
G
Gnb5
guanine nucleotide binding protein (G protein), beta 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of GNB5 mRNA
CTD
PMID:36117858
NCBI chr 9:75,213,570...75,253,205
Ensembl chr 9:75,213,570...75,253,158
G
Gng13
guanine nucleotide binding protein (G protein), gamma 13
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GNG13 mRNA
CTD
PMID:36117858
NCBI chr17:25,936,146...25,938,076
Ensembl chr17:25,936,145...25,938,380
G
Gng3
guanine nucleotide binding protein (G protein), gamma 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GNG3 mRNA
CTD
PMID:36117858
NCBI chr19:8,814,293...8,816,610
Ensembl chr19:8,814,297...8,816,558
G
Gng5
G protein subunit gamma 5
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of GNG5 mRNA
CTD
PMID:18386188
NCBI chr 3:146,205,591...146,211,298
Ensembl chr 3:146,205,562...146,211,327
G
Gngt2
guanine nucleotide binding protein (G protein), gamma transducing activity polypeptide 2
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of GNGT2 mRNA
CTD
PMID:22563483
NCBI chr11:95,733,045...95,736,557
Ensembl chr11:95,728,042...95,736,560
G
Gopc
golgi associated PDZ and coiled-coil motif containing
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GOPC mRNA
CTD
PMID:36117858
NCBI chr10:52,213,120...52,258,220
Ensembl chr10:52,211,946...52,258,220
G
Gpcpd1
glycerophosphocholine phosphodiesterase 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of GPCPD1 mRNA
CTD
PMID:36117858
NCBI chr 2:132,371,002...132,420,173
Ensembl chr 2:132,371,002...132,429,649
G
Gpr22
G protein-coupled receptor 22
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GPR22 mRNA
CTD
PMID:36117858
NCBI chr12:31,756,866...31,763,882
Ensembl chr12:31,756,866...31,763,946
G
Gpr27
G protein-coupled receptor 27
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of GPR27 mRNA
CTD
PMID:22563483
NCBI chr 6:99,669,328...99,672,027
Ensembl chr 6:99,669,640...99,672,027
G
Gprasp1
G protein-coupled receptor associated sorting protein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GPRASP1 mRNA
CTD
PMID:36117858
NCBI chr X:134,643,441...134,704,217
Ensembl chr X:134,643,482...134,704,223
G
Gprasp2
G protein-coupled receptor associated sorting protein 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GPRASP2 mRNA
CTD
PMID:36117858
NCBI chr X:134,739,786...134,745,480
Ensembl chr X:134,739,783...134,745,479
G
Gpx1
glutathione peroxidase 1
multiple interactions decreases expression decreases activity
ISO EXP
GPX1 protein results in decreased susceptibility to [Paraquat co-treated with Maneb] Maneb results in decreased expression of GPX1 mRNA [Maneb co-treated with Paraquat] results in increased expression of GPX1 mRNA Maneb results in decreased activity of GPX1 protein
CTD
PMID:15824117 PMID:26210702 PMID:28322069 PMID:29859004
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
G
Gpx4
glutathione peroxidase 4
increases expression multiple interactions
EXP ISO
Maneb results in increased expression of GPX4 mRNA [Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein]; NFE2L2 gene mutant form inhibits the reaction [Maneb results in increased expression of GPX4 mRNA]
CTD
PMID:23764462 PMID:30797899
NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273
G
Grb2
growth factor receptor bound protein 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA]
CTD
PMID:23963992
NCBI chr11:115,534,871...115,599,423
Ensembl chr11:115,534,871...115,599,423
G
Grid1
glutamate receptor, ionotropic, delta 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GRID1 mRNA
CTD
PMID:36117858
NCBI chr14:34,541,751...35,305,344
Ensembl chr14:34,542,065...35,305,336
G
Grik2
glutamate receptor, ionotropic, kainate 2 (beta 2)
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GRIK2 mRNA
CTD
PMID:36117858
NCBI chr10:48,969,776...49,666,523
Ensembl chr10:48,970,929...49,664,862
G
Grk6
G protein-coupled receptor kinase 6
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GRK6 mRNA
CTD
PMID:36117858
NCBI chr13:55,592,865...55,608,740
Ensembl chr13:55,592,885...55,608,740
G
Gsdme
gasdermin E
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GSDME mRNA
CTD
PMID:36117858
NCBI chr 6:50,167,013...50,240,837
Ensembl chr 6:50,165,868...50,240,842
G
Gsk3b
glycogen synthase kinase 3 beta
multiple interactions
EXP
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of GSK3B protein
CTD
PMID:19883720
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
G
Gspt2
G1 to S phase transition 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GSPT2 mRNA
CTD
PMID:36117858
NCBI chr X:93,679,675...93,682,168
Ensembl chr X:93,679,675...93,686,850
G
Gsr
glutathione reductase
multiple interactions
ISO EXP
[Acetylcysteine co-treated with Paraquat co-treated with Maneb] results in increased activity of GSR protein; [Silymarin co-treated with Maneb] results in increased activity of GSR protein; [Silymarin co-treated with Paraquat co-treated with Maneb] results in increased activity of GSR protein [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of GSR protein
CTD
PMID:23159886 PMID:23764462
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
G
Gsta4
glutathione S-transferase, alpha 4
multiple interactions increases expression increases activity
ISO
[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein; [Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA; Acetylcysteine promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein]; Acetylcysteine promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA]; Acetylcysteine promotes the reaction [Maneb results in increased expression of and results in increased activity of GSTA4 protein]; Acetylcysteine promotes the reaction [Maneb results in increased expression of GSTA4 mRNA]; Maneb results in increased expression of and results in increased activity of GSTA4 protein; Silymarin promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein]; Silymarin promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA]; Silymarin promotes the reaction [Maneb results in increased expression of and results in increased activity of GSTA4 protein]; Silymarin promotes the reaction [Maneb results in increased expression of GSTA4 mRNA] Maneb results in increased expression of GSTA4 mRNA; Maneb results in increased expression of GSTA4 protein Maneb results in increased activity of GSTA4 protein
CTD
PMID:20888808 PMID:23159886
NCBI chr 9:78,099,248...78,116,631
Ensembl chr 9:78,090,056...78,116,631
G
Gstp1
glutathione S-transferase, pi 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA]
CTD
PMID:23963992 PMID:36117858
NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985
G
Gucy1a2
guanylate cyclase 1, soluble, alpha 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of GUCY1A2 mRNA
CTD
PMID:36117858
NCBI chr 9:3,532,349...3,905,791
Ensembl chr 9:3,532,778...3,894,736
G
Guk1
guanylate kinase 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of GUK1 mRNA
CTD
PMID:18386188
NCBI chr11:59,074,696...59,083,068
Ensembl chr11:59,074,701...59,083,069
G
H2ac20
H2A clustered histone 20
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of H2AC20 mRNA
CTD
PMID:22563483
NCBI chr 3:96,127,728...96,128,209
Ensembl chr 3:96,127,677...96,128,196
G
H2ac4
H2A clustered histone 4
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of H2AC6 mRNA
CTD
PMID:22563483
NCBI chr13:23,935,061...23,935,577
Ensembl chr13:23,935,109...23,935,581
G
H2ax
H2A.X variant histone
multiple interactions
ISO
[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in increased expression of H2AX protein
CTD
PMID:34830855
NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374
G
H2bc9
H2B clustered histone 9
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of H2BC9 mRNA
CTD
PMID:22563483
NCBI chr13:23,727,093...23,727,614
Ensembl chr13:23,725,884...23,727,562
G
Habp4
hyaluronic acid binding protein 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HABP4 mRNA
CTD
PMID:36117858
NCBI chr13:64,309,680...64,334,351
Ensembl chr13:64,309,638...64,334,351
G
Hapln1
hyaluronan and proteoglycan link protein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HAPLN1 mRNA
CTD
PMID:36117858
NCBI chr13:89,688,654...89,759,951
Ensembl chr13:89,687,915...89,759,771
G
Hba-a1
hemoglobin alpha, adult chain 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HBA-A1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of HBA-A1 mRNA
CTD
PMID:18386188 PMID:36117858
NCBI chr11:32,233,672...32,234,486
Ensembl chr11:32,233,511...32,234,465
G
Hba-a2
hemoglobin alpha, adult chain 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HBA-A2 mRNA
CTD
PMID:36117858
NCBI chr11:32,246,492...32,247,310
Ensembl chr11:32,246,489...32,247,298
G
Hbb-bt
hemoglobin, beta adult t chain
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HBB-BT mRNA
CTD
PMID:36117858
NCBI chr 7:103,461,731...103,463,130
Ensembl chr 7:103,461,731...103,463,203
G
Hdac3
histone deacetylase 3
decreases activity
ISO
Maneb results in decreased activity of HDAC3 protein
CTD
PMID:21251949
NCBI chr18:38,070,024...38,088,073
Ensembl chr18:38,068,897...38,088,069
G
Hdac6
histone deacetylase 6
decreases activity multiple interactions
ISO EXP
Maneb results in decreased activity of HDAC6 protein [Maneb co-treated with Paraquat] results in decreased expression of HDAC6 mRNA
CTD
PMID:21251949 PMID:36117858
NCBI chr X:7,796,355...7,814,284
Ensembl chr X:7,796,359...7,814,128
G
Helq
helicase, POLQ-like
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HELQ mRNA
CTD
PMID:36117858
NCBI chr 5:100,910,010...100,946,529
Ensembl chr 5:100,910,011...100,946,464
G
Herc3
hect domain and RLD 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HERC3 mRNA
CTD
PMID:36117858
NCBI chr 6:58,808,440...58,897,383
Ensembl chr 6:58,808,450...58,897,383
G
Hes3
hes family bHLH transcription factor 3
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of HES3 mRNA
CTD
PMID:22563483
NCBI chr 4:152,369,707...152,376,133
Ensembl chr 4:152,370,429...152,376,119
G
Hey2
hairy/enhancer-of-split related with YRPW motif 2
multiple interactions
EXP
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEY2 mRNA; [Maneb co-treated with Paraquat] results in decreased expression of HEY2 mRNA
CTD
PMID:23017109 PMID:36117858
NCBI chr10:30,708,355...30,718,779
Ensembl chr10:30,708,355...30,718,797
G
Heyl
hairy/enhancer-of-split related with YRPW motif-like
multiple interactions
EXP
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEYL mRNA
CTD
PMID:23017109
NCBI chr 4:123,127,349...123,143,663
Ensembl chr 4:123,127,349...123,143,668
G
Hivep2
human immunodeficiency virus type I enhancer binding protein 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HIVEP2 mRNA
CTD
PMID:36117858
NCBI chr10:13,841,819...14,027,122
Ensembl chr10:13,841,819...14,027,118
G
Hk1
hexokinase 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of HK1 mRNA
CTD
PMID:18386188
NCBI chr10:62,104,634...62,215,699
Ensembl chr10:62,104,634...62,215,687
G
Hlf
hepatic leukemia factor
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of HLF mRNA
CTD
PMID:36117858
NCBI chr11:90,227,361...90,281,745
Ensembl chr11:90,227,362...90,281,721
G
Hmga2
high mobility group AT-hook 2
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of HMGA2 mRNA
CTD
PMID:18386188
NCBI chr10:120,197,173...120,312,374
Ensembl chr10:120,197,180...120,312,374
G
Hmgn5
high-mobility group nucleosome binding domain 5
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of HMGN5 mRNA
CTD
PMID:22563483
NCBI chr X:108,048,143...108,056,986
Ensembl chr X:108,048,140...108,057,010
G
Hmgxb3
HMG box domain containing 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HMGXB3 mRNA; [Maneb co-treated with Paraquat] results in increased expression of HMGXB3 mRNA
CTD
PMID:36117858
NCBI chr18:61,264,349...61,310,122
Ensembl chr18:61,264,349...61,310,122
G
Hmox1
heme oxygenase 1
increases expression multiple interactions
ISO EXP
Maneb results in increased expression of HMOX1 protein [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of HMOX1 protein
CTD
PMID:15527874 PMID:23764462
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
G
Hnmt
histamine N-methyltransferase
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HNMT mRNA
CTD
PMID:36117858
NCBI chr 2:23,892,923...23,939,756
Ensembl chr 2:23,892,922...23,939,406
G
Hnrnpk
heterogeneous nuclear ribonucleoprotein K
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of HNRNPK mRNA
CTD
PMID:18386188
NCBI chr13:58,538,946...58,551,157
Ensembl chr13:58,538,956...58,551,157
G
Homer1
homer scaffolding protein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HOMER1 mRNA
CTD
PMID:36117858
NCBI chr13:93,440,265...93,549,471
Ensembl chr13:93,436,143...93,541,637
G
Homer2
homer scaffolding protein 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of HOMER2 mRNA
CTD
PMID:36117858
NCBI chr 7:81,250,229...81,356,673
Ensembl chr 7:81,250,229...81,357,275
G
Hook1
hook microtubule tethering protein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HOOK1 mRNA
CTD
PMID:36117858
NCBI chr 4:95,855,418...95,913,649
Ensembl chr 4:95,855,477...95,913,650
G
Hpcal1
hippocalcin-like 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HPCAL1 mRNA
CTD
PMID:36117858
NCBI chr12:17,740,810...17,841,943
Ensembl chr12:17,740,857...17,841,934
G
Hpcal4
hippocalcin-like 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of HPCAL4 mRNA
CTD
PMID:36117858
NCBI chr 4:123,077,297...123,088,492
Ensembl chr 4:123,077,020...123,088,494
G
Hrk
harakiri, BCL2 interacting protein (contains only BH3 domain)
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HRK mRNA
CTD
PMID:36117858
NCBI chr 5:118,307,829...118,327,543
Ensembl chr 5:118,302,713...118,327,543
G
Hsd11b2
hydroxysteroid 11-beta dehydrogenase 2
decreases activity
ISO
Maneb results in decreased activity of HSD11B2 protein
CTD
PMID:22796344
NCBI chr 8:106,245,378...106,250,620
Ensembl chr 8:106,245,387...106,250,620
G
Hsf1
heat shock factor 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA]
CTD
PMID:23963992
NCBI chr15:76,361,562...76,385,355
Ensembl chr15:76,361,622...76,386,113
G
Hsp90aa1
heat shock protein 90, alpha (cytosolic), class A member 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HSP90AA1 mRNA; [Paraquat co-treated with Maneb] results in increased expression of HSP90AA1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSP90AA1 mRNA]
CTD
PMID:18386188 PMID:23963992
NCBI chr12:110,657,470...110,662,829
Ensembl chr12:110,657,039...110,669,162
G
Hspa1b
heat shock protein 1B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HSPA1B mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSPA1B mRNA]
CTD
PMID:23963992
NCBI chr17:35,175,405...35,178,214
Ensembl chr17:35,175,412...35,178,214
G
Hspa5
heat shock protein 5
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of HSPA5 mRNA
CTD
PMID:18386188
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
G
Hspa8
heat shock protein 8
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of HSPA8 mRNA
CTD
PMID:18386188
NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383
G
Htr2c
5-hydroxytryptamine (serotonin) receptor 2C
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HTR2C mRNA
CTD
PMID:36117858
NCBI chr X:145,745,509...145,980,273
Ensembl chr X:145,745,509...145,980,273
G
Hus1
HUS1 checkpoint clamp component
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of HUS1 mRNA
CTD
PMID:36117858
NCBI chr11:8,943,137...8,961,240
Ensembl chr11:8,943,137...8,961,191
G
Icam1
intercellular adhesion molecule 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of ICAM1 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ICAM1 mRNA]
CTD
PMID:32169474
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
G
Icam2
intercellular adhesion molecule 2
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of ICAM2 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ICAM2 mRNA]
CTD
PMID:32169474
NCBI chr11:106,268,482...106,278,948
Ensembl chr11:106,268,482...106,278,901
G
Idh3a
isocitrate dehydrogenase 3 (NAD+) alpha
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of IDH3A protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IDH3A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IDH3A protein]
CTD
PMID:23562983
NCBI chr 9:54,493,795...54,511,946
Ensembl chr 9:54,493,618...54,511,945
G
Ids
iduronate 2-sulfatase
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of IDS mRNA
CTD
PMID:36117858
NCBI chr X:69,386,675...69,429,437
Ensembl chr X:69,386,675...69,408,690
G
Ier3
immediate early response 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of IER3 mRNA
CTD
PMID:36117858
NCBI chr17:36,132,605...36,133,803
Ensembl chr17:36,132,576...36,133,815
G
Ier5l
immediate early response 5-like
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of IER5L mRNA
CTD
PMID:22563483
NCBI chr 2:30,362,643...30,364,211
Ensembl chr 2:30,361,549...30,364,231
G
Ifi27l2a
interferon, alpha-inducible protein 27 like 2A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of IFI27L2A mRNA
CTD
PMID:36117858
NCBI chr12:103,400,132...103,409,939
Ensembl chr12:103,408,426...103,409,939
G
Ifi47
interferon gamma inducible protein 47
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of IFI47 mRNA
CTD
PMID:36117858
NCBI chr11:48,967,414...48,987,814
Ensembl chr11:48,967,414...48,987,801
G
Ifng
interferon gamma
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA]
CTD
PMID:23963992
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
G
Igf1
insulin-like growth factor 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA]
CTD
PMID:23963992
NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904
G
Igsf21
immunoglobulin superfamily, member 21
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of IGSF21 mRNA
CTD
PMID:36117858
NCBI chr 4:139,754,163...139,974,294
Ensembl chr 4:139,754,157...139,974,095
G
Igsf5
immunoglobulin superfamily, member 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of IGSF5 mRNA
CTD
PMID:36117858
NCBI chr16:96,162,676...96,266,772
Ensembl chr16:96,162,868...96,223,321
G
Il1b
interleukin 1 beta
multiple interactions increases expression
ISO EXP
[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of IL1B mRNA] [Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA; [Maneb co-treated with Paraquat] results in increased expression of IL1B protein; [Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA; [Paraquat co-treated with Maneb] results in increased expression of IL1B protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA]; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]
CTD
PMID:23159886 PMID:23963992 PMID:29568078 PMID:32169474 PMID:32375810 PMID:34052309 More...
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
G
Il6
interleukin 6
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of IL6 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL6 mRNA]
CTD
PMID:32169474
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
G
Inhba
inhibin beta-A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of INHBA mRNA; [Paraquat co-treated with Maneb] affects the expression of INHBA mRNA
CTD
PMID:22563483 PMID:23017109
NCBI chr13:16,178,841...16,206,194
Ensembl chr13:16,186,436...16,206,206
G
Inka2
inka box actin regulator 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of FAM212B mRNA
CTD
PMID:36117858
NCBI chr 3:105,611,915...105,628,158
Ensembl chr 3:105,611,915...105,628,158
G
Inpp4a
inositol polyphosphate-4-phosphatase, type I
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of INPP4A mRNA
CTD
PMID:36117858
NCBI chr 1:37,338,908...37,449,821
Ensembl chr 1:37,338,946...37,449,817
G
Inpp4b
inositol polyphosphate-4-phosphatase, type II
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of INPP4B mRNA
CTD
PMID:36117858
NCBI chr 8:82,068,895...82,865,553
Ensembl chr 8:82,069,185...82,854,543
G
Inpp5d
inositol polyphosphate-5-phosphatase D
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of INPP5D mRNA
CTD
PMID:36117858
NCBI chr 1:87,548,034...87,648,232
Ensembl chr 1:87,548,034...87,648,229
G
Insig1
insulin induced gene 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of INSIG1 mRNA
CTD
PMID:36117858
NCBI chr 5:28,276,410...28,283,660
Ensembl chr 5:28,276,361...28,283,660
G
Iqsec3
IQ motif and Sec7 domain 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of IQSEC3 mRNA
CTD
PMID:36117858
NCBI chr 6:121,349,886...121,450,697
Ensembl chr 6:121,349,892...121,450,637
G
Irs2
insulin receptor substrate 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of IRS2 mRNA; [Maneb co-treated with Paraquat] results in increased expression of IRS2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IRS2 mRNA]
CTD
PMID:23963992 PMID:36117858
NCBI chr 8:11,034,681...11,058,929
Ensembl chr 8:11,034,681...11,058,458
G
Islr2
immunoglobulin superfamily containing leucine-rich repeat 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ISLR2 mRNA
CTD
PMID:36117858
NCBI chr 9:58,103,580...58,113,563
Ensembl chr 9:58,103,580...58,111,602
G
Isoc2b
isochorismatase domain containing 2b
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ISOC2B mRNA
CTD
PMID:36117858
NCBI chr 7:4,847,958...4,869,178
Ensembl chr 7:4,847,958...4,873,257
G
Itga7
integrin alpha 7
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ITGA7 mRNA
CTD
PMID:36117858
NCBI chr10:128,769,633...128,794,155
Ensembl chr10:128,769,645...128,794,155
G
Itgam
integrin alpha M
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ITGAM protein; [Paraquat co-treated with Maneb] results in increased expression of ITGAM mRNA; [Paraquat co-treated with Maneb] results in increased expression of ITGAM protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ITGAM protein]; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ITGAM protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ITGAM mRNA]
CTD
PMID:28202386 PMID:30797899 PMID:32169474 PMID:32375810
NCBI chr 7:127,661,812...127,717,663
Ensembl chr 7:127,661,812...127,717,663
G
Itgb8
integrin beta 8
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of ITGB8 mRNA
CTD
PMID:22563483
NCBI chr12:119,121,757...119,202,891
Ensembl chr12:119,121,757...119,202,537
G
Itpr1
inositol 1,4,5-trisphosphate receptor 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ITPR1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ITPR1 mRNA]
CTD
PMID:23963992
NCBI chr 6:108,190,044...108,528,077
Ensembl chr 6:108,190,057...108,528,070
G
Ivns1abp
influenza virus NS1A binding protein
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of IVNS1ABP mRNA
CTD
PMID:36117858
NCBI chr 1:151,220,237...151,240,196
Ensembl chr 1:151,220,228...151,240,173
G
Jpt1
Jupiter microtubule associated homolog 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of JPT1 mRNA
CTD
PMID:18386188
NCBI chr11:115,388,171...115,405,219
Ensembl chr11:115,388,179...115,405,213
G
Jun
jun proto-oncogene
multiple interactions
ISO
[Paraquat co-treated with Maneb] results in decreased expression of JUN mRNA; [Paraquat co-treated with Maneb] results in decreased expression of JUN protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of JUN mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of JUN protein]
CTD
PMID:27460631 PMID:33368748
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
G
Kcna2
potassium voltage-gated channel, shaker-related subfamily, member 2
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of KCNA2 mRNA
CTD
PMID:22563483
NCBI chr 3:106,998,203...107,022,321
Ensembl chr 3:107,008,462...107,022,321
G
Kcna5
potassium voltage-gated channel, shaker-related subfamily, member 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of KCNA5 mRNA
CTD
PMID:36117858
NCBI chr 6:126,509,514...126,512,518
Ensembl chr 6:126,509,514...126,512,375
G
Kcnc1
potassium voltage gated channel, Shaw-related subfamily, member 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of KCNC1 mRNA
CTD
PMID:36117858
NCBI chr 7:46,045,643...46,088,130
Ensembl chr 7:46,045,921...46,088,128
G
Kcnc3
potassium voltage gated channel, Shaw-related subfamily, member 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of KCNC3 mRNA
CTD
PMID:36117858
NCBI chr 7:44,236,405...44,254,175
Ensembl chr 7:44,240,088...44,254,178
G
Kcnd1
potassium voltage-gated channel, Shal-related family, member 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of KCND1 mRNA
CTD
PMID:36117858
NCBI chr X:7,686,907...7,704,517
Ensembl chr X:7,688,528...7,704,519
G
Kcnd3
potassium voltage-gated channel, Shal-related family, member 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of KCND3 mRNA
CTD
PMID:36117858
NCBI chr 3:105,359,206...105,581,318
Ensembl chr 3:105,359,646...105,581,318
G
Kcnh3
potassium voltage-gated channel, subfamily H (eag-related), member 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of KCNH3 mRNA
CTD
PMID:36117858
NCBI chr15:99,122,396...99,140,699
Ensembl chr15:99,122,742...99,140,698
G
Kcnj12
potassium inwardly-rectifying channel, subfamily J, member 12
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of KCNJ12 mRNA
CTD
PMID:36117858
NCBI chr11:60,912,970...60,964,095
Ensembl chr11:60,913,390...60,961,957
G
Kcnj3
potassium inwardly-rectifying channel, subfamily J, member 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of KCNJ3 mRNA
CTD
PMID:36117858
NCBI chr 2:55,301,814...55,488,157
Ensembl chr 2:55,325,982...55,488,157
G
Kcnk12
potassium channel, subfamily K, member 12
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of KCNK12 mRNA
CTD
PMID:36117858
NCBI chr17:88,049,100...88,106,329
Ensembl chr17:88,053,229...88,105,422
G
Kcnma1
potassium large conductance calcium-activated channel, subfamily M, alpha member 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of KCNMA1 mRNA
CTD
PMID:22563483
NCBI chr14:23,342,356...24,055,173
Ensembl chr14:23,339,499...24,064,559
G
Kcnmb4
potassium large conductance calcium-activated channel, subfamily M, beta member 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of KCNMB4 mRNA
CTD
PMID:36117858
NCBI chr10:116,251,951...116,309,787
Ensembl chr10:116,253,766...116,309,783
G
Kctd10
potassium channel tetramerisation domain containing 10
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of KCTD10 mRNA
CTD
PMID:36117858
NCBI chr 5:114,501,633...114,518,566
Ensembl chr 5:114,501,628...114,518,569
G
Khdrbs2
KH domain containing, RNA binding, signal transduction associated 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of KHDRBS2 mRNA
CTD
PMID:36117858
NCBI chr 1:32,211,683...32,744,305
Ensembl chr 1:32,211,795...32,697,649
G
Khdrbs3
KH domain containing, RNA binding, signal transduction associated 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of KHDRBS3 mRNA
CTD
PMID:36117858
NCBI chr15:68,800,155...68,973,064
Ensembl chr15:68,800,269...68,973,060
G
Kif1b
kinesin family member 1B
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of KIF1B mRNA
CTD
PMID:22563483
NCBI chr 4:149,260,776...149,392,762
Ensembl chr 4:149,260,776...149,392,150
G
Kif3b
kinesin family member 3B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of KIF3B mRNA
CTD
PMID:36117858
NCBI chr 2:153,132,028...153,175,310
Ensembl chr 2:153,133,333...153,175,310
G
Kit
KIT proto-oncogene receptor tyrosine kinase
decreases expression
ISO
Maneb results in decreased expression of KIT
CTD
PMID:25803990
NCBI chr 5:75,735,647...75,817,382
Ensembl chr 5:75,735,576...75,817,382
G
Klf2
Kruppel-like transcription factor 2 (lung)
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of KLF2 mRNA
CTD
PMID:22563483
NCBI chr 8:73,072,906...73,075,498
Ensembl chr 8:73,072,877...73,075,500
G
Klhl15
kelch-like 15
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of KLHL15 mRNA
CTD
PMID:22563483
NCBI chr X:93,275,884...93,321,330
Ensembl chr X:93,278,205...93,321,330
G
Klhl2
kelch-like 2, Mayven
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of KLHL2 mRNA
CTD
PMID:36117858
NCBI chr 8:65,192,707...65,302,821
Ensembl chr 8:65,192,709...65,302,669
G
Klhl32
kelch-like 32
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of KLHL32 mRNA
CTD
PMID:36117858
NCBI chr 4:24,612,559...24,851,150
Ensembl chr 4:24,612,554...24,851,124
G
Klhl42
kelch-like 42
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of KLHL42 mRNA
CTD
PMID:36117858
NCBI chr 6:146,990,783...147,014,276
Ensembl chr 6:146,992,877...147,014,276
G
Kri1
KRI1 homolog
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of KRI1 mRNA
CTD
PMID:36117858
NCBI chr 9:21,184,753...21,199,265
Ensembl chr 9:21,184,753...21,199,265
G
Lama5
laminin, alpha 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of LAMA5 mRNA
CTD
PMID:36117858
NCBI chr 2:179,818,166...179,867,652
Ensembl chr 2:179,818,166...179,867,652
G
Lamc2
laminin, gamma 2
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of LAMC2 mRNA
CTD
PMID:22563483
NCBI chr 1:152,998,502...153,062,193
Ensembl chr 1:152,998,502...153,062,193
G
Lcorl
ligand dependent nuclear receptor corepressor-like
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of LCORL mRNA
CTD
PMID:36117858
NCBI chr 5:45,854,523...46,015,213 NCBI chr 5:45,877,009...45,884,920
Ensembl chr 5:45,854,523...46,014,957
G
Ldha
lactate dehydrogenase A
increases activity
EXP
Maneb results in increased activity of LDHA protein
CTD
PMID:28322069
NCBI chr 7:46,491,698...46,505,051
Ensembl chr 7:46,490,899...46,505,051
G
Lifr
LIF receptor alpha
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of LIFR mRNA
CTD
PMID:22563483
NCBI chr15:7,120,091...7,226,970
Ensembl chr15:7,120,095...7,226,970
G
Limk2
LIM domain kinase 2
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of LIMK2 mRNA
CTD
PMID:18386188
NCBI chr11:3,293,297...3,359,238
Ensembl chr11:3,294,256...3,359,189
G
Lin7a
lin-7 homolog A, crumbs cell polarity complex component
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of LIN7A mRNA
CTD
PMID:36117858
NCBI chr10:107,107,410...107,261,007
Ensembl chr10:107,107,547...107,257,335
G
Lmln
leishmanolysin-like (metallopeptidase M8 family)
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of LMLN mRNA
CTD
PMID:36117858
NCBI chr16:32,881,974...32,948,065
Ensembl chr16:32,882,891...32,948,065
G
Lmo3
LIM domain only 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of LMO3 mRNA
CTD
PMID:36117858
NCBI chr 6:138,339,916...138,559,204
Ensembl chr 6:138,339,916...138,558,966
G
Loricrin
loricrin cornified envelope precursor protein
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of LORICRIN mRNA
CTD
PMID:22563483
NCBI chr 3:91,987,578...91,990,447
Ensembl chr 3:91,987,578...91,990,449
G
Lpl
lipoprotein lipase
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of LPL mRNA
CTD
PMID:36117858
NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100
G
Lrfn1
leucine rich repeat and fibronectin type III domain containing 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of LRFN1 mRNA
CTD
PMID:36117858
NCBI chr 7:28,151,194...28,167,667
Ensembl chr 7:28,151,405...28,167,667
G
Lrfn5
leucine rich repeat and fibronectin type III domain containing 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of LRFN5 mRNA
CTD
PMID:36117858
NCBI chr12:61,569,356...61,913,554
Ensembl chr12:61,569,936...61,905,128
G
Lrp4
low density lipoprotein receptor-related protein 4
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of LRP4 mRNA
CTD
PMID:22563483
NCBI chr 2:91,287,794...91,344,246
Ensembl chr 2:91,287,856...91,344,124
G
Lrrc17
leucine rich repeat containing 17
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of LRRC17 mRNA
CTD
PMID:18386188
NCBI chr 5:21,748,525...21,780,909
Ensembl chr 5:21,748,557...21,780,902
G
Lrrc24
leucine rich repeat containing 24
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of LRRC24 mRNA
CTD
PMID:36117858
NCBI chr15:76,599,476...76,606,373
Ensembl chr15:76,599,476...76,606,373
G
Lrrc41
leucine rich repeat containing 41
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of LRRC41 mRNA
CTD
PMID:18386188
NCBI chr 4:115,932,466...115,954,306
Ensembl chr 4:115,932,466...115,954,240
G
Lrrc4c
leucine rich repeat containing 4C
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of LRRC4C mRNA
CTD
PMID:36117858
NCBI chr 2:96,148,514...97,466,871
Ensembl chr 2:96,148,514...97,462,011
G
Lrrc7
leucine rich repeat containing 7
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of LRRC7 mRNA
CTD
PMID:36117858
NCBI chr 3:157,772,823...158,268,254
Ensembl chr 3:157,788,528...158,267,858 Ensembl chr 3:157,788,528...158,267,858
G
Lrrk2
leucine-rich repeat kinase 2
multiple interactions
EXP ISO
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of ACHE mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5R1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5RAP1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CHRM2 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of EFNB1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of FEZ1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEY2 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NDP mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NRG1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX6 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of POU3F3 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA; LRRK2 protein mutant form inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA] 3-(4-(morpholin-4-yl)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)benzonitrile inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of LRRK2 protein]; [Paraquat co-treated with Maneb] results in increased phosphorylation of LRRK2 protein; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of LRRK2 protein]; Plant Extracts inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of LRRK2 protein]
CTD
PMID:23017109 PMID:34897981
NCBI chr15:91,556,994...91,700,327
Ensembl chr15:91,557,378...91,700,323
G
Lrrn2
leucine rich repeat protein 2, neuronal
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of LRRN2 mRNA
CTD
PMID:36117858
NCBI chr 1:132,808,093...132,867,743
Ensembl chr 1:132,808,011...132,867,743
G
Lrrn3
leucine rich repeat protein 3, neuronal
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of LRRN3 mRNA
CTD
PMID:36117858
NCBI chr12:41,501,667...41,536,056
Ensembl chr12:41,501,667...41,536,430
G
Lrrtm3
leucine rich repeat transmembrane neuronal 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of LRRTM3 mRNA
CTD
PMID:36117858
NCBI chr10:63,764,276...63,926,034
Ensembl chr10:63,764,251...63,926,056
G
Lsm11
U7 snRNP-specific Sm-like protein LSM11
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of LSM11 mRNA
CTD
PMID:36117858
NCBI chr11:45,819,096...45,835,762
Ensembl chr11:45,819,096...45,835,762
G
Ltbp1
latent transforming growth factor beta binding protein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of LTBP1 mRNA
CTD
PMID:36117858
NCBI chr17:75,312,475...75,699,507
Ensembl chr17:75,312,563...75,699,507
G
Ly6a
lymphocyte antigen 6 family member A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of LY6A mRNA
CTD
PMID:36117858
NCBI chr15:74,866,726...74,869,880
Ensembl chr15:74,866,726...74,869,880
G
Lynx1
Ly6/neurotoxin 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of LYNX1 mRNA
CTD
PMID:18386188
NCBI chr15:74,619,705...74,624,828
Ensembl chr15:74,619,701...74,624,895
G
Lypd1
Ly6/Plaur domain containing 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of LYPD1 mRNA
CTD
PMID:36117858
NCBI chr 1:125,795,359...125,841,134
Ensembl chr 1:125,795,359...125,840,838
G
Lzts1
leucine zipper, putative tumor suppressor 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of LZTS1 mRNA
CTD
PMID:36117858
NCBI chr 8:69,585,311...69,636,901
Ensembl chr 8:69,585,321...69,636,877
G
Macf1
microtubule-actin crosslinking factor 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of MACF1 mRNA
CTD
PMID:18386188
NCBI chr 4:123,243,386...123,581,594
Ensembl chr 4:123,243,426...123,581,331
G
Madd
MAP-kinase activating death domain
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of MADD mRNA
CTD
PMID:36117858
NCBI chr 2:90,967,705...91,013,404
Ensembl chr 2:90,967,705...91,014,182
G
Map2
microtubule-associated protein 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA]
CTD
PMID:23963992
NCBI chr 1:66,214,337...66,481,742
Ensembl chr 1:66,214,432...66,481,742
G
Map2k1
mitogen-activated protein kinase kinase 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA]
CTD
PMID:23963992
NCBI chr 9:64,093,066...64,160,887
Ensembl chr 9:64,093,052...64,160,913
G
Map2k4
mitogen-activated protein kinase kinase 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MAP2K4 mRNA
CTD
PMID:36117858
NCBI chr11:65,579,070...65,679,185
Ensembl chr11:65,579,069...65,679,123
G
Map2k6
mitogen-activated protein kinase kinase 6
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA]
CTD
PMID:23963992
NCBI chr11:110,289,928...110,416,348
Ensembl chr11:110,289,948...110,416,348
G
Map3k7
mitogen-activated protein kinase kinase kinase 7
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of MAP3K7 mRNA
CTD
PMID:36117858
NCBI chr 4:31,963,659...32,023,470
Ensembl chr 4:31,964,097...32,023,467
G
Map9
microtubule-associated protein 9
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MAP9 mRNA
CTD
PMID:36117858
NCBI chr 3:82,265,379...82,302,575
Ensembl chr 3:82,265,351...82,302,575
G
Mapk1
mitogen-activated protein kinase 1
multiple interactions
ISO EXP
[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK1 protein [Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK1 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK1 protein]
CTD
PMID:15824117 PMID:30797899
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
G
Mapk15
mitogen-activated protein kinase 15
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of MAPK15 mRNA
CTD
PMID:22563483
NCBI chr15:75,865,581...75,871,002
Ensembl chr15:75,865,618...75,871,003
G
Mapk3
mitogen-activated protein kinase 3
multiple interactions
ISO EXP
[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK3 protein [Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK3 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK3 protein]
CTD
PMID:15824117 PMID:30797899
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
G
Mapk8
mitogen-activated protein kinase 8
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of MAPK8 mRNA
CTD
PMID:36117858
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
G
Mapt
microtubule-associated protein tau
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA]
CTD
PMID:23963992
NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916
G
Marchf9
membrane associated ring-CH-type finger 9
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of MARCHF9 mRNA
CTD
PMID:22563483
NCBI chr10:126,891,919...126,896,053
Ensembl chr10:126,890,880...126,896,053
G
Masp1
MBL associated serine protease 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MASP1 mRNA
CTD
PMID:36117858
NCBI chr16:23,261,778...23,340,127
Ensembl chr16:23,268,167...23,339,565
G
Matn2
matrilin 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of MATN2 mRNA
CTD
PMID:36117858
NCBI chr15:34,306,827...34,436,388
Ensembl chr15:34,306,823...34,436,419
G
Mb21d2
Mab-21 domain containing 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MB21D2 mRNA
CTD
PMID:36117858
NCBI chr16:28,644,928...28,748,802
Ensembl chr16:28,644,928...28,748,425
G
Mbd3
methyl-CpG binding domain protein 3
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of MBD3 mRNA; [Paraquat co-treated with Maneb] results in increased expression of MBD3 mRNA
CTD
PMID:18386188
NCBI chr10:80,228,373...80,235,365
Ensembl chr10:80,228,373...80,235,384
G
Mblac2
metallo-beta-lactamase domain containing 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MBLAC2 mRNA
CTD
PMID:36117858
NCBI chr13:81,859,536...81,901,394
Ensembl chr13:81,859,460...81,901,394
G
Mbnl1
muscleblind like splicing regulator 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of MBNL1 mRNA
CTD
PMID:18386188
NCBI chr 3:60,380,209...60,537,171
Ensembl chr 3:60,380,251...60,537,171
G
Mboat2
membrane bound O-acyltransferase domain containing 2
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of MBOAT2 mRNA
CTD
PMID:22563483
NCBI chr12:24,881,401...25,014,399
Ensembl chr12:24,880,878...25,014,396
G
Mcf2l
mcf.2 transforming sequence-like
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of MCF2L mRNA
CTD
PMID:36117858
NCBI chr 8:12,923,806...13,070,502
Ensembl chr 8:12,923,806...13,070,905
G
Mcl1
myeloid cell leukemia sequence 1
multiple interactions increases expression
ISO
[Paraquat co-treated with Maneb] results in increased expression of MCL1 protein Maneb results in increased expression of MCL1 protein
CTD
PMID:18266926
NCBI chr 3:95,564,017...95,583,553
Ensembl chr 3:95,566,099...95,570,487
G
Mcm6
minichromosome maintenance complex component 6
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MCM6 mRNA
CTD
PMID:36117858
NCBI chr 1:128,259,312...128,287,442
Ensembl chr 1:128,259,327...128,287,401
G
Mctp1
multiple C2 domains, transmembrane 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MCTP1 mRNA
CTD
PMID:36117858
NCBI chr13:76,530,481...77,181,403
Ensembl chr13:76,532,259...77,179,929
G
Mdga1
MAM domain containing glycosylphosphatidylinositol anchor 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MDGA1 mRNA
CTD
PMID:36117858
NCBI chr17:30,046,930...30,107,557
Ensembl chr17:30,046,923...30,189,061
G
Mdm4
transformed mouse 3T3 cell double minute 4
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of MDM4 mRNA
CTD
PMID:18386188
NCBI chr 1:132,913,843...132,958,325
Ensembl chr 1:132,887,222...132,958,299
G
Me3
malic enzyme 3, NADP(+)-dependent, mitochondrial
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ME3 mRNA
CTD
PMID:36117858
NCBI chr 7:89,281,492...89,503,423
Ensembl chr 7:89,281,600...89,503,567
G
Meak7
MTOR associated protein, eak-7 homolog
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TLDC1 mRNA
CTD
PMID:36117858
NCBI chr 8:120,486,802...120,505,173
Ensembl chr 8:120,486,815...120,505,155
G
Mef2c
myocyte enhancer factor 2C
multiple interactions
ISO
[Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased metabolism of MEF2C protein; [Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased metabolism of MEF2C protein
CTD
PMID:24290359
NCBI chr13:83,652,136...83,815,197
Ensembl chr13:83,652,153...83,815,199
G
Megf9
multiple EGF-like-domains 9
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of MEGF9 mRNA
CTD
PMID:36117858
NCBI chr 4:70,350,164...70,453,165
Ensembl chr 4:70,345,302...70,453,232
G
Meis3
Meis homeobox 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of MEIS3 mRNA
CTD
PMID:36117858
NCBI chr 7:15,908,684...15,920,435
Ensembl chr 7:15,909,015...15,920,429
G
Mfge8
milk fat globule EGF and factor V/VIII domain containing
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of MFGE8 mRNA
CTD
PMID:18386188
NCBI chr 7:78,783,516...78,798,808
Ensembl chr 7:78,783,516...78,798,808
G
Mfsd4a
major facilitator superfamily domain containing 4A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MFSD4A mRNA
CTD
PMID:36117858
NCBI chr 1:131,947,543...131,997,400
Ensembl chr 1:131,950,544...131,995,800
G
Mgat4c
MGAT4 family, member C
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MGAT4C mRNA
CTD
PMID:36117858
NCBI chr10:101,517,348...102,227,712
Ensembl chr10:101,517,348...102,227,330
G
Mgst3
microsomal glutathione S-transferase 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MGST3 mRNA
CTD
PMID:36117858
NCBI chr 1:167,199,535...167,221,410
Ensembl chr 1:167,199,535...167,221,410
G
Mical3
microtubule associated monooxygenase, calponin and LIM domain containing 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MICAL3 mRNA
CTD
PMID:36117858
NCBI chr 6:120,908,507...121,150,716
Ensembl chr 6:120,908,668...121,107,959
G
Mir124a-1hg
Mir124-1 host gene (non-protein coding)
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of MIR124A-1HG mRNA
CTD
PMID:36117858
NCBI chr14:64,825,564...64,831,410
Ensembl chr14:64,824,744...64,831,410
G
Mki67
antigen identified by monoclonal antibody Ki 67
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of MKI67 mRNA
CTD
PMID:36117858
NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090
G
Mpped1
metallophosphoesterase domain containing 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of MPPED1 mRNA
CTD
PMID:36117858
NCBI chr15:83,656,256...83,742,688
Ensembl chr15:83,663,668...83,742,695
G
Mrc1
mannose receptor, C type 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of MRC1 mRNA
CTD
PMID:29568078
NCBI chr 2:14,234,225...14,336,834
Ensembl chr 2:14,234,203...14,336,868
G
Mrpl15
mitochondrial ribosomal protein L15
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of MRPL15 mRNA
CTD
PMID:18386188
NCBI chr 1:4,843,432...4,855,949
Ensembl chr 1:4,843,429...4,855,962
G
Mrtfb
myocardin related transcription factor B
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of MRTFB mRNA
CTD
PMID:22563483
NCBI chr16:13,073,913...13,235,393
Ensembl chr16:13,074,345...13,235,393
G
Mt1
metallothionein 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of MT1 mRNA
CTD
PMID:18386188
NCBI chr 8:94,905,214...94,906,955
Ensembl chr 8:94,905,710...94,906,955
G
Mtcl1
microtubule crosslinking factor 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MTCL1 mRNA
CTD
PMID:36117858
NCBI chr17:66,643,975...66,760,672
Ensembl chr17:66,643,977...66,756,745
G
Mthfr
methylenetetrahydrofolate reductase
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of MTHFR mRNA
CTD
PMID:18386188
NCBI chr 4:148,123,534...148,144,019
Ensembl chr 4:148,123,534...148,144,008
G
Mtor
mechanistic target of rapamycin kinase
multiple interactions increases expression
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MTOR mRNA; [Paraquat co-treated with Maneb] results in increased expression of MTOR protein; Maneb promotes the reaction [Paraquat results in increased expression of MTOR protein]; Paraquat promotes the reaction [Maneb results in increased expression of MTOR protein]
CTD
PMID:22292029 PMID:26884967 PMID:36117858
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
G
Muc6
mucin 6, gastric
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of MUC6 mRNA
CTD
PMID:22563483
NCBI chr 7:141,212,404...141,241,659
Ensembl chr 7:141,213,373...141,241,641
G
Myadml2
myeloid-associated differentiation marker-like 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MYADML2 mRNA
CTD
PMID:36117858
NCBI chr11:120,536,857...120,539,188
Ensembl chr11:120,536,857...120,538,984
G
Myc
myelocytomatosis oncogene
multiple interactions
EXP
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of MYC protein
CTD
PMID:19883720
NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
G
Mycn
v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MYCN mRNA
CTD
PMID:36117858
NCBI chr12:12,986,094...12,991,837
Ensembl chr12:12,986,094...12,991,915
G
Myh7
myosin, heavy polypeptide 7, cardiac muscle, beta
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of MYH7 mRNA
CTD
PMID:36117858
NCBI chr14:55,208,141...55,232,083
Ensembl chr14:55,208,141...55,232,083
G
Myl9
myosin, light polypeptide 9, regulatory
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of MYL9 mRNA
CTD
PMID:36117858
NCBI chr 2:156,617,373...156,623,578
Ensembl chr 2:156,617,340...156,623,578
G
Mylip
myosin regulatory light chain interacting protein
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of MYLIP mRNA
CTD
PMID:36117858
NCBI chr13:45,543,197...45,565,498
Ensembl chr13:45,543,218...45,565,498
G
N6amt1
N-6 adenine-specific DNA methyltransferase 1 (putative)
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of N6AMT1 mRNA
CTD
PMID:36117858
NCBI chr16:87,151,073...87,165,537
Ensembl chr16:87,151,073...87,165,630
G
Naa25
N(alpha)-acetyltransferase 25, NatB auxiliary subunit
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NAA25 mRNA
CTD
PMID:36117858
NCBI chr 5:121,535,977...121,580,612
Ensembl chr 5:121,535,999...121,582,441
G
Nap1l2
nucleosome assembly protein 1-like 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NAP1L2 mRNA
CTD
PMID:36117858
NCBI chr X:102,227,782...102,230,259
Ensembl chr X:102,227,782...102,230,246
G
Nap1l3
nucleosome assembly protein 1-like 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NAP1L3 mRNA
CTD
PMID:36117858
NCBI chr X:121,304,257...121,307,082
Ensembl chr X:121,304,262...121,307,098
G
Nbea
neurobeachin
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NBEA mRNA
CTD
PMID:36117858
NCBI chr 3:55,532,616...56,091,169
Ensembl chr 3:55,532,616...56,091,122
G
Ncf1
neutrophil cytosolic factor 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] affects the localization of NCF1 protein; [Maneb co-treated with Paraquat] results in increased expression of NCF1 protein; [Paraquat co-treated with Maneb] results in increased expression of NCF1 protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NCF1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NCF1 protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] affects the localization of NCF1 protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NCF1 protein]
CTD
PMID:28202386 PMID:29568078 PMID:32375810 PMID:34052309
NCBI chr 5:134,248,907...134,258,479
Ensembl chr 5:134,248,907...134,258,479
G
Ncoa7
nuclear receptor coactivator 7
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NCOA7 mRNA
CTD
PMID:36117858
NCBI chr10:30,521,578...30,683,401
Ensembl chr10:30,504,995...30,679,322
G
Ndnf
neuron-derived neurotrophic factor
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of NDNF mRNA
CTD
PMID:36117858
NCBI chr 6:65,648,595...65,689,307
Ensembl chr 6:65,648,574...65,689,310
G
Ndp
Norrie disease (pseudoglioma) (human)
multiple interactions
EXP
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NDP mRNA
CTD
PMID:23017109
NCBI chr X:16,751,760...16,778,013
Ensembl chr X:16,751,760...16,778,013
G
Ndst3
N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NDST3 mRNA
CTD
PMID:36117858
NCBI chr 3:123,319,815...123,484,822
Ensembl chr 3:123,319,815...123,484,502
G
Necab3
N-terminal EF-hand calcium binding protein 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NECAB3 mRNA
CTD
PMID:36117858
NCBI chr 2:154,386,311...154,401,326
Ensembl chr 2:154,386,319...154,400,810
G
Necap1
NECAP endocytosis associated 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NECAP1 mRNA
CTD
PMID:36117858
NCBI chr 6:122,851,516...122,865,902
Ensembl chr 6:122,851,433...122,865,900
G
Nefm
neurofilament, medium polypeptide
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NEFM mRNA
CTD
PMID:36117858
NCBI chr14:68,356,994...68,362,453
Ensembl chr14:68,320,039...68,362,295
G
Nemp1
nuclear envelope integral membrane protein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NEMP1 mRNA
CTD
PMID:36117858
NCBI chr10:127,512,934...127,536,918
Ensembl chr10:127,502,770...127,536,918
G
Net1
neuroepithelial cell transforming gene 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of NET1 mRNA
CTD
PMID:36117858
NCBI chr13:3,932,018...3,968,220
Ensembl chr13:3,932,018...3,968,220
G
Neurl1a
neuralized E3 ubiquitin protein ligase 1A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NEURL1A mRNA
CTD
PMID:36117858
NCBI chr19:47,167,259...47,247,880
Ensembl chr19:47,167,259...47,247,880
G
Neurod1
neurogenic differentiation 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NEUROD1 mRNA
CTD
PMID:23017109
NCBI chr 2:79,282,981...79,286,980
Ensembl chr 2:79,282,865...79,287,095
G
Neurod2
neurogenic differentiation 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NEUROD2 mRNA
CTD
PMID:36117858
NCBI chr11:98,216,241...98,220,471
Ensembl chr11:98,216,241...98,220,474
G
Nfat5
nuclear factor of activated T cells 5
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of NFAT5 mRNA
CTD
PMID:22563483
NCBI chr 8:108,020,072...108,106,149
Ensembl chr 8:108,020,102...108,106,149
G
Nfe2l2
nuclear factor, erythroid derived 2, like 2
increases expression multiple interactions increases response to substance
ISO EXP
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of GCLC mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of PRDX1 mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXN1 mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXNRD1 mRNA; Maneb results in increased expression of NFE2L2 protein [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased abundance of Glutathione; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of GSR protein; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of HMOX1 protein; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in increased abundance of Manganese; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in increased abundance of Thiobarbituric Acid Reactive Substances; NFE2L2 gene mutant form inhibits the reaction [Maneb results in increased expression of GPX4 mRNA]
CTD
PMID:21402726 PMID:23764462
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
G
Nfib
nuclear factor I/B
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of NFIB mRNA
CTD
PMID:22563483
NCBI chr 4:82,208,410...82,424,988
Ensembl chr 4:82,208,410...82,623,987
G
Nfkb1
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA]
CTD
PMID:23963992
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
G
Nfkbia
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased phosphorylation of and results in decreased expression of NFKBIA protein; [Paraquat co-treated with Maneb] results in increased degradation of and results in increased phosphorylation of NFKBIA protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased phosphorylation of and results in decreased expression of NFKBIA protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased degradation of and results in increased phosphorylation of NFKBIA protein]
CTD
PMID:28202386 PMID:29568078
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
G
Ngp
neutrophilic granule protein
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of NGP mRNA
CTD
PMID:22563483
NCBI chr 9:110,248,876...110,252,080
Ensembl chr 9:110,248,815...110,252,080
G
Nhp2
NHP2 ribonucleoprotein
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of NHP2 mRNA
CTD
PMID:36117858
NCBI chr11:51,510,600...51,514,545
Ensembl chr11:51,510,562...51,514,541
G
Ninl
ninein-like
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NINL mRNA
CTD
PMID:36117858
NCBI chr 2:150,776,439...150,851,330
Ensembl chr 2:150,776,439...150,881,302
G
Nipal3
NIPA-like domain containing 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NIPAL3 mRNA
CTD
PMID:36117858
NCBI chr 4:135,173,454...135,222,283
Ensembl chr 4:135,172,731...135,222,349
G
Nipbl
NIPBL cohesin loading factor
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of NIPBL mRNA
CTD
PMID:22563483
NCBI chr15:8,319,308...8,494,799
Ensembl chr15:8,320,101...8,473,947
G
Nlgn1
neuroligin 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NLGN1 mRNA
CTD
PMID:36117858
NCBI chr 3:25,475,972...26,387,504
Ensembl chr 3:25,480,379...26,386,609
G
Nlrp3
NLR family, pyrin domain containing 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of NLRP3 protein; [Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NLRP3 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein]
CTD
PMID:32375810 PMID:34052309
NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782
G
Nmnat1
nicotinamide nucleotide adenylyltransferase 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NMNAT1 mRNA
CTD
PMID:36117858
NCBI chr 4:149,552,026...149,569,667
Ensembl chr 4:149,552,029...149,569,659
G
Nmnat2
nicotinamide nucleotide adenylyltransferase 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NMNAT2 mRNA
CTD
PMID:36117858
NCBI chr 1:152,830,532...152,995,012
Ensembl chr 1:152,830,744...152,995,007
G
Nog
noggin
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NOG mRNA
CTD
PMID:23017109
NCBI chr11:89,191,464...89,193,385
Ensembl chr11:89,191,464...89,193,158
G
Nol4
nucleolar protein 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NOL4 mRNA
CTD
PMID:36117858
NCBI chr18:22,826,209...23,174,926
Ensembl chr18:22,826,238...23,174,710
G
Nos2
nitric oxide synthase 2, inducible
multiple interactions increases expression
EXP ISO
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; [Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA; [Maneb co-treated with Paraquat] results in increased expression of NOS2 protein; [Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA; [Paraquat co-treated with Maneb] results in increased expression of NOS2 protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Genistein inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; pimagedine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; prolinedithiocarbamate inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA] Maneb results in increased expression of NOS2 mRNA [Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of NOS2 mRNA]
CTD
PMID:20455021 PMID:23159886 PMID:23963992 PMID:28202386 PMID:29568078 PMID:30797899 PMID:32375810 PMID:34052309 More...
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
G
Nova1
NOVA alternative splicing regulator 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NOVA1 mRNA
CTD
PMID:36117858
NCBI chr12:46,744,678...46,866,143
Ensembl chr12:46,741,300...46,865,712
G
Nox1
NADPH oxidase 1
multiple interactions
ISO
[Paraquat co-treated with Maneb] results in increased expression of NOX1 mRNA; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOX1 mRNA]; diphenyleneiodonium inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOX1 mRNA]
CTD
PMID:30797899
NCBI chr X:132,987,170...133,038,455
Ensembl chr X:132,987,170...133,122,705
G
Nps
neuropeptide S
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of NPS mRNA
CTD
PMID:22563483
NCBI chr 7:134,870,348...134,874,671
Ensembl chr 7:134,860,432...134,874,671
G
Nqo1
NAD(P)H dehydrogenase, quinone 1
increases expression
ISO
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of NQO1 mRNA
CTD
PMID:21402726
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
G
Nr2f2
nuclear receptor subfamily 2, group F, member 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NR2F2 mRNA
CTD
PMID:36117858
NCBI chr 7:70,001,694...70,016,494
Ensembl chr 7:70,001,692...70,016,483
G
Nr4a1
nuclear receptor subfamily 4, group A, member 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of NR4A1 mRNA
CTD
PMID:22563483
NCBI chr15:101,151,783...101,172,676
Ensembl chr15:101,152,150...101,172,676
G
Nr4a2
nuclear receptor subfamily 4, group A, member 2
multiple interactions
ISO
[Paraquat co-treated with Maneb] results in decreased expression of NR4A2 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of NR4A2 protein
CTD
PMID:29152652
NCBI chr 2:56,996,845...57,014,152
Ensembl chr 2:56,996,842...57,014,015
G
Nrg1
neuregulin 1
multiple interactions
EXP
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NRG1 mRNA
CTD
PMID:23017109
NCBI chr 8:32,299,493...33,381,858
Ensembl chr 8:32,304,579...33,374,825 Ensembl chr 8:32,304,579...33,374,825
G
Nrip2
nuclear receptor interacting protein 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NRIP2 mRNA
CTD
PMID:36117858
NCBI chr 6:128,374,780...128,386,747
Ensembl chr 6:128,376,259...128,393,390
G
Nrn1
neuritin 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NRN1 mRNA
CTD
PMID:36117858
NCBI chr13:36,909,596...36,918,451
Ensembl chr13:36,909,335...36,919,105
G
Nrtn
neurturin
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of NRTN mRNA
CTD
PMID:22563483
NCBI chr17:57,058,323...57,064,548
Ensembl chr17:57,058,325...57,064,530
G
Ntn1
netrin 1
multiple interactions
EXP
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA; [Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA
CTD
PMID:23017109
NCBI chr11:68,100,190...68,277,652
Ensembl chr11:68,100,190...68,291,649
G
Ntn4
netrin 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NTN4 mRNA
CTD
PMID:36117858
NCBI chr10:93,476,911...93,581,834
Ensembl chr10:93,476,543...93,583,069
G
Ntng1
netrin G1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NTNG1 mRNA
CTD
PMID:36117858
NCBI chr 3:109,687,366...110,057,291
Ensembl chr 3:109,687,356...110,051,327
G
Ntrk2
neurotrophic tyrosine kinase, receptor, type 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA]
CTD
PMID:23963992
NCBI chr13:58,954,363...59,281,782
Ensembl chr13:58,954,383...59,281,784
G
Nudt11
nudix hydrolase 11
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of NUDT10 mRNA
CTD
PMID:36117858
NCBI chr X:5,959,488...5,966,805
Ensembl chr X:5,959,507...5,967,164
G
Nyap1
neuronal tyrosine-phosphorylated phosphoinositide 3-kinase adaptor 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of NYAP1 mRNA
CTD
PMID:36117858
NCBI chr 5:137,729,144...137,739,430
Ensembl chr 5:137,728,161...137,739,869
G
Oaz2
ornithine decarboxylase antizyme 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of OAZ2 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of OAZ2 mRNA]
CTD
PMID:23963992
NCBI chr 9:65,583,830...65,597,582
Ensembl chr 9:65,575,283...65,597,582
G
Ogfod1
2-oxoglutarate and iron-dependent oxygenase domain containing 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of OGFOD1 mRNA
CTD
PMID:36117858
NCBI chr 8:94,763,782...94,794,550
Ensembl chr 8:94,763,826...94,794,549
G
Onecut2
one cut domain, family member 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ONECUT2 mRNA
CTD
PMID:36117858
NCBI chr18:64,473,098...64,531,559
Ensembl chr18:64,473,091...64,534,058
G
Osbpl6
oxysterol binding protein-like 6
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of OSBPL6 mRNA
CTD
PMID:36117858
NCBI chr 2:76,236,848...76,430,991
Ensembl chr 2:76,236,852...76,430,991
G
P2ry4
pyrimidinergic receptor P2Y, G-protein coupled, 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of P2RY4 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of P2RY4 mRNA]
CTD
PMID:23963992
NCBI chr X:99,631,964...99,638,533
Ensembl chr X:99,633,760...99,638,475
G
Pak6
p21 (RAC1) activated kinase 6
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PAK6 mRNA
CTD
PMID:36117858
NCBI chr 2:118,493,531...118,528,501
Ensembl chr 2:118,493,784...118,528,501
G
Pamr1
peptidase domain containing associated with muscle regeneration 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PAMR1 mRNA
CTD
PMID:36117858
NCBI chr 2:102,380,325...102,473,386
Ensembl chr 2:102,380,357...102,473,386
G
Park7
Parkinson disease (autosomal recessive, early onset) 7
multiple interactions decreases activity
ISO
3-(4-(morpholin-4-yl)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)benzonitrile inhibits the reaction [[Paraquat co-treated with Maneb] results in increased oxidation of PARK7 protein]; [Paraquat co-treated with Maneb] results in increased oxidation of PARK7 protein; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased oxidation of PARK7 protein]; Maneb results in decreased activity of and results in increased oxidation of PARK7 protein; Plant Extracts inhibits the reaction [[Paraquat co-treated with Maneb] results in increased oxidation of PARK7 protein] Maneb results in decreased activity of PARK7 protein
CTD
PMID:34897981 PMID:36842454
NCBI chr 4:150,981,590...150,994,378
Ensembl chr 4:150,981,590...150,998,894
G
Parm1
prostate androgen-regulated mucin-like protein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PARM1 mRNA
CTD
PMID:36117858
NCBI chr 5:91,665,559...91,771,870
Ensembl chr 5:91,665,474...91,774,753
G
Pax5
paired box 5
multiple interactions
EXP
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX5 mRNA
CTD
PMID:23017109
NCBI chr 4:44,524,748...44,710,694
Ensembl chr 4:44,524,757...44,710,487
G
Pax6
paired box 6
multiple interactions
EXP
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX6 mRNA
CTD
PMID:23017109
NCBI chr 2:105,499,241...105,528,755
Ensembl chr 2:105,499,245...105,527,709
G
Pcbd1
pterin 4 alpha carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor 1 alpha (TCF1) 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PCBD1 mRNA
CTD
PMID:36117858
NCBI chr10:60,925,110...60,930,108
Ensembl chr10:60,925,110...60,930,103
G
Pcdh11x
protocadherin 11 X-linked
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PCDH11X mRNA
CTD
PMID:36117858
NCBI chr X:119,199,954...119,820,319
Ensembl chr X:119,199,956...119,820,316
G
Pcdh18
protocadherin 18
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PCDH18 mRNA
CTD
PMID:36117858
NCBI chr 3:49,697,745...49,711,723
Ensembl chr 3:49,697,745...49,711,774
G
Pcdh19
protocadherin 19
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of PCDH19 mRNA
CTD
PMID:36117858
NCBI chr X:132,483,609...132,589,802
Ensembl chr X:132,483,609...132,589,736
G
Pcdh7
protocadherin 7
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of PCDH7 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PCDH7 mRNA]
CTD
PMID:23963992
NCBI chr 5:57,873,487...58,290,578
Ensembl chr 5:57,875,309...58,290,572
G
Pcdh9
protocadherin 9
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of PCDH9 mRNA
CTD
PMID:36117858
NCBI chr14:93,251,136...94,132,619
Ensembl chr14:93,250,846...94,128,115
G
Pcdhb20
protocadherin beta 20
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PCDHB14 mRNA
CTD
PMID:36117858
NCBI chr18:37,637,332...37,640,713
Ensembl chr18:37,637,317...37,640,875
G
Pcgf2
polycomb group ring finger 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PCGF2 mRNA
CTD
PMID:36117858
NCBI chr11:97,579,647...97,593,260
Ensembl chr11:97,579,649...97,591,323
G
Pclaf
PCNA clamp associated factor
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of PCLAF mRNA
CTD
PMID:36117858
NCBI chr 9:65,797,605...65,810,833
Ensembl chr 9:65,797,519...65,810,548
G
Pcna
proliferating cell nuclear antigen
multiple interactions
EXP
3-bromo-7-nitroindazole inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of PCNA protein]; [Paraquat co-treated with Maneb] results in decreased expression of PCNA protein
CTD
PMID:23985028
NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234
G
Pcp2
Purkinje cell protein 2 (L7)
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of PCP2 mRNA
CTD
PMID:22563483
NCBI chr 8:3,673,369...3,675,547
Ensembl chr 8:3,673,371...3,675,545
G
Pdcd10
programmed cell death 10
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of PDCD10 mRNA
CTD
PMID:18386188
NCBI chr 3:75,423,797...75,464,159
Ensembl chr 3:75,423,797...75,464,163
G
Pde10a
phosphodiesterase 10A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PDE10A mRNA
CTD
PMID:36117858
NCBI chr17:8,742,719...9,205,480
Ensembl chr17:8,744,204...9,205,480
G
Pde1b
phosphodiesterase 1B, Ca2+-calmodulin dependent
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PDE1B mRNA; [Maneb co-treated with Paraquat] results in increased expression of PDE1B mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PDE1B mRNA]
CTD
PMID:23963992 PMID:36117858
NCBI chr15:103,411,461...103,438,483
Ensembl chr15:103,411,461...103,438,479
G
Pde2a
phosphodiesterase 2A, cGMP-stimulated
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PDE2A mRNA
CTD
PMID:36117858
NCBI chr 7:101,070,905...101,162,026
Ensembl chr 7:101,060,093...101,162,026 Ensembl chr 7:101,060,093...101,162,026
G
Pdgfra
platelet derived growth factor receptor, alpha polypeptide
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of PDGFRA mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PDGFRA mRNA]
CTD
PMID:23963992
NCBI chr 5:75,311,988...75,358,867
Ensembl chr 5:75,312,953...75,358,876
G
Pdha1
pyruvate dehydrogenase E1 alpha 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PDHA1 mRNA; [Maneb co-treated with Paraquat] results in increased expression of PDHA1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PDHA1 protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PDHA1 mRNA]
CTD
PMID:23562983 PMID:23963992
NCBI chr X:158,905,215...158,921,426
Ensembl chr X:158,905,205...158,921,409
G
Pdyn
prodynorphin
multiple interactions
ISO
[Paraquat co-treated with Maneb] results in decreased expression of PDYN
CTD
PMID:24376148
NCBI chr 2:129,528,469...129,541,858
Ensembl chr 2:129,528,485...129,541,764
G
Pdzd2
PDZ domain containing 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PDZD2 mRNA
CTD
PMID:36117858
NCBI chr15:12,359,797...12,740,052
Ensembl chr15:12,359,797...12,740,010
G
Pdzd4
PDZ domain containing 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PDZD4 mRNA; [Maneb co-treated with Paraquat] results in increased expression of PDZD4 mRNA
CTD
PMID:36117858
NCBI chr X:72,836,963...72,868,649
Ensembl chr X:72,836,965...72,868,575
G
Pear1
platelet endothelial aggregation receptor 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of PEAR1 mRNA
CTD
PMID:36117858
NCBI chr 3:87,656,404...87,676,262
Ensembl chr 3:87,655,197...87,676,273
G
Pebp1
phosphatidylethanolamine binding protein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PEBP1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PEBP1 protein]
CTD
PMID:23562983
NCBI chr 5:117,420,716...117,425,629
Ensembl chr 5:117,420,719...117,425,690
G
Peg10
paternally expressed 10
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PEG10 mRNA
CTD
PMID:36117858
NCBI chr 6:4,747,306...4,760,517
Ensembl chr 6:4,747,306...4,760,517
G
Perp
PERP, TP53 apoptosis effector
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of PERP mRNA
CTD
PMID:36117858
NCBI chr10:18,720,819...18,732,821
Ensembl chr10:18,720,768...18,732,821
G
Pfkfb4
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PFKFB4 mRNA
CTD
PMID:36117858
NCBI chr 9:108,817,336...108,861,302
Ensembl chr 9:108,820,846...108,861,296
G
Pgap1
post-GPI attachment to proteins 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PGAP1 mRNA
CTD
PMID:36117858
NCBI chr 1:54,512,159...54,596,843
Ensembl chr 1:54,512,153...54,596,843
G
Pgm2
phosphoglucomutase 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PGM2 mRNA
CTD
PMID:36117858
NCBI chr 5:64,250,258...64,285,698
Ensembl chr 5:64,250,293...64,285,694
G
Pgm2l1
phosphoglucomutase 2-like 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PGM2L1 mRNA
CTD
PMID:36117858
NCBI chr 7:99,876,471...99,928,079
Ensembl chr 7:99,876,601...99,928,075
G
Pgs1
phosphatidylglycerophosphate synthase 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of PGS1 mRNA
CTD
PMID:18386188
NCBI chr11:117,876,505...117,914,837
Ensembl chr11:117,877,118...117,914,837
G
Pigc
phosphatidylinositol glycan anchor biosynthesis, class C
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of PIGC mRNA
CTD
PMID:18386188
NCBI chr 1:161,796,757...161,801,029
Ensembl chr 1:161,796,755...161,801,004
G
Pigw
phosphatidylinositol glycan anchor biosynthesis, class W
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PIGW mRNA
CTD
PMID:36117858
NCBI chr11:84,767,139...84,771,111
Ensembl chr11:84,767,141...84,771,111
G
Pik3r3
phosphoinositide-3-kinase regulatory subunit 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of PIK3R3 mRNA
CTD
PMID:36117858
NCBI chr 4:116,078,593...116,160,253
Ensembl chr 4:116,078,815...116,160,253 Ensembl chr 4:116,078,815...116,160,253
G
Pitpnm3
PITPNM family member 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of PITPNM3 mRNA
CTD
PMID:36117858
NCBI chr11:71,938,354...72,026,715
Ensembl chr11:71,938,354...72,026,604
G
Pkib
protein kinase inhibitor beta, cAMP dependent, testis specific
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PKIB mRNA
CTD
PMID:36117858
NCBI chr10:57,508,077...57,617,208
Ensembl chr10:57,508,077...57,617,208
G
Plce1
phospholipase C, epsilon 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of PLCE1 mRNA
CTD
PMID:22563483
NCBI chr19:38,469,438...38,773,549
Ensembl chr19:38,469,557...38,773,474
G
Plekhm2
pleckstrin homology domain containing, family M (with RUN domain) member 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PLEKHM2 mRNA
CTD
PMID:36117858
NCBI chr 4:141,353,043...141,391,457
Ensembl chr 4:141,353,045...141,392,210
G
Plpp4
phospholipid phosphatase 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PLPP4 mRNA
CTD
PMID:36117858
NCBI chr 7:128,858,114...128,993,138
Ensembl chr 7:128,858,755...128,993,136
G
Plxna1
plexin A1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PLXNA1 mRNA
CTD
PMID:36117858
NCBI chr 6:89,293,295...89,339,595
Ensembl chr 6:89,293,296...89,339,602
G
Plxnc1
plexin C1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PLXNC1 mRNA
CTD
PMID:36117858
NCBI chr10:94,626,728...94,780,875
Ensembl chr10:94,626,728...94,780,697
G
Pmaip1
phorbol-12-myristate-13-acetate-induced protein 1
increases expression
ISO
Maneb results in increased expression of PMAIP1 mRNA; Maneb results in increased expression of PMAIP1 protein
CTD
PMID:18266926
NCBI chr18:66,591,675...66,598,629
Ensembl chr18:66,591,604...66,598,636
G
Pnoc
prepronociceptin
multiple interactions
ISO
[Paraquat co-treated with Maneb] results in increased expression of PNOC
CTD
PMID:24376148
NCBI chr14:65,638,931...65,662,908
Ensembl chr14:65,638,122...65,662,921
G
Polr1b
polymerase (RNA) I polypeptide B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of POLR1B mRNA
CTD
PMID:36117858
NCBI chr 2:128,942,891...128,969,980
Ensembl chr 2:128,942,915...128,968,514
G
Polr1c
polymerase (RNA) I polypeptide C
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of POLR1C mRNA
CTD
PMID:18386188
NCBI chr17:46,554,846...46,558,971
Ensembl chr17:46,554,846...46,558,980
G
Polr2k
polymerase (RNA) II (DNA directed) polypeptide K
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of POLR2K mRNA
CTD
PMID:22563483
NCBI chr15:36,174,156...36,177,158
Ensembl chr15:36,174,156...36,177,156
G
Pom121
nuclear pore membrane protein 121
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of POM121 mRNA
CTD
PMID:36117858
NCBI chr 5:135,404,994...135,433,587
Ensembl chr 5:135,404,995...135,423,400
G
Pou3f3
POU domain, class 3, transcription factor 3
multiple interactions
EXP
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of POU3F3 mRNA
CTD
PMID:23017109
NCBI chr 1:42,734,928...42,739,370
Ensembl chr 1:42,734,085...42,742,336
G
Ppfia3
protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PPFIA3 mRNA; [Maneb co-treated with Paraquat] results in increased expression of PPFIA3 mRNA
CTD
PMID:36117858
NCBI chr 7:44,988,550...45,016,443
Ensembl chr 7:44,988,546...45,016,443
G
Ppip5k1
diphosphoinositol pentakisphosphate kinase 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PPIP5K1 mRNA
CTD
PMID:36117858
NCBI chr 2:121,141,038...121,186,138
Ensembl chr 2:121,141,042...121,185,877
G
Ppp1r3f
protein phosphatase 1, regulatory subunit 3F
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PPP1R3F mRNA
CTD
PMID:36117858
NCBI chr X:7,424,815...7,440,541
Ensembl chr X:7,423,535...7,440,522
G
Ppp2r2c
protein phosphatase 2, regulatory subunit B, gamma
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PPP2R2C mRNA
CTD
PMID:36117858
NCBI chr 5:37,024,187...37,112,422
Ensembl chr 5:37,025,857...37,112,422
G
Ppp6r1
protein phosphatase 6, regulatory subunit 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PPP6R1 mRNA
CTD
PMID:36117858
NCBI chr 7:4,634,494...4,661,949
Ensembl chr 7:4,634,494...4,662,018
G
Ppwd1
peptidylprolyl isomerase domain and WD repeat containing 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PPWD1 mRNA
CTD
PMID:36117858
NCBI chr13:104,340,102...104,365,378
Ensembl chr13:104,341,632...104,365,351
G
Prdm15
PR domain containing 15
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PRDM15 mRNA
CTD
PMID:36117858
NCBI chr16:97,592,720...97,653,076
Ensembl chr16:97,592,667...97,653,050
G
Prdx1
peroxiredoxin 1
increases expression
ISO
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of PRDX1 mRNA
CTD
PMID:21402726
NCBI chr 4:116,542,796...116,557,196
Ensembl chr 4:116,542,741...116,558,019
G
Prdx3
peroxiredoxin 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein]
CTD
PMID:23562983
NCBI chr19:60,852,504...60,862,976
Ensembl chr19:60,852,489...60,862,994
G
Prkaca
protein kinase, cAMP dependent, catalytic, alpha
multiple interactions
ISO
[Paraquat co-treated with Maneb] results in decreased expression of PRKACA mRNA; [Paraquat co-treated with Maneb] results in decreased expression of PRKACA protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of PRKACA mRNA]
CTD
PMID:27460631 PMID:33368748
NCBI chr 8:84,699,607...84,723,073
Ensembl chr 8:84,699,622...84,723,072
G
Prkcz
protein kinase C, zeta
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of PRKCZ mRNA
CTD
PMID:18386188
NCBI chr 4:155,344,579...155,445,856
Ensembl chr 4:155,344,586...155,445,818
G
Prkn
parkin RBR E3 ubiquitin protein ligase
multiple interactions
EXP
3-bromo-7-nitroindazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased nitrosation of PRKN protein]; [Paraquat co-treated with Maneb] results in increased expression of PRKN protein; [Paraquat co-treated with Maneb] results in increased nitrosation of PRKN protein
CTD
PMID:22563483 PMID:23985028
NCBI chr17:11,059,227...12,282,257
Ensembl chr17:11,059,271...12,282,248
G
Prl
prolactin
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of PRL mRNA
CTD
PMID:22563483
NCBI chr13:27,241,553...27,249,187
Ensembl chr13:27,241,553...27,249,188
G
Prmt8
protein arginine N-methyltransferase 8
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PRMT8 mRNA
CTD
PMID:36117858
NCBI chr 6:127,665,972...127,746,430
Ensembl chr 6:127,665,974...127,746,435
G
Prr7
proline rich 7 (synaptic)
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of PRR7 mRNA
CTD
PMID:22563483
NCBI chr13:55,612,080...55,620,968
Ensembl chr13:55,612,080...55,620,967
G
Prrt1
proline-rich transmembrane protein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of PRRT1 mRNA
CTD
PMID:36117858
NCBI chr17:34,848,396...34,852,108
Ensembl chr17:34,848,507...34,852,100
G
Psap
prosaposin
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of PSAP mRNA
CTD
PMID:18386188
NCBI chr10:60,113,436...60,138,379
Ensembl chr10:60,113,449...60,138,376
G
Psen1
presenilin 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of PSEN1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PSEN1 mRNA]
CTD
PMID:23963992
NCBI chr12:83,734,926...83,781,869
Ensembl chr12:83,734,926...83,781,973
G
Psmb1
proteasome (prosome, macropain) subunit, beta type 1
multiple interactions
ISO
Maneb inhibits the reaction [Paraquat results in decreased expression of PSMB1 mRNA]
CTD
PMID:26498265
NCBI chr17:15,695,983...15,718,538
Ensembl chr17:15,695,283...15,720,013
G
Psmc4
proteasome (prosome, macropain) 26S subunit, ATPase, 4
multiple interactions
EXP ISO
[Maneb co-treated with Paraquat] results in decreased expression of PSMC4 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PSMC4 mRNA] [Paraquat co-treated with Maneb] results in decreased expression of PSMC4 mRNA
CTD
PMID:23963992 PMID:26498265
NCBI chr 7:27,741,127...27,749,517
Ensembl chr 7:27,741,132...27,749,526
G
Ptchd4
patched domain containing 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of PTCHD4 mRNA
CTD
PMID:36117858
NCBI chr17:42,626,646...43,004,339
Ensembl chr17:42,626,838...42,815,968
G
Ptk2b
PTK2 protein tyrosine kinase 2 beta
multiple interactions
EXP
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of PTK2B protein modified form; [Maneb co-treated with Paraquat] results in decreased expression of PTK2B mRNA
CTD
PMID:19883720 PMID:36117858
NCBI chr14:66,390,706...66,518,549
Ensembl chr14:66,390,706...66,518,501
G
Ptpn4
protein tyrosine phosphatase, non-receptor type 4
affects activity
ISO
Maneb affects the activity of PTPN4 protein
CTD
PMID:23611293
NCBI chr 1:119,580,197...119,765,281
Ensembl chr 1:119,580,197...119,765,343
G
Ptpn9
protein tyrosine phosphatase, non-receptor type 9
affects activity
ISO
Maneb affects the activity of PTPN9 protein
CTD
PMID:23611293
NCBI chr 9:56,902,252...56,970,092
Ensembl chr 9:56,902,207...56,970,091
G
Ptprf
protein tyrosine phosphatase receptor type F
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PTPRF mRNA
CTD
PMID:36117858
NCBI chr 4:118,065,410...118,148,602
Ensembl chr 4:118,065,410...118,148,602
G
Ptpro
protein tyrosine phosphatase receptor type O
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PTPRO mRNA
CTD
PMID:36117858
NCBI chr 6:137,229,189...137,440,251
Ensembl chr 6:137,229,317...137,440,231
G
Ptpru
protein tyrosine phosphatase receptor type U
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of PTPRU mRNA
CTD
PMID:36117858
NCBI chr 4:131,495,768...131,565,617
Ensembl chr 4:131,495,768...131,565,599
G
Rab27a
RAB27A, member RAS oncogene family
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RAB27A mRNA
CTD
PMID:36117858
NCBI chr 9:72,952,092...73,004,905
Ensembl chr 9:72,952,136...73,004,911
G
Rab40b
Rab40B, member RAS oncogene family
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RAB40B mRNA
CTD
PMID:36117858
NCBI chr11:121,246,951...121,279,080
Ensembl chr11:121,246,951...121,279,077
G
Raf1
v-raf-leukemia viral oncogene 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RAF1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of RAF1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of RAF1 mRNA]
CTD
PMID:23963992
NCBI chr 6:115,595,530...115,653,596
Ensembl chr 6:115,595,028...115,653,596
G
Ralgapb
Ral GTPase activating protein, beta subunit (non-catalytic)
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of RALGAPB mRNA
CTD
PMID:36117858
NCBI chr 2:158,251,722...158,341,173
Ensembl chr 2:158,251,768...158,341,173
G
Rapgefl1
Rap guanine nucleotide exchange factor (GEF)-like 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RAPGEFL1 mRNA
CTD
PMID:36117858
NCBI chr11:98,727,611...98,744,519
Ensembl chr11:98,727,611...98,744,523
G
Rars1
arginyl-tRNA synthetase 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of RARS mRNA
CTD
PMID:36117858
NCBI chr11:35,699,207...35,725,355
Ensembl chr11:35,699,208...35,725,333
G
Rasgef1a
RasGEF domain family, member 1A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of RASGEF1A mRNA
CTD
PMID:36117858
NCBI chr 6:117,988,466...118,068,507
Ensembl chr 6:117,988,399...118,068,507
G
Rasgrf2
RAS protein-specific guanine nucleotide-releasing factor 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RASGRF2 mRNA
CTD
PMID:36117858
NCBI chr13:92,028,526...92,268,584
Ensembl chr13:92,028,519...92,268,164
G
Rasgrp1
RAS guanyl releasing protein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of RASGRP1 mRNA
CTD
PMID:36117858
NCBI chr 2:117,110,464...117,173,358
Ensembl chr 2:117,110,474...117,173,482
G
Rassf8
Ras association (RalGDS/AF-6) domain family (N-terminal) member 8
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RASSF8 mRNA
CTD
PMID:36117858
NCBI chr 6:145,692,292...145,766,805
Ensembl chr 6:145,692,474...145,766,805
G
Rb1
RB transcriptional corepressor 1
multiple interactions increases expression
ISO
[Maneb co-treated with Paraquat] results in increased expression of RB1 mRNA; Acetylcysteine inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of RB1 mRNA]; Acetylcysteine inhibits the reaction [Maneb results in increased expression of RB1 mRNA]
CTD
PMID:29859004
NCBI chr14:73,430,298...73,563,446
Ensembl chr14:73,421,113...73,563,262
G
Rbx1
ring-box 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of RBX1 mRNA
CTD
PMID:18386188
NCBI chr15:81,350,517...81,360,570
Ensembl chr15:81,350,497...81,360,570
G
Rcan1
regulator of calcineurin 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RCAN1 mRNA; [Maneb co-treated with Paraquat] results in increased expression of RCAN1 mRNA
CTD
PMID:36117858
NCBI chr16:92,188,839...92,263,057
Ensembl chr16:92,188,841...92,267,755
G
Rela
v-rel reticuloendotheliosis viral oncogene homolog A (avian)
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased phosphorylation of RELA protein; [Paraquat co-treated with Maneb] results in increased phosphorylation of RELA protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased phosphorylation of RELA protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of RELA protein]
CTD
PMID:28202386 PMID:29568078
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
G
Rflnb
refilin B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of RFLNB mRNA
CTD
PMID:36117858
NCBI chr11:75,910,020...75,918,608
Ensembl chr11:75,910,020...75,918,608
G
Rgs4
regulator of G-protein signaling 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RGS4 mRNA
CTD
PMID:36117858
NCBI chr 1:169,569,046...169,575,211
Ensembl chr 1:169,569,046...169,575,211
G
Rgs7
regulator of G protein signaling 7
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RGS7 mRNA
CTD
PMID:36117858
NCBI chr 1:174,886,642...175,320,287
Ensembl chr 1:174,886,653...175,320,066
G
Rims3
regulating synaptic membrane exocytosis 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RIMS3 mRNA
CTD
PMID:36117858
NCBI chr 4:120,711,976...120,753,777
Ensembl chr 4:120,712,013...120,753,776
G
Ripk1
receptor (TNFRSF)-interacting serine-threonine kinase 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of RIPK1 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of RIPK1 mRNA]
CTD
PMID:23963992
NCBI chr13:34,181,072...34,219,153
Ensembl chr13:34,186,346...34,221,130
G
Rit2
Ras-like without CAAX 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RIT2 mRNA
CTD
PMID:36117858
NCBI chr18:31,107,367...31,450,181
Ensembl chr18:31,106,542...31,450,343
G
Rnd1
Rho family GTPase 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RND1 mRNA
CTD
PMID:36117858
NCBI chr15:98,567,086...98,575,342
Ensembl chr15:98,561,302...98,575,342
G
Rnf150
ring finger protein 150
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RNF150 mRNA
CTD
PMID:36117858
NCBI chr 8:83,589,889...83,817,900
Ensembl chr 8:83,589,985...83,817,897
G
Rnf157
ring finger protein 157
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of RNF157 mRNA
CTD
PMID:36117858
NCBI chr11:116,227,179...116,303,859
Ensembl chr11:116,227,179...116,303,858
G
Rnf208
ring finger protein 208
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RNF208 mRNA
CTD
PMID:36117858
NCBI chr 2:25,132,941...25,134,273
Ensembl chr 2:25,132,941...25,134,274
G
Rnf220
ring finger protein 220
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of RNF220 mRNA
CTD
PMID:36117858
NCBI chr 4:117,128,660...117,354,249
Ensembl chr 4:117,128,660...117,354,249
G
Rock1
Rho-associated coiled-coil containing protein kinase 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of ROCK1 mRNA
CTD
PMID:22563483
NCBI chr18:10,064,401...10,182,225
Ensembl chr18:10,064,401...10,182,045
G
Rora
RAR-related orphan receptor alpha
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RORA mRNA
CTD
PMID:36117858
NCBI chr 9:68,560,627...69,295,528
Ensembl chr 9:68,561,068...69,295,528
G
Rpl12
ribosomal protein L12
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of RPL12 mRNA
CTD
PMID:18386188
NCBI chr 2:32,851,724...32,854,057
Ensembl chr 2:32,851,571...32,855,357
G
Rpl19
ribosomal protein L19
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RPL19 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of RPL19 mRNA]
CTD
PMID:23963992
NCBI chr11:97,912,829...97,921,319
Ensembl chr11:97,917,536...97,921,318
G
Rpl41
ribosomal protein L41
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of RPL41 mRNA
CTD
PMID:18386188
NCBI chr10:128,383,979...128,385,037
Ensembl chr10:128,383,983...128,385,174
G
Rpl8
ribosomal protein L8
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of RPL8 mRNA
CTD
PMID:18386188
NCBI chr15:76,788,271...76,790,518
Ensembl chr15:76,788,278...76,790,514
G
Rpl9
ribosomal protein L9
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of RPL9 mRNA
CTD
PMID:18386188
NCBI chr 5:65,545,707...65,548,774
Ensembl chr 5:65,545,707...65,548,787
G
Rprm
reprimo, TP53 dependent G2 arrest mediator candidate
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RPRM mRNA
CTD
PMID:36117858
NCBI chr 2:53,974,105...53,975,564
Ensembl chr 2:53,974,105...53,975,564
G
Rps12
ribosomal protein S12
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of RPS12 mRNA
CTD
PMID:18386188
NCBI chr10:23,661,042...23,664,297
Ensembl chr10:23,661,081...23,663,173
G
Rps15
ribosomal protein S15
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of RPS15 mRNA
CTD
PMID:18386188
NCBI chr10:80,128,265...80,129,948
Ensembl chr10:80,128,287...80,129,948
G
Rps27
ribosomal protein S27
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of RPS27 mRNA
CTD
PMID:18386188
NCBI chr 3:90,119,974...90,120,955
Ensembl chr 3:90,119,829...90,120,958
G
Rps6ka2
ribosomal protein S6 kinase, polypeptide 2
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of RPS6KA2 mRNA
CTD
PMID:18386188
NCBI chr17:7,356,384...7,570,714
Ensembl chr17:7,292,942...7,570,726
G
Rrp12
ribosomal RNA processing 12 homolog
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RRP12 mRNA
CTD
PMID:36117858
NCBI chr19:41,847,922...41,884,592
Ensembl chr19:41,851,290...41,884,612
G
Rtn4
reticulon 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of RTN4 mRNA
CTD
PMID:23017109
NCBI chr11:29,642,898...29,694,414
Ensembl chr11:29,642,947...29,694,331
G
Rtn4r
reticulon 4 receptor
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of RTN4R mRNA
CTD
PMID:36117858
NCBI chr16:17,945,506...17,970,272
Ensembl chr16:17,945,506...17,970,272
G
Rtn4rl2
reticulon 4 receptor-like 2
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of RTN4RL2 mRNA
CTD
PMID:22563483
NCBI chr 2:84,701,653...84,718,985
Ensembl chr 2:84,702,268...84,717,054
G
S100a8
S100 calcium binding protein A8 (calgranulin A)
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of S100A8 mRNA
CTD
PMID:22563483
NCBI chr 3:90,576,378...90,577,341
Ensembl chr 3:90,576,285...90,577,342
G
S100a9
S100 calcium binding protein A9 (calgranulin B)
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of S100A9 mRNA
CTD
PMID:22563483
NCBI chr 3:90,599,937...90,603,028
Ensembl chr 3:90,599,939...90,603,028
G
Saa2
serum amyloid A 2
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of SAA2 mRNA
CTD
PMID:22563483
NCBI chr 7:46,401,257...46,403,737
Ensembl chr 7:46,401,214...46,403,737
G
Sacs
sacsin
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SACS mRNA
CTD
PMID:36117858
NCBI chr14:61,375,870...61,478,142
Ensembl chr14:61,375,906...61,478,144
G
Samd10
sterile alpha motif domain containing 10
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SAMD10 mRNA
CTD
PMID:36117858
NCBI chr 2:181,237,008...181,241,227
Ensembl chr 2:181,237,011...181,241,005
G
Samd14
sterile alpha motif domain containing 14
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SAMD14 mRNA
CTD
PMID:36117858
NCBI chr11:94,900,213...94,916,913
Ensembl chr11:94,900,705...94,916,913
G
Samd4
sterile alpha motif domain containing 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SAMD4 mRNA
CTD
PMID:36117858
NCBI chr14:47,120,414...47,343,274
Ensembl chr14:47,120,311...47,343,272
G
Scamp2
secretory carrier membrane protein 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SCAMP2 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SCAMP2 mRNA]
CTD
PMID:23963992
NCBI chr 9:57,468,227...57,496,081
Ensembl chr 9:57,468,226...57,496,078
G
Scand1
SCAN domain-containing 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of SCAND1 mRNA
CTD
PMID:22563483
NCBI chr 2:156,153,766...156,154,624
Ensembl chr 2:156,153,766...156,154,667
G
Scn2a
sodium channel, voltage-gated, type II, alpha
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SCN2A mRNA
CTD
PMID:36117858
NCBI chr 2:65,451,108...65,597,791
Ensembl chr 2:65,451,115...65,597,791
G
Scn3b
sodium channel, voltage-gated, type III, beta
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SCN3B mRNA
CTD
PMID:36117858
NCBI chr 9:40,180,512...40,202,914
Ensembl chr 9:40,180,513...40,202,914
G
Sdhb
succinate dehydrogenase complex, subunit B, iron sulfur (Ip)
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of SDHB mRNA
CTD
PMID:18386188
NCBI chr 4:140,688,582...140,706,509
Ensembl chr 4:140,688,514...140,706,504
G
Sema3e
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3E
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of SEMA3E mRNA
CTD
PMID:36117858
NCBI chr 5:14,075,290...14,306,703
Ensembl chr 5:14,075,290...14,306,703
G
Sema4d
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D
multiple interactions
EXP
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of SEMA4D mRNA
CTD
PMID:23017109
NCBI chr13:51,839,565...51,947,823
Ensembl chr13:51,839,565...51,947,783
G
Sema5a
sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SEMA5A mRNA
CTD
PMID:36117858
NCBI chr15:32,244,959...32,696,487
Ensembl chr15:32,244,956...32,696,487
G
Sema6b
sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SEMA6B mRNA
CTD
PMID:36117858
NCBI chr17:56,430,085...56,447,343
Ensembl chr17:56,430,085...56,447,343
G
Serp2
stress-associated endoplasmic reticulum protein family member 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SERP2 mRNA
CTD
PMID:36117858
NCBI chr14:76,770,252...76,794,518
Ensembl chr14:76,770,254...76,794,329
G
Setd6
SET domain containing 6
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SETD6 mRNA
CTD
PMID:36117858
NCBI chr 8:96,442,211...96,448,135
Ensembl chr 8:96,442,509...96,445,638
G
Sfxn2
sideroflexin 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of SFXN2 mRNA
CTD
PMID:36117858
NCBI chr19:46,561,798...46,585,340
Ensembl chr19:46,561,804...46,586,505
G
Sgsm1
small G protein signaling modulator 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SGSM1 mRNA
CTD
PMID:36117858
NCBI chr 5:113,391,086...113,458,654
Ensembl chr 5:113,391,086...113,458,652
G
Sgsm2
small G protein signaling modulator 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of SGSM2 mRNA
CTD
PMID:36117858
NCBI chr11:74,740,088...74,787,929
Ensembl chr11:74,740,087...74,787,886
G
Sgsm3
small G protein signaling modulator 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SGSM3 mRNA
CTD
PMID:36117858
NCBI chr15:80,861,966...80,896,491
Ensembl chr15:80,861,966...80,896,491
G
Sgtb
small glutamine-rich tetratricopeptide repeat (TPR)-containing, beta
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SGTB mRNA; [Maneb co-treated with Paraquat] results in increased expression of SGTB mRNA
CTD
PMID:36117858
NCBI chr13:104,246,233...104,278,369
Ensembl chr13:104,246,249...104,278,243
G
Sh3rf1
SH3 domain containing ring finger 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SH3RF1 mRNA
CTD
PMID:36117858
NCBI chr 8:61,677,117...61,918,327
Ensembl chr 8:61,676,906...61,849,105
G
Sh3yl1
Sh3 domain YSC-like 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SH3YL1 mRNA
CTD
PMID:36117858
NCBI chr12:30,961,622...31,010,159
Ensembl chr12:30,961,667...31,010,161
G
Shisa7
shisa family member 7
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SHISA7 mRNA
CTD
PMID:36117858
NCBI chr 7:4,828,551...4,847,788
Ensembl chr 7:4,828,551...4,847,695
G
Shisa9
shisa family member 9
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SHISA9 mRNA
CTD
PMID:36117858
NCBI chr16:11,801,457...12,088,768
Ensembl chr16:11,801,977...12,088,766
G
Shtn1
shootin 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SHTN1 mRNA
CTD
PMID:36117858
NCBI chr19:58,961,790...59,064,536
Ensembl chr19:58,961,788...59,064,532
G
Sipa1l3
signal-induced proliferation-associated 1 like 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SIPA1L3 mRNA
CTD
PMID:36117858
NCBI chr 7:29,016,687...29,218,694
Ensembl chr 7:29,019,797...29,218,066
G
Sirt1
sirtuin 1
decreases activity
ISO
Maneb results in decreased activity of SIRT1 protein
CTD
PMID:21251949
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
G
Sirt2
sirtuin 2
decreases activity
ISO
Maneb results in decreased activity of SIRT2 protein
CTD
PMID:21251949
NCBI chr 7:28,466,192...28,488,086
Ensembl chr 7:28,466,160...28,488,086
G
Sirt3
sirtuin 3
decreases activity
ISO
Maneb results in decreased activity of SIRT3 protein
CTD
PMID:21251949
NCBI chr 7:140,443,576...140,462,222
Ensembl chr 7:140,443,579...140,462,222
G
Skp2
S-phase kinase-associated protein 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of SKP2 mRNA
CTD
PMID:36117858
NCBI chr15:9,112,070...9,155,512
Ensembl chr15:9,112,073...9,155,512
G
Slc12a2
solute carrier family 12, member 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SLC12A2 mRNA
CTD
PMID:36117858
NCBI chr18:58,011,505...58,079,893
Ensembl chr18:58,011,750...58,079,893
G
Slc17a6
solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SLC17A6 mRNA
CTD
PMID:36117858
NCBI chr 7:51,271,578...51,320,874
Ensembl chr 7:51,271,754...51,320,867
G
Slc17a8
solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 8
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of SLC17A8 mRNA
CTD
PMID:22563483
NCBI chr10:89,409,882...89,457,111
Ensembl chr10:89,409,882...89,457,115
G
Slc18a2
solute carrier family 18 (vesicular monoamine), member 2
multiple interactions decreases expression
EXP
[Paraquat co-treated with Maneb] results in decreased expression of SLC18A2 mRNA; Ketoconazole inhibits the reaction [Maneb results in decreased expression of SLC18A2 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of SLC18A2 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of SLC18A2 mRNA]
CTD
PMID:18386188 PMID:20964710 PMID:22334051
NCBI chr19:59,249,310...59,284,444
Ensembl chr19:59,249,328...59,284,444
G
Slc1a5
solute carrier family 1 (neutral amino acid transporter), member 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SLC1A5 mRNA
CTD
PMID:36117858
NCBI chr 7:16,515,259...16,532,199
Ensembl chr 7:16,515,265...16,532,199
G
Slc22a2
solute carrier family 22 (organic cation transporter), member 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SLC22A2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SLC22A2 mRNA]
CTD
PMID:23963992
NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375
G
Slc25a42
solute carrier family 25, member 42
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SLC25A42 mRNA
CTD
PMID:36117858
NCBI chr 8:70,636,990...70,664,931
Ensembl chr 8:70,636,990...70,664,955
G
Slc25a53
solute carrier family 25, member 53
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SLC25A53 mRNA
CTD
PMID:36117858
NCBI chr X:135,881,865...135,939,051
Ensembl chr X:135,881,865...135,939,051
G
Slc2a3
solute carrier family 2 (facilitated glucose transporter), member 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SLC2A3 mRNA
CTD
PMID:36117858
NCBI chr 6:122,704,783...122,779,149
Ensembl chr 6:122,704,768...122,778,599
G
Slc36a4
solute carrier family 36 (proton/amino acid symporter), member 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SLC36A4 mRNA
CTD
PMID:36117858
NCBI chr 9:15,621,034...15,653,684
Ensembl chr 9:15,621,034...15,654,657
G
Slc39a14
solute carrier family 39 (zinc transporter), member 14
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SLC39A14 mRNA
CTD
PMID:36117858
NCBI chr14:70,540,916...70,588,873
Ensembl chr14:70,540,918...70,588,874
G
Slc39a6
solute carrier family 39 (metal ion transporter), member 6
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SLC39A6 mRNA
CTD
PMID:36117858
NCBI chr18:24,712,938...24,736,874
Ensembl chr18:24,712,938...24,736,874
G
Slc40a1
solute carrier family 40 (iron-regulated transporter), member 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of SLC40A1 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of SLC40A1 protein]
CTD
PMID:30797899
NCBI chr 1:45,947,230...45,965,690
Ensembl chr 1:45,947,228...45,965,683
G
Slc5a7
solute carrier family 5 (choline transporter), member 7
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of SLC5A7 mRNA
CTD
PMID:22563483
NCBI chr17:54,580,618...54,606,071
Ensembl chr17:54,580,618...54,606,062
G
Slc6a2
solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of SLC6A2 mRNA
CTD
PMID:22563483
NCBI chr 8:93,687,100...93,728,295
Ensembl chr 8:93,686,707...93,728,295
G
Slc6a3
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3
multiple interactions affects response to substance
EXP ISO
[Paraquat co-treated with Maneb] results in decreased expression of SLC6A3 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of SLC6A3 protein SLC6A3 gene polymorphism affects the susceptibility to Maneb
CTD
PMID:11124998 PMID:18386188 PMID:19590691
NCBI chr13:73,684,270...73,726,791
Ensembl chr13:73,684,866...73,726,791
G
Slc7a1
solute carrier family 7 (cationic amino acid transporter, y+ system), member 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of SLC7A1 mRNA
CTD
PMID:36117858
NCBI chr 5:148,264,220...148,336,714
Ensembl chr 5:148,264,220...148,336,714
G
Slc7a6
solute carrier family 7 (cationic amino acid transporter, y+ system), member 6
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SLC7A6 mRNA
CTD
PMID:36117858
NCBI chr 8:106,894,718...106,925,346
Ensembl chr 8:106,895,489...106,925,338
G
Slc8a1
solute carrier family 8 (sodium/calcium exchanger), member 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of SLC8A1 mRNA
CTD
PMID:22563483
NCBI chr17:81,680,534...82,045,816
Ensembl chr17:81,680,534...82,045,806
G
Slc8a3
solute carrier family 8 (sodium/calcium exchanger), member 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SLC8A3 mRNA
CTD
PMID:36117858
NCBI chr12:81,244,686...81,380,506
Ensembl chr12:81,244,689...81,379,954
G
Slc9a8
solute carrier family 9 (sodium/hydrogen exchanger), member 8
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SLC9A8 mRNA
CTD
PMID:36117858
NCBI chr 2:167,261,678...167,318,920
Ensembl chr 2:167,263,632...167,318,920
G
Slf1
SMC5-SMC6 complex localization factor 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SLF1 mRNA
CTD
PMID:36117858
NCBI chr13:77,191,207...77,283,632
Ensembl chr13:77,191,207...77,283,592
G
Slfn2
schlafen 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of SLFN2 mRNA
CTD
PMID:36117858
NCBI chr11:82,955,938...82,961,504
Ensembl chr11:82,955,938...82,961,504
G
Slitrk4
SLIT and NTRK-like family, member 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SLITRK4 mRNA
CTD
PMID:36117858
NCBI chr X:63,308,489...63,320,951
Ensembl chr X:63,308,491...63,320,602
G
Slitrk5
SLIT and NTRK-like family, member 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SLITRK5 mRNA
CTD
PMID:36117858
NCBI chr14:111,912,547...111,920,576
Ensembl chr14:111,912,529...111,920,573
G
Smim13
small integral membrane protein 13
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SMIM13 mRNA
CTD
PMID:36117858
NCBI chr13:41,403,320...41,430,053
Ensembl chr13:41,403,320...41,430,053
G
Smoc2
SPARC related modular calcium binding 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SMOC2 mRNA
CTD
PMID:36117858
NCBI chr17:14,499,768...14,625,052
Ensembl chr17:14,499,768...14,625,052
G
Snca
synuclein, alpha
multiple interactions increases response to substance
EXP ISO
[Maneb co-treated with Paraquat] results in increased phosphorylation of SNCA protein; [Paraquat co-treated with Maneb] promotes the reaction [SNCA protein binds to SNCA protein]; [Paraquat co-treated with Maneb] results in increased expression of SNCA protein; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ADORA1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of APBB1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ASCL1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP2 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DLL1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD2 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD5 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEYL mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX5 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of SEMA4D mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased phosphorylation of SNCA protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] promotes the reaction [SNCA protein binds to SNCA protein]]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of SNCA protein]; SNCA protein inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] promotes the reaction [SNCA protein binds to SNCA protein]] [Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased abundance of Nitric Oxide; [Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased metabolism of MEF2C protein; [Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased abundance of Nitric Oxide; [Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased metabolism of MEF2C protein; Maneb promotes the reaction [Paraquat results in increased expression of SNCA protein]; Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]; Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]; SNCA protein mutant form results in increased susceptibility to [Paraquat co-treated with Maneb]; SNCA protein results in increased susceptibility to [Maneb co-treated with Paraquat]
CTD
PMID:23017109 PMID:24290359 PMID:26498265 PMID:27324791 PMID:29568078 PMID:32375810 PMID:34052309 More...
NCBI chr 6:60,708,557...60,806,839
Ensembl chr 6:60,708,559...60,806,839
G
Snx19
sorting nexin 19
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SNX19 mRNA
CTD
PMID:36117858
NCBI chr 9:30,338,284...30,378,437
Ensembl chr 9:30,338,404...30,378,029
G
Socs2
suppressor of cytokine signaling 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of SOCS2 mRNA
CTD
PMID:36117858
NCBI chr10:95,219,765...95,253,176
Ensembl chr10:95,221,224...95,253,042
G
Sod1
superoxide dismutase 1, soluble
multiple interactions
ISO EXP
SOD1 protein results in decreased susceptibility to [Paraquat co-treated with Maneb] [Paraquat co-treated with Maneb] results in decreased expression of SOD1 mRNA [Maneb co-treated with Paraquat] results in increased expression of SOD1 mRNA
CTD
PMID:15824117 PMID:18386188 PMID:29859004
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
G
Sod2
superoxide dismutase 2, mitochondrial
multiple interactions decreases expression
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein] Maneb results in decreased expression of SOD2 mRNA
CTD
PMID:23562983 PMID:26210702
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
G
Sorcs3
sortilin-related VPS10 domain containing receptor 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SORCS3 mRNA
CTD
PMID:36117858
NCBI chr19:48,194,464...48,793,944
Ensembl chr19:48,194,464...48,793,944
G
Sowaha
sosondowah ankyrin repeat domain family member A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SOWAHA mRNA
CTD
PMID:36117858
NCBI chr11:53,367,405...53,371,022
Ensembl chr11:53,367,400...53,371,101
G
Sox12
SRY (sex determining region Y)-box 12
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SOX12 mRNA
CTD
PMID:36117858
NCBI chr 2:152,235,531...152,239,966
Ensembl chr 2:152,235,531...152,239,983
G
Spats2
spermatogenesis associated, serine-rich 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of SPATS2 mRNA
CTD
PMID:36117858
NCBI chr15:99,023,783...99,111,096
Ensembl chr15:99,023,797...99,111,096
G
Spint2
serine protease inhibitor, Kunitz type 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SPINT2 mRNA
CTD
PMID:36117858
NCBI chr 7:28,955,755...28,981,484
Ensembl chr 7:28,955,748...28,981,337
G
Spp1
secreted phosphoprotein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SPP1 mRNA
CTD
PMID:36117858
NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916
G
Sptbn2
spectrin beta, non-erythrocytic 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SPTBN2 mRNA
CTD
PMID:36117858
NCBI chr19:4,761,236...4,804,006
Ensembl chr19:4,761,195...4,802,388
G
Srrm4
serine/arginine repetitive matrix 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SRRM4 mRNA
CTD
PMID:36117858
NCBI chr 5:116,577,331...116,729,882
Ensembl chr 5:116,577,334...116,729,876
G
Ss18l1
SS18, nBAF chromatin remodeling complex subunit like 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SS18L1 mRNA
CTD
PMID:36117858
NCBI chr 2:179,684,276...179,711,994
Ensembl chr 2:179,684,302...179,711,994
G
St6galnac5
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ST6GALNAC5 mRNA
CTD
PMID:36117858
NCBI chr 3:152,525,522...152,687,847
Ensembl chr 3:152,522,718...152,687,883
G
St8sia5
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ST8SIA5 mRNA
CTD
PMID:36117858
NCBI chr18:77,273,529...77,343,146
Ensembl chr18:77,273,535...77,346,467
G
Stat3
signal transducer and activator of transcription 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of STAT3 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT3 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT3 mRNA]
CTD
PMID:23963992
NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366
G
Stat4
signal transducer and activator of transcription 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of STAT4 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT4 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT4 mRNA]
CTD
PMID:23963992
NCBI chr 1:52,026,265...52,146,348
Ensembl chr 1:52,026,307...52,146,348
G
Stmn1
stathmin 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein]
CTD
PMID:23562983
NCBI chr 4:134,195,631...134,201,154
Ensembl chr 4:134,195,631...134,201,154
G
Ston2
stonin 2
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of STON2 mRNA
CTD
PMID:22563483
NCBI chr12:91,599,686...91,753,237
Ensembl chr12:91,641,586...91,652,887 Ensembl chr12:91,641,586...91,652,887
G
Strbp
spermatid perinuclear RNA binding protein
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of STRBP mRNA
CTD
PMID:22563483
NCBI chr 2:37,459,880...37,593,890
Ensembl chr 2:37,373,240...37,593,871
G
Stx1a
syntaxin 1A (brain)
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of STX1A mRNA
CTD
PMID:36117858
NCBI chr 5:135,051,473...135,079,954
Ensembl chr 5:135,052,336...135,079,954
G
Stxbp5l
syntaxin binding protein 5-like
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of STXBP5L mRNA
CTD
PMID:36117858
NCBI chr16:36,927,437...37,205,377
Ensembl chr16:36,935,304...37,205,324
G
Sumo1
small ubiquitin-like modifier 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of SUMO1 mRNA
CTD
PMID:18386188
NCBI chr 1:59,678,593...59,709,993
Ensembl chr 1:59,625,717...59,709,993
G
Sv2b
synaptic vesicle glycoprotein 2b
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of SV2B mRNA
CTD
PMID:36117858
NCBI chr 7:74,764,642...74,959,143
Ensembl chr 7:74,764,642...74,959,010
G
Synj2
synaptojanin 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SYNJ2 mRNA
CTD
PMID:36117858
NCBI chr17:5,991,555...6,106,041
Ensembl chr17:5,991,555...6,094,565
G
Syt13
synaptotagmin XIII
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SYT13 mRNA
CTD
PMID:36117858
NCBI chr 2:92,745,446...92,786,403
Ensembl chr 2:92,745,443...92,786,403
G
Syt16
synaptotagmin XVI
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SYT16 mRNA
CTD
PMID:36117858
NCBI chr12:74,044,490...74,314,690
Ensembl chr12:74,044,435...74,320,041
G
Syt5
synaptotagmin V
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of SYT5 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SYT5 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SYT5 mRNA]
CTD
PMID:23963992
NCBI chr 7:4,542,764...4,550,540
Ensembl chr 7:4,542,764...4,550,540
G
Tac1
tachykinin 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TAC1 mRNA; [Maneb co-treated with Paraquat] results in increased expression of TAC1 mRNA
CTD
PMID:36117858
NCBI chr 6:7,555,061...7,562,978
Ensembl chr 6:7,554,879...7,565,834
G
Tafa5
TAFA chemokine like family member 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of FAM19A5 mRNA
CTD
PMID:36117858
NCBI chr15:87,428,405...87,643,565
Ensembl chr15:87,428,500...87,643,565
G
Tap1
transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of TAP1 mRNA
CTD
PMID:36117858
NCBI chr17:34,406,530...34,416,199
Ensembl chr17:34,406,527...34,416,199
G
Tbc1d9
TBC1 domain family, member 9
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TBC1D9 mRNA
CTD
PMID:36117858
NCBI chr 8:83,891,981...83,999,569
Ensembl chr 8:83,891,981...83,999,563
G
Tbck
TBC1 domain containing kinase
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of TBCK mRNA
CTD
PMID:22563483
NCBI chr 3:132,389,874...132,547,451
Ensembl chr 3:132,389,905...132,547,449
G
Tbr1
T-box brain transcription factor 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TBR1 mRNA
CTD
PMID:36117858
NCBI chr 2:61,633,228...61,644,458
Ensembl chr 2:61,633,274...61,644,458
G
Tbxa2r
thromboxane A2 receptor
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of TBXA2R mRNA
CTD
PMID:36117858
NCBI chr10:81,164,102...81,171,008
Ensembl chr10:81,164,565...81,171,006
G
Tceal3
transcription elongation factor A (SII)-like 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TCEAL3 mRNA
CTD
PMID:36117858
NCBI chr X:135,491,586...135,569,127
Ensembl chr X:135,491,591...135,569,127
G
Tceal6
transcription elongation factor A (SII)-like 6
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TCEAL6 mRNA
CTD
PMID:36117858
NCBI chr X:134,109,435...134,111,436
Ensembl chr X:134,109,436...134,111,436
G
Tcf20
transcription factor 20
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of TCF20 mRNA
CTD
PMID:36117858
NCBI chr15:82,692,648...82,872,304
Ensembl chr15:82,692,637...82,872,073
G
Tecr
trans-2,3-enoyl-CoA reductase
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of TECR mRNA
CTD
PMID:18386188
NCBI chr 8:84,298,327...84,321,120
Ensembl chr 8:84,298,327...84,334,600
G
Tenm1
teneurin transmembrane protein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of TENM1 mRNA
CTD
PMID:36117858
NCBI chr X:41,616,743...42,518,045
Ensembl chr X:41,616,743...42,518,003
G
Tfip11
tuftelin interacting protein 11
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of TFIP11 mRNA
CTD
PMID:36117858
NCBI chr 5:112,474,235...112,485,939
Ensembl chr 5:112,474,224...112,485,939
G
Tgfb1
transforming growth factor, beta 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of TGFB1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TGFB1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TGFB1 mRNA]
CTD
PMID:23963992
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
G
Tgfb3
transforming growth factor, beta 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TGFB3 mRNA
CTD
PMID:36117858
NCBI chr12:86,103,517...86,125,815
Ensembl chr12:86,103,519...86,125,815
G
Th
tyrosine hydroxylase
multiple interactions decreases expression
EXP ISO
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; [Paraquat co-treated with Maneb] results in decreased expression of TH protein; [Paraquat co-treated with Maneb] results in increased expression of TH protein; Genistein inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; Ketoconazole inhibits the reaction [Maneb results in decreased expression of TH protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TH protein]; pimagedine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; prolinedithiocarbamate inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TH protein] [Paraquat co-treated with Maneb] results in decreased expression of TH; [Paraquat co-treated with Maneb] results in decreased expression of TH mRNA; [Paraquat co-treated with Maneb] results in decreased expression of TH protein
CTD
PMID:11124998 PMID:18386188 PMID:20455021 PMID:20964710 PMID:22334051 PMID:24376148 PMID:24486957 PMID:29152652 More...
NCBI chr 7:142,446,516...142,453,732
Ensembl chr 7:142,446,489...142,484,865
G
Them6
thioesterase superfamily member 6
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of THEM6 mRNA
CTD
PMID:36117858
NCBI chr15:74,593,083...74,596,222
Ensembl chr15:74,593,053...74,596,488
G
Thrb
thyroid hormone receptor beta
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of THRB mRNA
CTD
PMID:36117858
NCBI chr14:4,429,599...4,810,538
Ensembl chr14:4,431,611...4,809,435
G
Timm13
translocase of inner mitochondrial membrane 13
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of TIMM13 mRNA
CTD
PMID:18386188
NCBI chr10:80,735,284...80,736,803
Ensembl chr10:80,735,284...80,736,803
G
Tlcd3b
TLC domain containing 3B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of FAM57B mRNA
CTD
PMID:36117858
NCBI chr 7:126,413,213...126,429,391
Ensembl chr 7:126,396,840...126,429,391
G
Tmc4
transmembrane channel-like gene family 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TMC4 mRNA
CTD
PMID:36117858
NCBI chr 7:3,668,790...3,680,522
Ensembl chr 7:3,668,789...3,680,552
G
Tmem132a
transmembrane protein 132A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TMEM132A mRNA
CTD
PMID:36117858
NCBI chr19:10,835,193...10,847,569
Ensembl chr19:10,835,186...10,847,304
G
Tmem150c
transmembrane protein 150C
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TMEM150C mRNA
CTD
PMID:36117858
NCBI chr 5:100,225,731...100,313,463
Ensembl chr 5:100,225,731...100,307,667
G
Tmem151b
transmembrane protein 151B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TMEM151B mRNA
CTD
PMID:36117858
NCBI chr17:45,852,879...45,860,624
Ensembl chr17:45,852,878...45,860,603
G
Tmem38a
transmembrane protein 38A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of TMEM38A mRNA
CTD
PMID:36117858
NCBI chr 8:73,325,033...73,341,128
Ensembl chr 8:73,325,899...73,341,126
G
Tmem42
transmembrane protein 42
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of TMEM42 mRNA
CTD
PMID:22563483
NCBI chr 9:122,850,072...122,852,556
Ensembl chr 9:122,850,391...122,852,770
G
Tmem87a
transmembrane protein 87A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TMEM87A mRNA
CTD
PMID:36117858
NCBI chr 2:120,185,790...120,234,597
Ensembl chr 2:120,185,793...120,234,594
G
Tmem8b
transmembrane protein 8B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TMEM8B mRNA
CTD
PMID:36117858
NCBI chr 4:43,668,971...43,692,668
Ensembl chr 4:43,668,971...43,692,668
G
Tnf
tumor necrosis factor
increases expression multiple interactions
ISO EXP
Maneb results in increased expression of TNF mRNA [Paraquat co-treated with Maneb] results in increased expression of TNF mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of TNF mRNA] [Maneb co-treated with Paraquat] results in increased expression of TNF mRNA; [Paraquat co-treated with Maneb] results in increased expression of TNF mRNA; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]
CTD
PMID:23159886 PMID:23963992 PMID:28202386 PMID:29568078 PMID:30797899 PMID:32169474 PMID:32375810 PMID:34052309 More...
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
G
Tnfaip3
tumor necrosis factor, alpha-induced protein 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of TNFAIP3 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNFAIP3 mRNA]
CTD
PMID:23963992
NCBI chr10:18,876,658...18,891,158
Ensembl chr10:18,876,658...18,891,405
G
Tnfrsf21
tumor necrosis factor receptor superfamily, member 21
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TNFRSF21 mRNA
CTD
PMID:36117858
NCBI chr17:43,327,446...43,400,079
Ensembl chr17:43,327,446...43,400,080
G
Tnk2
tyrosine kinase, non-receptor, 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TNK2 mRNA
CTD
PMID:36117858
NCBI chr16:32,462,699...32,502,311
Ensembl chr16:32,462,692...32,502,311
G
Tnr
tenascin R
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TNR mRNA
CTD
PMID:23017109 PMID:36117858
NCBI chr 1:159,351,170...159,759,299
Ensembl chr 1:159,351,339...159,759,299
G
Traf3ip2
TRAF3 interacting protein 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of ACT1 protein
CTD
PMID:23562983
NCBI chr10:39,488,930...39,531,303
Ensembl chr10:39,488,930...39,531,303
G
Traf6
TNF receptor-associated factor 6
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of TRAF6 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TRAF6 mRNA]
CTD
PMID:23963992
NCBI chr 2:101,508,765...101,532,013
Ensembl chr 2:101,508,774...101,532,014
G
Tram1l1
translocation associated membrane protein 1-like 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TRAM1L1 mRNA
CTD
PMID:36117858
NCBI chr 3:124,114,686...124,116,909
Ensembl chr 3:124,114,504...124,118,392
G
Trim32
tripartite motif-containing 32
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TRIM32 mRNA
CTD
PMID:36117858
NCBI chr 4:65,523,223...65,534,477
Ensembl chr 4:65,523,223...65,534,475
G
Trmt61a
tRNA methyltransferase 61A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TRMT61A mRNA
CTD
PMID:36117858
NCBI chr12:111,644,539...111,650,336
Ensembl chr12:111,644,539...111,650,336
G
Tro
trophinin
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TRO mRNA
CTD
PMID:36117858
NCBI chr X:149,427,706...149,440,579
Ensembl chr X:149,428,300...149,440,579
G
Trp53
transformation related protein 53
multiple interactions
EXP
3-bromo-7-nitroindazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TRP53 protein]; [Maneb co-treated with Paraquat] results in increased expression of TRP53 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of TRP53 protein; [Paraquat co-treated with Maneb] results in increased activity of TRP53 protein modified form; [Paraquat co-treated with Maneb] results in increased expression of TRP53 protein; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TRP53 mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TRP53 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of TRP53 protein modified form]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TRP53 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TRP53 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of TRP53 protein modified form]
CTD
PMID:20964710 PMID:23963992 PMID:23985028
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
G
Trp53bp1
transformation related protein 53 binding protein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TRP53BP1 mRNA
CTD
PMID:36117858
NCBI chr 2:121,025,316...121,126,830
Ensembl chr 2:121,023,762...121,101,888
G
Trpc3
transient receptor potential cation channel, subfamily C, member 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TRPC3 mRNA
CTD
PMID:36117858
NCBI chr 3:36,674,626...36,744,276
Ensembl chr 3:36,674,631...36,744,316
G
Trpc4
transient receptor potential cation channel, subfamily C, member 4
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of TRPC4 mRNA
CTD
PMID:36117858
NCBI chr 3:54,063,441...54,225,892
Ensembl chr 3:54,063,456...54,225,892
G
Trpm3
transient receptor potential cation channel, subfamily M, member 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TRPM3 mRNA; [Paraquat co-treated with Maneb] affects the expression of TRPM3 mRNA
CTD
PMID:22563483 PMID:36117858
NCBI chr19:22,114,789...22,972,774
Ensembl chr19:22,116,410...22,972,774
G
Tspan5
tetraspanin 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of TSPAN5 mRNA
CTD
PMID:36117858
NCBI chr 3:138,447,609...138,610,194
Ensembl chr 3:138,447,956...138,613,666
G
Tspoap1
TSPO associated protein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TSPOAP1 mRNA
CTD
PMID:36117858
NCBI chr11:87,649,022...87,676,754
Ensembl chr11:87,651,367...87,676,754
G
Tspyl5
testis-specific protein, Y-encoded-like 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TSPYL5 mRNA
CTD
PMID:36117858
NCBI chr15:33,684,021...33,688,029
Ensembl chr15:33,684,021...33,688,030
G
Ttc27
tetratricopeptide repeat domain 27
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TTC27 mRNA
CTD
PMID:36117858
NCBI chr17:75,024,730...75,170,565
Ensembl chr17:75,024,727...75,170,565
G
Ttyh3
tweety family member 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of TTYH3 mRNA
CTD
PMID:36117858
NCBI chr 5:140,606,332...140,634,826
Ensembl chr 5:140,606,333...140,634,786
G
Tuba1a
tubulin, alpha 1A
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein]
CTD
PMID:23562983
NCBI chr15:98,847,728...98,851,382
Ensembl chr15:98,847,718...98,851,584
G
Tuba1b
tubulin, alpha 1B
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of TUBA1B mRNA
CTD
PMID:18386188
NCBI chr15:98,829,310...98,832,271
Ensembl chr15:98,829,306...98,832,446
G
Tubb5
tubulin, beta 5 class I
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TUBB5 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of TUBB5 mRNA]
CTD
PMID:23963992
NCBI chr17:36,144,812...36,149,193
Ensembl chr17:36,144,813...36,149,198
G
Tusc1
tumor suppressor candidate 1
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of TUSC1 mRNA
CTD
PMID:22563483
NCBI chr 4:93,222,385...93,223,748
Ensembl chr 4:93,222,375...93,223,748
G
Txn1
thioredoxin 1
increases expression
ISO
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXN1 mRNA
CTD
PMID:21402726
NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411
G
Txnrd1
thioredoxin reductase 1
increases expression
ISO
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXNRD1 mRNA
CTD
PMID:21402726
NCBI chr10:82,669,785...82,733,558
Ensembl chr10:82,669,785...82,733,546
G
Tyro3
TYRO3 protein tyrosine kinase 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of TYRO3 mRNA
CTD
PMID:36117858
NCBI chr 2:119,628,123...119,648,585
Ensembl chr 2:119,628,214...119,648,585
G
Uba1
ubiquitin-like modifier activating enzyme 1
multiple interactions
ISO
Maneb results in decreased activity of and results in decreased ubiquitination of UBA1 protein
CTD
PMID:25714994
NCBI chr X:20,524,660...20,549,420
Ensembl chr X:20,524,565...20,549,418
G
Ubb
ubiquitin B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of UBB mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of UBB mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of UBB mRNA]
CTD
PMID:23963992
NCBI chr11:62,442,329...62,444,037
Ensembl chr11:62,441,997...62,444,039
G
Ubc
ubiquitin C
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of UBC mRNA
CTD
PMID:18386188
NCBI chr 5:125,463,029...125,467,081
Ensembl chr 5:125,463,029...125,467,266
G
Ube2v1
ubiquitin-conjugating enzyme E2 variant 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of UBE2V1 mRNA
CTD
PMID:36117858
NCBI chr 2:167,449,559...167,473,933
Ensembl chr 2:167,449,558...167,474,015
G
Ubp1
upstream binding protein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of UBP1 mRNA
CTD
PMID:36117858
NCBI chr 9:113,760,002...113,807,095
Ensembl chr 9:113,760,002...113,806,270
G
Ubr3
ubiquitin protein ligase E3 component n-recognin 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of UBR3 mRNA
CTD
PMID:36117858
NCBI chr 2:69,727,276...69,854,354
Ensembl chr 2:69,727,590...69,854,357
G
Ubxn7
UBX domain protein 7
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of UBXN7 mRNA
CTD
PMID:22563483
NCBI chr16:32,151,023...32,212,568
Ensembl chr16:32,151,075...32,212,565
G
Uchl1
ubiquitin carboxy-terminal hydrolase L1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of UCHL1 protein; [Paraquat co-treated with Maneb] results in decreased expression of UCHL1 mRNA
CTD
PMID:18386188 PMID:23562983
NCBI chr 5:66,833,464...66,844,577
Ensembl chr 5:66,833,434...66,844,577
G
Uchl5
ubiquitin carboxyl-terminal esterase L5
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in increased expression of UCHL5 mRNA
CTD
PMID:18386188
NCBI chr 1:143,652,993...143,683,204
Ensembl chr 1:143,653,010...143,683,204
G
Uevld
UEV and lactate/malate dehyrogenase domains
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of UEVLD mRNA
CTD
PMID:36117858
NCBI chr 7:46,572,964...46,608,275
Ensembl chr 7:46,572,964...46,608,275
G
Ugcg
UDP-glucose ceramide glucosyltransferase
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of UGCG mRNA
CTD
PMID:36117858
NCBI chr 4:59,189,452...59,222,833
Ensembl chr 4:59,189,257...59,222,833
G
Unc13c
unc-13 homolog C
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of UNC13C mRNA; [Paraquat co-treated with Maneb] affects the expression of UNC13C mRNA
CTD
PMID:22563483 PMID:36117858
NCBI chr 9:73,386,704...73,915,421
Ensembl chr 9:73,386,704...73,876,248
G
Unc5d
unc-5 netrin receptor D
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of UNC5D mRNA
CTD
PMID:36117858
NCBI chr 8:29,136,745...29,709,698
Ensembl chr 8:29,136,745...29,709,664
G
Upf3b
UPF3 regulator of nonsense transcripts homolog B (yeast)
multiple interactions
EXP
[Paraquat co-treated with Maneb] results in decreased expression of UPF3B mRNA
CTD
PMID:18386188
NCBI chr X:36,355,331...36,374,124
Ensembl chr X:36,355,331...36,373,975
G
Uqcrc1
ubiquinol-cytochrome c reductase core protein 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of UQCRC1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of UQCRC1 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of UQCRC1 protein]
CTD
PMID:23562983
NCBI chr 9:108,765,716...108,778,709
Ensembl chr 9:108,765,701...108,778,691
G
Urb1
URB1 ribosome biogenesis 1 homolog (S. cerevisiae)
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of URB1 mRNA
CTD
PMID:36117858
NCBI chr16:90,548,415...90,607,312
Ensembl chr16:90,548,415...90,607,301
G
Usp13
ubiquitin specific peptidase 13 (isopeptidase T-3)
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of USP13 mRNA
CTD
PMID:36117858
NCBI chr 3:32,870,432...32,992,224
Ensembl chr 3:32,871,695...32,992,220
G
Usp28
ubiquitin specific peptidase 28
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of USP28 mRNA
CTD
PMID:36117858
NCBI chr 9:48,896,577...48,953,817
Ensembl chr 9:48,896,675...48,953,817
G
Usp29
ubiquitin specific peptidase 29
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of USP29 mRNA
CTD
PMID:36117858
NCBI chr 7:6,733,560...6,970,219
Ensembl chr 7:6,733,577...6,970,218
G
Usp35
ubiquitin specific peptidase 35
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of USP35 mRNA
CTD
PMID:36117858
NCBI chr 7:96,958,610...96,981,502
Ensembl chr 7:96,958,587...96,981,227
G
Utp14b
UTP14B small subunit processome component
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of UTP14B mRNA
CTD
PMID:22563483
NCBI chr 1:78,635,600...78,645,305
Ensembl chr 1:78,635,755...78,649,229
G
Vamp5
vesicle-associated membrane protein 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of VAMP5 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of VAMP5 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of VAMP5 mRNA]
CTD
PMID:23963992
NCBI chr 6:72,345,032...72,357,451
Ensembl chr 6:72,345,777...72,357,451
G
Vcpkmt
valosin containing protein lysine (K) methyltransferase
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of VCPKMT mRNA
CTD
PMID:36117858
NCBI chr12:69,623,504...69,629,883
Ensembl chr12:69,624,402...69,629,884
G
Vegfa
vascular endothelial growth factor A
multiple interactions
EXP
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA
CTD
PMID:23017109
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
G
Vegfc
vascular endothelial growth factor C
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of VEGFC mRNA
CTD
PMID:36117858
NCBI chr 8:54,530,567...54,639,489
Ensembl chr 8:54,530,641...54,640,131
G
Vps13b
vacuolar protein sorting 13B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of VPS13B mRNA
CTD
PMID:36117858
NCBI chr15:35,371,264...35,931,375
Ensembl chr15:35,371,306...35,931,375
G
Vps37d
vacuolar protein sorting 37D
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of VPS37D mRNA
CTD
PMID:36117858
NCBI chr 5:135,101,751...135,107,197
Ensembl chr 5:135,101,754...135,107,120
G
Vps45
vacuolar protein sorting 45
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of VPS45 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of VPS45 mRNA]
CTD
PMID:23963992
NCBI chr 3:95,907,144...95,969,715
Ensembl chr 3:95,907,144...95,965,778
G
Vwf
Von Willebrand factor
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of VWF mRNA
CTD
PMID:36117858
NCBI chr 6:125,529,911...125,663,642
Ensembl chr 6:125,523,737...125,663,642
G
Wasf3
WASP family, member 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in increased expression of WASF3 mRNA
CTD
PMID:36117858
NCBI chr 5:146,317,411...146,410,425
Ensembl chr 5:146,321,795...146,410,425
G
Wdr55
WD repeat domain 55
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of WDR55 mRNA
CTD
PMID:36117858
NCBI chr18:36,893,275...36,896,761
Ensembl chr18:36,893,273...36,896,863
G
Wee1
WEE 1 homolog 1 (S. pombe)
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of WEE1 mRNA
CTD
PMID:36117858
NCBI chr 7:109,721,266...109,742,506
Ensembl chr 7:109,721,253...109,742,493
G
Wfdc18
WAP four-disulfide core domain 18
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of WFDC18 mRNA
CTD
PMID:36117858
NCBI chr11:83,599,830...83,602,186
Ensembl chr11:83,599,841...83,602,174
G
Wfs1
wolframin ER transmembrane glycoprotein
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of WFS1 mRNA
CTD
PMID:36117858
NCBI chr 5:37,123,448...37,146,326
Ensembl chr 5:37,123,448...37,146,549
G
Wnk2
WNK lysine deficient protein kinase 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of WNK2 mRNA
CTD
PMID:36117858
NCBI chr13:49,189,778...49,302,110
Ensembl chr13:49,189,779...49,301,490
G
Wnk3
WNK lysine deficient protein kinase 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of WNK3 mRNA
CTD
PMID:36117858
NCBI chr X:149,951,774...150,103,190
Ensembl chr X:149,981,074...150,103,148
G
Wnt1
wingless-type MMTV integration site family, member 1
multiple interactions
ISO
[Paraquat co-treated with Maneb] results in decreased expression of WNT1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of WNT1 protein
CTD
PMID:29152652
NCBI chr15:98,687,738...98,691,711
Ensembl chr15:98,687,738...98,691,718
G
Wnt5a
wingless-type MMTV integration site family, member 5A
multiple interactions
ISO
[Paraquat co-treated with Maneb] results in increased expression of WNT5A mRNA; [Paraquat co-treated with Maneb] results in increased expression of WNT5A protein
CTD
PMID:29152652
NCBI chr14:28,224,962...28,249,405
Ensembl chr14:28,226,707...28,249,405
G
Wnt7b
wingless-type MMTV integration site family, member 7B
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of WNT7B mRNA
CTD
PMID:36117858
NCBI chr15:85,419,638...85,466,022
Ensembl chr15:85,419,638...85,466,674
G
Xylt1
xylosyltransferase 1
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of XYLT1 mRNA
CTD
PMID:36117858
NCBI chr 7:116,980,214...117,266,853
Ensembl chr 7:116,980,214...117,272,803
G
Yjefn3
YjeF N-terminal domain containing 3
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of YJEFN3 mRNA
CTD
PMID:36117858
NCBI chr 8:70,340,438...70,346,633
Ensembl chr 8:70,340,438...70,355,362
G
Zbtb11
zinc finger and BTB domain containing 11
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ZBTB11 mRNA
CTD
PMID:36117858
NCBI chr16:55,791,820...55,829,276
Ensembl chr16:55,794,246...55,829,276
G
Zbtb40
zinc finger and BTB domain containing 40
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ZBTB40 mRNA
CTD
PMID:36117858
NCBI chr 4:136,707,043...136,776,129
Ensembl chr 4:136,707,043...136,776,112
G
Zbtb44
zinc finger and BTB domain containing 44
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of ZBTB44 mRNA
CTD
PMID:22563483
NCBI chr 9:30,941,016...30,987,181
Ensembl chr 9:30,941,940...30,987,181
G
Zcchc12
zinc finger, CCHC domain containing 12
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ZCCHC12 mRNA
CTD
PMID:36117858
NCBI chr X:35,459,553...35,462,817
Ensembl chr X:35,459,557...35,462,811
G
Zdbf2
zinc finger, DBF-type containing 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ZDBF2 mRNA
CTD
PMID:36117858
NCBI chr 1:63,239,517...63,353,735
Ensembl chr 1:63,312,424...63,353,735
G
Zdhhc2
zinc finger, DHHC domain containing 2
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ZDHHC2 mRNA
CTD
PMID:36117858
NCBI chr 8:40,876,526...40,946,178
Ensembl chr 8:40,876,856...40,963,309
G
Zdhhc5
zinc finger, DHHC domain containing 5
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ZDHHC5 mRNA
CTD
PMID:36117858
NCBI chr 2:84,518,264...84,545,508
Ensembl chr 2:84,518,314...84,545,524
G
Zfp131
zinc finger protein 131
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ZFP131 mRNA; [Maneb co-treated with Paraquat] results in increased expression of ZFP131 mRNA
CTD
PMID:36117858
NCBI chr13:120,226,722...120,253,070
Ensembl chr13:120,226,723...120,252,425
G
Zfp286
zinc finger protein 286
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ZFP286 mRNA
CTD
PMID:36117858
NCBI chr11:62,640,003...62,680,385
Ensembl chr11:62,643,403...62,680,288
G
Zfp287
zinc finger protein 287
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ZFP287 mRNA
CTD
PMID:36117858
NCBI chr11:62,583,270...62,622,749
Ensembl chr11:62,591,182...62,622,731
G
Zfp346
zinc finger protein 346
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ZFP346 mRNA
CTD
PMID:36117858
NCBI chr13:55,253,079...55,282,884
Ensembl chr13:55,253,124...55,282,638
G
Zfp580
zinc finger protein 580
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of ZFP580 mRNA
CTD
PMID:22563483
NCBI chr 7:5,041,682...5,056,722
Ensembl chr 7:5,054,537...5,056,722
G
Zfp626
zinc finger protein 626
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ZFP626 mRNA
CTD
PMID:36117858
NCBI chr 7:27,504,165...27,522,348
Ensembl chr 7:27,506,621...27,522,341
G
Zfp874a
zinc finger protein 874a
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ZFP874A mRNA
CTD
PMID:36117858
NCBI chr13:67,588,550...67,599,743
Ensembl chr13:67,572,668...67,599,743
G
Zfp941
zinc finger protein 941
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ZFP941 mRNA
CTD
PMID:36117858
NCBI chr 7:140,387,366...140,402,114
Ensembl chr 7:140,387,362...140,402,091
G
Zfyve28
zinc finger, FYVE domain containing 28
multiple interactions
EXP
[Maneb co-treated with Paraquat] results in decreased expression of ZFYVE28 mRNA
CTD
PMID:36117858
NCBI chr 5:34,352,237...34,445,796
Ensembl chr 5:34,352,237...34,445,793
G
Zhx3
zinc fingers and homeoboxes 3
multiple interactions
EXP
[Paraquat co-treated with Maneb] affects the expression of ZHX3 mRNA
CTD
PMID:22563483
NCBI chr 2:160,612,367...160,714,910
Ensembl chr 2:160,590,628...160,714,918
G
Ache
acetylcholinesterase
affects activity multiple interactions
ISO
mancozeb affects the activity of ACHE protein [carbendazim co-treated with mancozeb] results in increased activity of ACHE protein
CTD
PMID:10641187 PMID:33217513
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
G
Actg1
actin, gamma, cytoplasmic 1
increases expression
EXP
mancozeb results in increased expression of ACTG1 protein
CTD
PMID:21375462
NCBI chr11:120,236,513...120,239,321
Ensembl chr11:120,236,516...120,239,368
G
Actmap
actin maturation protease
decreases expression
ISO
mancozeb results in decreased expression of ACTMAP mRNA
CTD
PMID:33396126
NCBI chr 7:26,894,973...26,909,611
Ensembl chr 7:26,895,206...26,909,611
G
Adam24
ADAM metallopeptidase domain 24
increases expression
ISO
mancozeb results in increased expression of NPIPB11 mRNA
CTD
PMID:33396126
NCBI chr 8:41,128,118...41,135,238
Ensembl chr 8:41,128,118...41,135,238
G
Akt1
thymoma viral proto-oncogene 1
multiple interactions
EXP
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of AKT1 protein; [alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of AKT1 protein
CTD
PMID:19883720
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
G
Alb
albumin
decreases expression
EXP
mancozeb results in decreased expression of ALB protein
CTD
PMID:21375462
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
G
Aldh2
aldehyde dehydrogenase 2, mitochondrial
decreases activity multiple interactions
ISO
mancozeb results in decreased activity of ALDH2 protein [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of ALDH2 mRNA; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of and results in decreased activity of ALDH2 protein
CTD
PMID:17010440 PMID:34830855
NCBI chr 5:121,704,090...121,731,887
Ensembl chr 5:121,704,090...121,731,887
G
Aldh5a1
aldhehyde dehydrogenase family 5, subfamily A1
decreases activity
ISO
mancozeb results in decreased activity of ALDH5A1 protein
CTD
PMID:17010440
NCBI chr13:25,091,562...25,121,740
Ensembl chr13:25,091,562...25,121,644
G
Angptl1
angiopoietin-like 1
decreases expression
ISO
mancozeb results in decreased expression of ANGPTL1 mRNA
CTD
PMID:33396126
NCBI chr 1:156,666,495...156,688,648
Ensembl chr 1:156,666,132...156,688,648
G
Anxa2
annexin A2
decreases expression
EXP
mancozeb results in decreased expression of ANXA2 protein
CTD
PMID:21375462
NCBI chr 9:69,360,978...69,399,074
Ensembl chr 9:69,360,902...69,399,077
G
Ar
androgen receptor
multiple interactions decreases expression decreases activity
ISO
mancozeb inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; mancozeb inhibits the reaction [Metribolone binds to and results in increased activity of AR protein] mancozeb results in decreased expression of AR mRNA mancozeb results in decreased activity of AR protein
CTD
PMID:23871939 PMID:33396126
NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821
G
Atp1a2
ATPase, Na+/K+ transporting, alpha 2 polypeptide
decreases expression
ISO
mancozeb results in decreased expression of ATP1A2 mRNA
CTD
PMID:33396126
NCBI chr 1:172,099,276...172,125,631
Ensembl chr 1:172,099,276...172,125,631
G
Bax
BCL2-associated X protein
increases expression multiple interactions
ISO EXP
mancozeb results in increased expression of BAX mRNA mancozeb results in increased expression of BAX protein [Sulfur co-treated with mancozeb co-treated with metrafenone] results in decreased expression of BAX mRNA; [Sulfur co-treated with mancozeb] results in decreased expression of BAX mRNA; lupeol inhibits the reaction [mancozeb results in increased expression of BAX mRNA]
CTD
PMID:27235710 PMID:35564597 PMID:35617905
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
G
Bcl2
B cell leukemia/lymphoma 2
decreases expression multiple interactions
ISO EXP
mancozeb results in decreased expression of BCL2 mRNA mancozeb results in decreased expression of BCL2 protein [Sulfur co-treated with mancozeb co-treated with metrafenone] results in decreased expression of BCL2 mRNA; [Sulfur co-treated with mancozeb] results in decreased expression of BCL2 mRNA; lupeol inhibits the reaction [mancozeb results in decreased expression of BCL2 mRNA] alpha-Tocopherol inhibits the reaction [mancozeb results in decreased expression of BCL2 protein]
CTD
PMID:16005924 PMID:27235710 PMID:35564597 PMID:35617905
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
G
Car3
carbonic anhydrase 3
increases expression
EXP
mancozeb results in increased expression of CAR3 protein
CTD
PMID:21375462
NCBI chr 3:14,928,598...14,937,441
Ensembl chr 3:14,928,572...14,937,583
G
Casp3
caspase 3
increases activity increases expression increases cleavage multiple interactions
ISO EXP
mancozeb results in increased activity of CASP3 protein mancozeb results in increased expression of CASP3 protein mancozeb results in increased cleavage of CASP3 protein Acetylcysteine inhibits the reaction [mancozeb results in increased cleavage of CASP3 protein]
CTD
PMID:22824503 PMID:30037311 PMID:35617905
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
G
Casp7
caspase 7
increases activity
ISO
mancozeb results in increased activity of CASP7 protein
CTD
PMID:22824503
NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776
G
Casp8
caspase 8
increases activity
ISO
mancozeb results in increased activity of CASP8 protein
CTD
PMID:22824503
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
G
Casp9
caspase 9
increases activity increases expression
ISO EXP
mancozeb results in increased activity of CASP9 protein mancozeb results in increased expression of CASP9 protein
CTD
PMID:22824503 PMID:35617905
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
G
Cat
catalase
multiple interactions decreases activity
ISO EXP
Acetylcysteine inhibits the reaction [mancozeb results in decreased activity of CAT protein]; lupeol inhibits the reaction [mancozeb results in decreased activity of CAT protein]; Quercetin inhibits the reaction [mancozeb results in decreased activity of CAT protein] Colforsin inhibits the reaction [mancozeb results in decreased activity of CAT protein]
CTD
PMID:23024109 PMID:27235710 PMID:29283200 PMID:30037311 PMID:35617905 PMID:36007320 More...
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
G
Ccdc106
coiled-coil domain containing 106
decreases expression
ISO
mancozeb results in decreased expression of CCDC106 mRNA
CTD
PMID:33396126
NCBI chr 7:5,056,870...5,063,784
Ensembl chr 7:5,023,552...5,063,784
G
Ccnd1
cyclin D1
multiple interactions increases expression
EXP ISO
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of CCND1 protein mancozeb results in increased expression of CCND1 protein
CTD
PMID:19883720 PMID:21375462
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
G
Cdc25c
cell division cycle 25C
increases phosphorylation
ISO
mancozeb results in increased phosphorylation of CDC25C protein
CTD
PMID:21375462
NCBI chr18:34,866,046...34,884,644
Ensembl chr18:34,866,046...34,884,586
G
Cdkn1a
cyclin dependent kinase inhibitor 1A
multiple interactions increases expression
ISO
lupeol inhibits the reaction [mancozeb results in increased expression of CDKN1A mRNA]
CTD
PMID:27235710
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
G
Cfap126
cilia and flagella associated protein 126
decreases expression
ISO
mancozeb results in decreased expression of CFAP126 mRNA
CTD
PMID:33396126
NCBI chr 1:170,941,326...170,954,525
Ensembl chr 1:170,941,487...170,954,536
G
Cldn16
claudin 16
decreases expression
ISO
mancozeb results in decreased expression of CLDN16 mRNA
CTD
PMID:33396126
NCBI chr16:26,281,885...26,301,515
Ensembl chr16:26,281,885...26,301,515
G
Ctf1
cardiotrophin 1
decreases expression
ISO
mancozeb results in decreased expression of CTF1 mRNA
CTD
PMID:33396126
NCBI chr 7:127,311,872...127,317,360
Ensembl chr 7:127,311,908...127,317,364
G
Cxcl15
C-X-C motif chemokine ligand 15
multiple interactions
ISO
[Glyphosate co-treated with 2,4-Dichlorophenoxyacetic Acid co-treated with mancozeb co-treated with Atrazine] results in increased expression of CXCL8 protein; mancozeb inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL8 protein]
CTD
PMID:16112155 PMID:37236337
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
G
Cycs
cytochrome c, somatic
increases expression
ISO
mancozeb results in increased expression of CYCS protein
CTD
PMID:27016407
NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
G
Cyp1a1
cytochrome P450, family 1, subfamily a, polypeptide 1
decreases activity decreases expression
ISO
mancozeb results in decreased activity of CYP1A1 protein mancozeb results in decreased expression of CYP1A1 protein
CTD
PMID:1946188 PMID:31096615
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
G
Cyp2b10
cytochrome P450, family 2, subfamily b, polypeptide 10
decreases expression
ISO
mancozeb results in decreased expression of CYP2B6 protein
CTD
PMID:31096615
NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049
G
Cyp2e1
cytochrome P450, family 2, subfamily e, polypeptide 1
decreases expression
ISO
mancozeb results in decreased expression of CYP2E1 mRNA
CTD
PMID:31096615
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
G
Ddit4
DNA-damage-inducible transcript 4
increases expression
ISO
mancozeb results in increased expression of DDIT4 protein
CTD
PMID:24764117
NCBI chr10:59,785,497...59,787,592
Ensembl chr10:59,785,491...59,787,656
G
Dnmt1
DNA methyltransferase 1
decreases expression
EXP
mancozeb results in decreased expression of DNMT1 protein
CTD
PMID:36007320
NCBI chr 9:20,818,501...20,871,084
Ensembl chr 9:20,818,505...20,871,184
G
Dnmt3a
DNA methyltransferase 3A
decreases expression
EXP
mancozeb results in decreased expression of DNMT3A protein
CTD
PMID:36007320
NCBI chr12:3,851,559...3,964,442
Ensembl chr12:3,856,007...3,964,443
G
Dusp1
dual specificity phosphatase 1
decreases expression
EXP
mancozeb results in decreased expression of DUSP1 mRNA
CTD
PMID:36007320
NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102
G
Efcab12
EF-hand calcium binding domain 12
decreases expression
ISO
mancozeb results in decreased expression of EFCAB12 mRNA
CTD
PMID:33396126
NCBI chr 6:115,787,695...115,815,177
Ensembl chr 6:115,787,857...115,815,373
G
Efna1
ephrin A1
decreases expression
EXP
mancozeb results in decreased expression of EFNA1 mRNA
CTD
PMID:36007320
NCBI chr 3:89,179,037...89,188,258
Ensembl chr 3:89,179,040...89,188,449
G
Efna3
ephrin A3
decreases expression
EXP
mancozeb results in decreased expression of EFNA3 mRNA
CTD
PMID:36007320
NCBI chr 3:89,221,200...89,231,359
Ensembl chr 3:89,221,206...89,230,272
G
Elk1
ELK1, member of ETS oncogene family
increases phosphorylation
ISO
mancozeb results in increased phosphorylation of ELK1 protein
CTD
PMID:21375462
NCBI chr X:20,799,634...20,816,847
Ensembl chr X:20,799,634...20,816,847
G
Esr1
estrogen receptor 1 (alpha)
decreases expression
ISO
mancozeb results in decreased expression of ESR1 mRNA
CTD
PMID:33396126
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
G
Esr2
estrogen receptor 2 (beta)
decreases expression
ISO
mancozeb results in decreased expression of ESR2 mRNA; mancozeb results in decreased expression of ESR2 protein
CTD
PMID:33396126
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
G
F3
coagulation factor III
increases expression
ISO
mancozeb results in increased expression of F3 protein
CTD
PMID:25569083
NCBI chr 3:121,517,186...121,528,701
Ensembl chr 3:121,517,186...121,528,697
G
Fos
FBJ osteosarcoma oncogene
decreases expression
EXP
mancozeb results in decreased expression of FOS mRNA
CTD
PMID:36007320
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
G
Gadd45a
growth arrest and DNA-damage-inducible 45 alpha
increases expression decreases expression multiple interactions
ISO EXP
mancozeb results in increased expression of GADD45A mRNA mancozeb results in decreased expression of GADD45A mRNA lupeol inhibits the reaction [mancozeb results in increased expression of GADD45A mRNA]
CTD
PMID:27235710 PMID:36007320
NCBI chr 6:67,012,080...67,014,391
Ensembl chr 6:67,012,080...67,014,441
G
Glyatl3
glycine-N-acyltransferase-like 3
decreases expression
ISO
mancozeb results in decreased expression of GLYATL3 mRNA
CTD
PMID:33396126
NCBI chr17:41,214,599...41,229,469
Ensembl chr17:41,215,509...41,225,241
G
Got1
glutamic-oxaloacetic transaminase 1, soluble
affects activity
ISO
mancozeb affects the activity of GOT1 protein
CTD
PMID:10641187
NCBI chr19:43,488,191...43,514,743
Ensembl chr19:43,488,191...43,513,044
G
Gpt
glutamic pyruvic transaminase, soluble
affects activity multiple interactions
ISO
mancozeb affects the activity of GPT protein [2-cyano-N-((ethylamino)carbonyl)-2-(methoxyimino)acetamide co-treated with mancozeb] results in increased expression of GPT protein; Resveratrol inhibits the reaction [[2-cyano-N-((ethylamino)carbonyl)-2-(methoxyimino)acetamide co-treated with mancozeb] results in increased expression of GPT protein]
CTD
PMID:10641187 PMID:37009748
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
G
Gpx1
glutathione peroxidase 1
decreases expression multiple interactions
EXP
mancozeb results in decreased expression of GPX1 mRNA Acetylcysteine inhibits the reaction [mancozeb results in decreased expression of GPX1 mRNA]
CTD
PMID:30037311
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
G
Gsk3b
glycogen synthase kinase 3 beta
multiple interactions
EXP
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of GSK3B protein
CTD
PMID:19883720
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
G
H2ax
H2A.X variant histone
multiple interactions
ISO
[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in increased expression of H2AX protein
CTD
PMID:34830855
NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374
G
Hdac3
histone deacetylase 3
decreases activity
ISO
mancozeb results in decreased activity of HDAC3 protein
CTD
PMID:21251949
NCBI chr18:38,070,024...38,088,073
Ensembl chr18:38,068,897...38,088,069
G
Hdac6
histone deacetylase 6
decreases activity
ISO
mancozeb results in decreased activity of HDAC6 protein
CTD
PMID:21251949
NCBI chr X:7,796,355...7,814,284
Ensembl chr X:7,796,359...7,814,128
G
Hnrnpm
heterogeneous nuclear ribonucleoprotein M
increases expression
EXP
mancozeb results in increased expression of HNRNPM protein
CTD
PMID:21375462
NCBI chr17:33,865,207...33,904,432
Ensembl chr17:33,865,207...33,905,834
G
Hspa1b
heat shock protein 1B
increases expression
EXP
mancozeb results in increased expression of HSPA1B mRNA
CTD
PMID:36007320
NCBI chr17:35,175,405...35,178,214
Ensembl chr17:35,175,412...35,178,214
G
Ifitm2
interferon induced transmembrane protein 2
decreases expression
ISO
mancozeb results in decreased expression of IFITM2 mRNA
CTD
PMID:33396126
NCBI chr 7:140,534,750...140,539,602
Ensembl chr 7:140,534,750...140,535,900
G
Ifng
interferon gamma
multiple interactions
EXP
mancozeb affects the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of TNF protein]
CTD
PMID:15742816
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
G
Ighm
immunoglobulin heavy constant mu
increases expression
ISO
mancozeb results in increased expression of IGHM mRNA
CTD
PMID:33396126
NCBI chr12:113,382,446...113,386,350
Ensembl chr12:113,382,178...113,386,350
G
Ighv5-4
immunoglobulin heavy variable 5-4
decreases expression
ISO
mancozeb results in decreased expression of IGHV3-38 mRNA
CTD
PMID:33396126
NCBI chr12:113,561,068...113,561,361
Ensembl chr12:113,561,066...113,561,597
G
Il1b
interleukin 1 beta
multiple interactions
ISO
mancozeb inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]
CTD
PMID:16112155
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
G
Il2
interleukin 2
affects expression
ISO
mancozeb affects the expression of IL2 protein
CTD
PMID:9012323
NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108
G
Itgb3
integrin beta 3
decreases expression
ISO
mancozeb results in decreased expression of ITGB3 mRNA; mancozeb results in decreased expression of ITGB3 protein
CTD
PMID:33396126
NCBI chr11:104,498,826...104,561,302
Ensembl chr11:104,498,826...104,561,302
G
Kcnq2
potassium voltage-gated channel, subfamily Q, member 2
increases activity
ISO
mancozeb results in increased activity of KCNQ2 protein
CTD
PMID:23542819
NCBI chr 2:180,717,372...180,777,368
Ensembl chr 2:180,717,372...180,777,093
G
Kiss1
KiSS-1 metastasis-suppressor
affects expression
ISO
mancozeb affects the expression of KISS1 mRNA
CTD
PMID:23660487
NCBI chr 1:133,249,625...133,257,460
Ensembl chr 1:133,237,565...133,257,460 Ensembl chr 1:133,237,565...133,257,460
G
Krt6a
keratin 6A
decreases expression
EXP
mancozeb results in decreased expression of KRT6A protein
CTD
PMID:21375462
NCBI chr15:101,598,363...101,602,746
Ensembl chr15:101,598,345...101,602,742
G
Krtap2-20
keratin associated protein 2-20
decreases expression
ISO
mancozeb results in decreased expression of KRTAP2-2 mRNA
CTD
PMID:33396126
NCBI chr11:99,510,424...99,511,230
Ensembl chr11:99,510,445...99,511,261
G
Ltb4r2
leukotriene B4 receptor 2
increases expression
ISO
mancozeb results in increased expression of LTB4R2 mRNA
CTD
PMID:33396126
NCBI chr14:55,995,379...56,001,523
Ensembl chr14:55,998,885...56,002,595
G
Map3k5
mitogen-activated protein kinase kinase kinase 5
increases expression
EXP
mancozeb results in increased expression of MAP3K5 mRNA
CTD
PMID:36007320
NCBI chr10:19,809,847...20,018,496
Ensembl chr10:19,810,218...20,018,499
G
Map3k6
mitogen-activated protein kinase kinase kinase 6
increases expression
EXP
mancozeb results in increased expression of MAP3K6 mRNA
CTD
PMID:36007320
NCBI chr 4:132,965,290...132,980,240
Ensembl chr 4:132,968,129...132,980,240
G
Mapk1
mitogen-activated protein kinase 1
multiple interactions
ISO
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [mancozeb results in increased activity of MAPK1 protein]; mancozeb results in increased localization of and results in increased activity of MAPK1 protein
CTD
PMID:21375462
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
G
Mapk3
mitogen-activated protein kinase 3
multiple interactions
ISO
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [mancozeb results in increased activity of MAPK3 protein]; mancozeb results in increased localization of and results in increased activity of MAPK3 protein
CTD
PMID:21375462
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
G
Mdm2
transformed mouse 3T3 cell double minute 2
increases expression multiple interactions
ISO
mancozeb results in increased expression of MDM2 mRNA lupeol inhibits the reaction [mancozeb results in increased expression of MDM2 mRNA]
CTD
PMID:27235710
NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663
G
Mir421
microRNA 421
increases expression
ISO
mancozeb results in increased expression of MIR421 mRNA
CTD
PMID:33396126
NCBI chr X:102,616,527...102,616,602
Ensembl chr X:102,616,527...102,616,602
G
mt-Cytb
cytochrome b, mitochondrial
decreases expression
EXP
mancozeb results in decreased expression of CYTB mRNA
CTD
PMID:35617905
NCBI chr MT:14,145...15,288
Ensembl chr MT:14,145...15,288
G
mt-Nd3
NADH dehydrogenase 3, mitochondrial
decreases expression
EXP
mancozeb results in decreased expression of ND3 mRNA
CTD
PMID:35617905
NCBI chr MT:9,459...9,806
Ensembl chr MT:9,459...9,806
G
mt-Nd4l
NADH dehydrogenase 4L, mitochondrial
decreases expression
EXP
mancozeb results in decreased expression of ND4L mRNA
CTD
PMID:35617905
NCBI chr MT:9,877...10,173
Ensembl chr MT:9,877...10,173
G
mt-Nd6
NADH dehydrogenase 6, mitochondrial
decreases expression
EXP
mancozeb results in decreased expression of ND6 mRNA
CTD
PMID:35617905
NCBI chr MT:13,552...14,070
Ensembl chr MT:13,552...14,070
G
Muc1
mucin 1, transmembrane
decreases expression
ISO
mancozeb results in decreased expression of MUC1 mRNA; mancozeb results in decreased expression of MUC1 protein
CTD
PMID:33396126
NCBI chr 3:89,136,363...89,140,688
Ensembl chr 3:89,136,364...89,140,688
G
Myc
myelocytomatosis oncogene
multiple interactions decreases expression increases expression
EXP ISO
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of MYC protein mancozeb results in decreased expression of MYC mRNA mancozeb results in increased expression of MYC protein mancozeb results in decreased expression of MYC protein alpha-Tocopherol inhibits the reaction [mancozeb results in decreased expression of MYC protein]
CTD
PMID:16005924 PMID:19883720 PMID:36007320
NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
G
Nhlrc1
NHL repeat containing 1
decreases expression
ISO
mancozeb results in decreased expression of NHLRC1 mRNA
CTD
PMID:33396126
NCBI chr13:47,166,033...47,168,326
Ensembl chr13:47,166,033...47,168,326
G
Nos2
nitric oxide synthase 2, inducible
multiple interactions increases expression
EXP
Acetylcysteine inhibits the reaction [mancozeb results in increased expression of NOS2 mRNA]
CTD
PMID:30037311
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
G
Nox4
NADPH oxidase 4
multiple interactions increases expression
EXP
Acetylcysteine inhibits the reaction [mancozeb results in increased expression of NOX4 mRNA]
CTD
PMID:30037311
NCBI chr 7:86,893,638...87,047,918
Ensembl chr 7:86,895,304...87,047,918
G
Nr4a1
nuclear receptor subfamily 4, group A, member 1
decreases expression
EXP
mancozeb results in decreased expression of NR4A1 mRNA
CTD
PMID:36007320
NCBI chr15:101,151,783...101,172,676
Ensembl chr15:101,152,150...101,172,676
G
Odc1
ornithine decarboxylase, structural 1
increases activity
EXP
mancozeb results in increased activity of ODC1 protein
CTD
PMID:1733566
NCBI chr12:17,594,906...17,601,503
Ensembl chr12:17,594,795...17,601,506
G
Ogg1
8-oxoguanine DNA-glycosylase 1
decreases expression multiple interactions
ISO
mancozeb results in decreased expression of OGG1 mRNA lupeol inhibits the reaction [mancozeb results in decreased expression of OGG1 mRNA]
CTD
PMID:27235710
NCBI chr 6:113,303,959...113,311,149
Ensembl chr 6:113,303,933...113,312,029
G
Park7
Parkinson disease (autosomal recessive, early onset) 7
multiple interactions
ISO
mancozeb results in decreased activity of and results in increased oxidation of PARK7 protein
CTD
PMID:36842454
NCBI chr 4:150,981,590...150,994,378
Ensembl chr 4:150,981,590...150,998,894
G
Pcdhb20
protocadherin beta 20
decreases expression
ISO
mancozeb results in decreased expression of PCDHB14 mRNA
CTD
PMID:33396126
NCBI chr18:37,637,332...37,640,713
Ensembl chr18:37,637,317...37,640,875
G
Prdx2
peroxiredoxin 2
increases expression
EXP
mancozeb results in increased expression of PRDX2 protein
CTD
PMID:21375462
NCBI chr 8:85,696,251...85,701,440
Ensembl chr 8:85,696,216...85,701,463
G
Prl
prolactin
multiple interactions increases expression
EXP ISO
[mancozeb co-treated with imidacloprid] results in increased expression of PRL protein mancozeb results in increased expression of PRL mRNA
CTD
PMID:24530807 PMID:33396126
NCBI chr13:27,241,553...27,249,187
Ensembl chr13:27,241,553...27,249,188
G
Ptges
prostaglandin E synthase
increases expression decreases expression multiple interactions
ISO EXP
mancozeb results in increased expression of PTGES mRNA mancozeb results in decreased expression of PTGES protein lupeol inhibits the reaction [mancozeb results in increased expression of PTGES mRNA]
CTD
PMID:27235710 PMID:32446389
NCBI chr 2:30,779,483...30,793,309
Ensembl chr 2:30,779,483...30,819,875
G
Ptges3
prostaglandin E synthase 3
decreases expression
EXP
mancozeb results in decreased expression of PTGES3 mRNA
CTD
PMID:32446389
NCBI chr10:127,894,851...127,913,123
Ensembl chr10:127,894,823...127,913,141
G
Ptgs2
prostaglandin-endoperoxide synthase 2
increases expression
ISO EXP
mancozeb results in increased expression of PTGS2 protein
CTD
PMID:21375462 PMID:32446389
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
G
Ptk2b
PTK2 protein tyrosine kinase 2 beta
multiple interactions
EXP
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of PTK2B protein modified form
CTD
PMID:19883720
NCBI chr14:66,390,706...66,518,549
Ensembl chr14:66,390,706...66,518,501
G
Pvalb
parvalbumin
increases expression
EXP
mancozeb results in increased expression of PVALB protein
CTD
PMID:21375462
NCBI chr15:78,075,312...78,090,600
Ensembl chr15:78,075,314...78,090,600
G
Rela
v-rel reticuloendotheliosis viral oncogene homolog A (avian)
increases phosphorylation affects localization multiple interactions
ISO
mancozeb results in increased phosphorylation of RELA protein mancozeb affects the localization of RELA protein Acetylcysteine inhibits the reaction [mancozeb affects the localization of RELA protein]; lupeol inhibits the reaction [mancozeb affects the localization of RELA protein]; mancozeb inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of RELA protein]
CTD
PMID:16112155 PMID:21375462 PMID:27235710
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
G
S100a6
S100 calcium binding protein A6 (calcyclin)
increases expression
EXP ISO
mancozeb results in increased expression of S100A6 protein
CTD
PMID:21375462
NCBI chr 3:90,520,491...90,531,797
Ensembl chr 3:90,520,189...90,531,488
G
S100a9
S100 calcium binding protein A9 (calgranulin B)
increases expression
EXP ISO
mancozeb results in increased expression of S100A9 protein
CTD
PMID:21375462
NCBI chr 3:90,599,937...90,603,028
Ensembl chr 3:90,599,939...90,603,028
G
Scx
scleraxis scleraxis bHLH transcription factor
decreases expression
ISO
mancozeb results in decreased expression of SCX mRNA
CTD
PMID:33396126
NCBI chr15:76,341,594...76,343,668
Ensembl chr15:76,341,652...76,343,658
G
Sdhc
succinate dehydrogenase complex, subunit C, integral membrane protein
decreases expression
EXP
mancozeb results in decreased expression of SDHC mRNA
CTD
PMID:35617905
NCBI chr 1:170,956,726...170,978,209
Ensembl chr 1:170,954,734...170,978,172
G
Septin11
septin 11
increases expression
ISO
mancozeb results in increased expression of SEPTIN11 mRNA
CTD
PMID:33396126
NCBI chr 5:93,227,445...93,329,237
Ensembl chr 5:93,241,296...93,324,306
G
Serpinf1
serine (or cysteine) peptidase inhibitor, clade F, member 1
decreases expression
ISO
mancozeb results in decreased expression of SERPINF1 mRNA
CTD
PMID:33396126
NCBI chr11:75,300,855...75,313,449
Ensembl chr11:75,300,595...75,313,527
G
Sirt1
sirtuin 1
decreases activity
ISO
mancozeb results in decreased activity of SIRT1 protein
CTD
PMID:21251949
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
G
Sirt2
sirtuin 2
decreases activity
ISO
mancozeb results in decreased activity of SIRT2 protein
CTD
PMID:21251949
NCBI chr 7:28,466,192...28,488,086
Ensembl chr 7:28,466,160...28,488,086
G
Sirt3
sirtuin 3
decreases activity
ISO
mancozeb results in decreased activity of SIRT3 protein
CTD
PMID:21251949
NCBI chr 7:140,443,576...140,462,222
Ensembl chr 7:140,443,579...140,462,222
G
Slc14a1
solute carrier family 14 (urea transporter), member 1
decreases expression
ISO
mancozeb results in decreased expression of SLC14A1 mRNA
CTD
PMID:33396126
NCBI chr18:78,143,306...78,185,334
Ensembl chr18:78,143,306...78,185,334
G
Slc5a5
solute carrier family 5 (sodium iodide symporter), member 5
multiple interactions
ISO
mancozeb inhibits the reaction [SLC5A5 protein results in increased uptake of Iodine]
CTD
PMID:27979590
NCBI chr 8:71,335,529...71,345,429
Ensembl chr 8:71,335,533...71,345,401
G
Snord82
small nucleolar RNA, C/D box 82
increases expression
ISO
mancozeb results in increased expression of SNORD82 mRNA
CTD
PMID:33396126
NCBI chr 1:86,283,982...86,284,049
Ensembl chr 1:86,283,983...86,284,052
G
Sod1
superoxide dismutase 1, soluble
decreases expression decreases activity
EXP
mancozeb results in decreased expression of SOD1 protein mancozeb results in decreased activity of SOD1 protein
CTD
PMID:21375462 PMID:35617905
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
G
Stfa3
stefin A3
increases expression
EXP
mancozeb results in increased expression of STFA3 protein
CTD
PMID:21375462
NCBI chr16:36,270,899...36,275,754
Ensembl chr16:36,270,899...36,275,754
G
Sult2b1
sulfotransferase family, cytosolic, 2B, member 1
decreases expression
ISO
mancozeb results in decreased expression of SULT2B1 mRNA
CTD
PMID:33396126
NCBI chr 7:45,379,405...45,409,096
Ensembl chr 7:45,379,407...45,434,093
G
Tek
TEK receptor tyrosine kinase
increases activity
ISO
mancozeb results in increased activity of TEK protein
CTD
PMID:21251949
NCBI chr 4:94,627,322...94,763,213
Ensembl chr 4:94,627,526...94,763,213
G
Tgfb1i1
transforming growth factor beta 1 induced transcript 1
decreases expression
ISO
mancozeb results in decreased expression of TGFB1I1 mRNA
CTD
PMID:33396126
NCBI chr 7:127,845,963...127,852,884
Ensembl chr 7:127,845,984...127,854,871
G
Tnf
tumor necrosis factor
multiple interactions
EXP ISO
mancozeb affects the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of TNF protein] mancozeb inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; mancozeb inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; mancozeb inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of TNF protein]
CTD
PMID:15742816 PMID:15893782 PMID:16112155
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
G
Tpi1
triosephosphate isomerase 1
increases expression
EXP
mancozeb results in increased expression of TPI1 protein
CTD
PMID:21375462
NCBI chr 6:124,787,549...124,791,121
Ensembl chr 6:124,787,549...124,791,259
G
Tpo
thyroid peroxidase
decreases activity
ISO
mancozeb results in decreased activity of TPO protein
CTD
PMID:9418944
NCBI chr12:30,104,658...30,182,983
Ensembl chr12:30,104,658...30,182,623
G
Trp53
transformation related protein 53
decreases expression increases expression multiple interactions
ISO EXP
mancozeb results in decreased expression of TRP53 mRNA; mancozeb results in decreased expression of TRP53 protein mancozeb results in increased expression of TP53 mRNA lupeol inhibits the reaction [mancozeb results in increased expression of TP53 mRNA]
CTD
PMID:22369882 PMID:27235710
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
G
Tshb
thyroid stimulating hormone, beta subunit
multiple interactions
EXP
[mancozeb co-treated with imidacloprid] results in increased expression of TSHB protein
CTD
PMID:24530807
NCBI chr 3:102,684,621...102,718,175
Ensembl chr 3:102,682,781...102,690,034
G
Xrcc1
X-ray repair complementing defective repair in Chinese hamster cells 1
decreases expression multiple interactions
ISO
mancozeb results in decreased expression of XRCC1 mRNA lupeol inhibits the reaction [mancozeb results in decreased expression of XRCC1 mRNA]
CTD
PMID:27235710
NCBI chr 7:24,246,124...24,272,863
Ensembl chr 7:24,245,714...24,272,865
G
Zfp358
zinc finger protein 358
decreases expression
ISO
mancozeb results in decreased expression of ZNF358 mRNA
CTD
PMID:33396126
NCBI chr 8:3,543,138...3,547,208
Ensembl chr 8:3,543,138...3,547,208
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all